UNC | LINEBERGER COMPREHENSIVE CANCER CENTER

UNIVERSITY CANCER RESEARCH FUND

2025 Legislative Report

THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Annual Financial Report to the Joint Legislative Education Oversight Committee
and the Office of State Budget and Management
Submitted November 1, 2025 in accordance with G.S.116-29.1

LETTER FROM THE CHAIR

As chair of the University Cancer Research Fund Committee, I am pleased to share our annual legislative report on North Carolina's nation-leading investment in cancer care and research: the University Cancer Research Fund (UCRF).

Cancer remains one of the leading causes of death in our state and the world. To fuel innovative research focused on improving cancer prevention, treatment and outcomes in North Carolina, the North Carolina General Assembly established the UCRF in 2007.

UNC Lineberger Comprehensive Cancer Center, the state's only public National Cancer Institute-designated comprehensive cancer center, works closely with UNC Health and other partners throughout North Carolina to make important discoveries that have real, meaningful impacts on patients and communities. The UCRF has been a key source of support for this work by funding critical shared resources and infrastructure, seeding groundbreaking research, and helping to recruit and retain some of the world's best scientists and clinicians.

In addition to its research impacts, the UCRF continues to generate significant economic value for our state, producing more than a 13-to-1 return on the state's investment in Fiscal Year 2025. Some of the financial benefits highlighted in this year's report include:

- Recruiting and retaining 18 faculty members who are experts in their fields;
- Supporting more than 1,550 high-paying research-related jobs in North Carolina;
- Leveraging $210.8 million in competitive federal research grants and contributing to more than $253.7 million in total external funding; and
- Generating $25.4 million in state and local tax revenues and a total direct and indirect economic impact of $807.7 million.

Thanks in no small part to the UCRF, UNC Lineberger is uniquely positioned to remain a leader in cancer research on a global scale that stands to benefit our fellow citizens from all 100 counties in our state. On behalf of those patients, and the researchers and clinicians striving to better prevent, diagnose and treat cancer, we thank the General Assembly for its ongoing support.

With gratitude,

Lee H. Roberts
Chancellor
Chair, Cancer Research Fund Committee



INTRODUCTION

HISTORY

Concerned by the widespread incidence of cancer in North Carolina and worldwide, the N.C. General Assembly created a landmark investment in cancer care and research in 2007: the University Cancer Research Fund.

The UCRF supports cancer care and research at the UNC Lineberger Comprehensive Cancer Center and UNC Health, and with their academic, clinical, research and public health partners across North Carolina. Initially funded through a combination of state appropriations, tobacco settlement funds and taxes on non-cigarette tobacco products, UCRF is now funded solely with General Fund appropriations. The total 2025 allocation to the UCRF was $59.5 million. To ensure that these funds are utilized as effectively as possible, the General Assembly also established the Cancer Research Fund Committee to provide ongoing oversight and accountability. The committee developed a strategic plan to target UCRF resources where they can have maximum impact:

- Strategic research priorities in genetics, novel therapies and cancer outcomes;
- Clinical excellence through selective opportunities that enable UNC Lineberger to continue as a global leader in a rapidly changing field of research; and
- Critical infrastructure such as technology, training, outreach and other core resources.

A new strategic plan was recently completed to continue the responsible and innovative use of UCRF resources in this dynamic, evolving field of research. Next year's report will describe researchers' activities in accordance with the new plan.

Complementing the state's ongoing support of the UCRF are two major capital investments also funded by the General Assembly. The N.C. Basnight Cancer Hospital, approved by the legislature in 2004 and opened in 2009, is UNC Lineberger's clinical home and serves patients from all 100 North Carolina counties. The staff at the hospital and its affiliated clinics oversaw more than 250,000 patient visits in Fiscal Year 2025. In 2010, lawmakers funded Marsico Hall, a cutting-edge research facility that opened in 2014, housing highly advanced equipment and technology that accelerates research capabilities and facilitates cross-disciplinary collaboration.

The Cancer Research Fund Committee publishes regular reports on UCRF-supported activities and submits annual financial reports to the General Assembly that include the UCRF's economic impacts, detailed budget and expenditure accounts, information on external funds leveraged by UCRF support and other performance metrics. As these reports have shown, the UCRF continues to generate significant economic and health benefits for North Carolina, ensuring that UNC Lineberger remains a global leader in the fight against cancer while caring for patients throughout our state.

Outreach Across North Carolina

UCRF investments in faculty, staff and program development are deployed across North Carolina to devise better ways to prevent, detect early, treat and measure the impact of cancer on our citizens. The map on the following page provides a snapshot of the reach and breadth of UCRF's impact on North Carolina.

OUTREACH

Outreach Across North Carolina 2024–2025



A. Cancer Data Resources
- Electronic Patient-Reported Outcomes (ePROs) during cancer treatment
- Cancer Information and Population Health Resource (CIPHR)
- UNC Health Registry
- Characterizing delays in cancer diagnosis for underserved populations
- Carolina senior registry
- Rapid case ascertainment
- Improving the diagnosis of gastrointestinal cancers
- Carolina Breast Cancer Study, 4

B. Understanding Cancer Differences
- Link between obesity, racial disparities and endometrial cancer
- American Indian men and experiences with prostate cancer communication
- Access to and value of treatment innovation study
- Improving colorectal cancer screening through community pharmacies
- Oncology navigation to enhance equity
- Well Empowered
- South Eastern Consortium for Lung Cancer Health Equity
- Ancestry-related RNA splicing and immune expression in metastatic breast cancer
- Barriers and Facilitators in Black Participant Enrollment in Endocrine Therapy Trial
- Financial hardship among LGBTQ+ cancer survivors and caregivers
- The Carolina Endometrial Cancer Study
- CHANCE-2 (Carolina Head and Neck Cancer Study, Phase 2)
- Carolina Thyroid Cohort Study
- Centering equity in hereditary breast and ovarian cancer genetic testing
- Comparative effectiveness and survivorship health in bladder cancer
- Bladder cancer survivorship
- Understanding financial impacts and improving cost literacy among young adult cancer survivors
- Disparities in the diagnosis of cancer in the ER
- Multi-level driver of liver cancer disparities
- Health equity impacts of electronic health record data bias
- Diagnostic delay in ovarian and uterine cancer
- Breast cancer mortality disparities: Integrating biology and access
- Impact of spatial heterogeneity in tumor and microenvironment on recurrence
- Integrating biology and access to understand metastatic breast cancer disparities
- Southern liver health cohort
- Breast cancer drivers in Black women: Society to cells
- Using genomic data to understand fast-growing breast cancer
- Lung cancer disparities among American Indians
- Cancer disparities among American Indians

C. Cancer Screening
- Shared decision making, utilization and outcomes of lung cancer screening
- Remote colorectal cancer screening intervention
- Evaluating lung cancer screening patterns and outcomes
- Community-based breast cancer screening and surveillance
- Breast Cancer Sociodemographic Disparities Study
- Community-based breast cancer screening and surveillance
- SCORE: Scaling Colorectal Cancer Screening Through Outreach, Referral, and Engagement
- Carolina Cancer Screening Initiative
- Digital outreach intervention for lung cancer screening
- Cancer Screening Research Network NC Hub
- Promoting genomic screening among diverse populations

D. Cancer Survivorship
- Physical activity intervention with Black colorectal cancer survivors
- Supportive care for patients with cancer-related fatigue
- Supportive care for lymphoma patients with cancer-related fatigue
- Evaluating an end-of-life predictive tool for breast cancer
- Patient-reported measure to identify treatment priorities of patients with advanced blood cancers
- Spanish adaptation of an exercise program for patients with cancer (Get REAL & HEEL)
- Social needs of breast and gynecological cancer patients and caregivers
- Mobile health strategies to promote weight management among adolescent and young adult cancer survivors
- Addressing financial toxicity in rural oncology
- Intervention to increase endocrine therapy adherence
- Impact of structural racism among breast cancer survivors
- Cancer survivorship risk models
- Optimizing endocrine therapy adherence

E. Clinic-Based Prevention
- Duke & UNC Tobacco Treatment Specialist Credentialing Program
- Maximizing HPV vaccine uptake in young cancer survivors

F. Community-Based Prevention/Education
- Fort Bragg tobacco control
- Overcoming barriers to cancer screening through online intervention
- Cancer disparities among American Indians: Youth and young adult cancer risk factors
- UNC Superfund Research Program
- Processes of maintaining healthy diet during prostate cancer survivorship
- Educational tools to advance equity in cancer clinical trial participation
- Impact of e-cigarette prevention messages on adolescents
- Quantitative models of cell cycle arrest
- ASPiRE: Advancing Science & Practice in the Retail Environment
- Reducing health disparities through tobacco regulation
- Promoting cancer family History sharing among Black Americans
- Impacts of neighborhood development on physical activity in Latine and Black communities

G. Improving Treatment Outcomes
- Support during treatment for endometrial cancer
- Diet and drugs to treat endometrial cancer
- Quality of life & physical activity in Black breast cancer survivors
- Mobile health app to promote participation of Black women in breast cancer clinical trials
- Palliative care for patients with acute myeloid leukemia - SCOPE Leukemia
- Support of family caregivers of diverse patients with cancer and diabetes
- Improving clinical trial equity and access
- Care gaps and needs in adolescent and young adult cancers
- Funding translational breast cancer research
- Testing a prognostic calculator in patients with breast cancer
- System for risk differences in patients with lung cancer
- Treatment decision making tool for acute myeloid leukemia
- Funding patients lodging
- Personalizing kidney cancer communication to support decision-making
- Integrating molecular pathology, radiology and genetics to improve breast cancer risk prediction
- PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer
- UNC Cancer Network telehealth lectures
- UNC Cancer Network e-tumor boards

H. Patient/Community Advisory Board
- Promoting Resilience in Stress Management for Metastatic Breast Cancer (PRISM-MBC)
- Improving childhood cancer survivorship
- Virtual Testis Cancer Lay Support and Survivorship (VITALSS Study)
- Nutrition support to prevent malnutrition among gastroesophageal cancer patients

ECONOMIC IMPACT

ECONOMIC IMPACT

To estimate the UCRF's economic impact for Fiscal Year 2025, UNC Lineberger again hired the nationally respected consulting firm Tripp Umbach. The full report is included in the Appendix. The Fund's overall economic impact is calculated as the sum of its direct, indirect and induced impacts. Direct impact resulted from two major sources: expenditures from the UCRF itself, and the expenditure of UCRF-attributable research funds awarded to UNC Lineberger by federal, foundation and other sources. The indirect and induced impact was calculated by applying standard multipliers to direct expenditures.

Using standard methodologies, Tripp Umbach estimated that in Fiscal Year 2025, the UCRF:

- Had an overall economic impact of $807.7 million, including $407.9 million in direct spending and $399.8 million in indirect and induced impact attributable to external grant funding and downstream spending by employees, vendors and contractors.
- Supported 3,868 high-paying research-related jobs, including the direct support of 1,556 jobs and 2,312 jobs through increased extramural funding and the indirect and induced impacts of those direct jobs and the spending generated within North Carolina.
- Resulted in more than $25.4 million in state and local tax revenues to North Carolina.
- Generated $13.57 in economic impact for every UCRF dollar spent.

Tripp Umbach has performed economic analyses of the UCRF since Fiscal Year 2013. Earlier economic analyses were conducted, using slightly different methodologies, by SRA International and the UNC Center for Competitive Economies (Frank Hawkins Kenan Institute of Private Enterprise).

Faculty Job Creation and Retention

UNC Lineberger's world-class faculty are at the heart of our work. They drive our research vision; train future doctors and scientists; invest in staff, equipment and technology; and generate research funds from other sources both inside and outside our state. Their creative, collaborative research breaks ground with impactful scientific and clinical advancements that can lead to earlier detection and diagnosis, more effective treatments and better prevention programs.

Since it was created in 2007, the UCRF has made it possible to recruit or retain 431 top leaders in their fields.

- **Recruitment:** Thanks to the UCRF, UNC Lineberger successfully recruited 14 faculty this year and 350 since 2007. These renowned cancer experts deliver high-quality care for patients and lead innovative research in areas that are critical to improving cancer prevention, diagnosis and treatment in North Carolina.
- **Retention:** The UCRF has supported the retention of 2 faculty this year and 81 since 2007, ensuring that outstanding talent remains at UNC Lineberger to continue their research and clinical work.

ECONOMIC IMPACT

Extramural Funding Growth

The UCRF is keeping UNC Lineberger at the forefront of research nationally and is leveraging significant amounts of extramural research funds. Almost all of these funds come from outside the state, adding significantly to North Carolina's economy. In Fiscal Year 2025, UCRF recipients leveraged $210.8 million in competitive federal research grants. This continued growth in federal grant funding is especially noteworthy as competition for these research dollars has become more intense in recent years.

Total external funding directly attributable to the UCRF was $253.7 million in annual total cost dollars. This amount is based on a snapshot of active attributable extramural funding held by faculty in the first quarter of Fiscal Year 2025, representing one year of funding. This shows a tremendous growth in UCRF-related extramural funding since $5 million in Fiscal Year 2008. A complete list of the awards is included in the Appendix.

Intellectual Property, Innovation and Entrepreneurship

Getting new discoveries from the lab into the clinic, where they can help patients, is one of UNC Lineberger's top priorities. UCRF-backed innovations and discoveries have helped to create jobs and launch companies to convert these research findings into clinical advances.

In partnership with UNC's North Carolina Translational and Clinical Sciences Institute (NC TraCS), the UCRF promotes an entrepreneurial mindset and supports specialized staff to maximize the development and licensing of university intellectual property. Dozens of startup companies affiliated with UNC, nearly all of which are based in North Carolina, have launched or expanded their reach with the help of the UCRF and other sources of support. Collectively, these companies have a workforce of approximately 500 employees in North Carolina alone.

EpiCypher
GeneCentric
G1 THERAPEUTICS
Liquidia
Symberix, Inc
ENFUEGO THERAPEUTICS
LED RADIOFLUIDICS
stridebio
Triangle Biotechnology
CELL Microsystems
PREDICTIVE
Counter Tools
CONTINUITY BIOSCIENCES
IMMvention
Sapere Bio
ChemoGLO
ALTIS BIOSYSTEMS
SNP Therapeutics
ADVANCED Nutrigenomics
EPIGENOS
ribometrix



RESEARCH IMPACT

Guiding Principles

Based on the strategic plan, the UCRF is invested in research areas where UNC Lineberger can have meaningful and lasting impact, targeting three specific research priorities:

- **Understanding the Role of Genetics in Cancer Causation and Treatment:** Discovering the genes that predispose families to cancer and predispose cancer patients to poor treatment outcomes — specifically, investigating various genetic mutations that contribute to treatment failure in certain cancer subtypes.
- **Developing Novel Therapeutics:** Creating innovative therapies that target the specific vulnerabilities of treatment-resistant cancers and finding new ways of delivering treatments that lessen toxic side effects for patients. This research theme relates closely to the genetics research priority, capitalizes on research advances in cancer immunotherapy and generates key findings to be used in clinical applications as quickly as possible.
- **Optimizing NC Cancer Outcomes:** Improving the quality of oncology and survivor care while leveraging population-based datasets that track the occurrence and treatment of cancer across North Carolina, supporting innovative research aimed at improving community prevention and early detection. The ultimate goal is to understand cancer at an unprecedented level in order to design research interventions that holistically address both public health and patient challenges at the practice, health system and community levels.

In addition to the three research priorities, UCRF funds are invested in key infrastructure, shared resources and clinical excellence to best position UNC Lineberger to seize research or clinical opportunities as they arise, providing the top minds in the field with critical resources that keep UNC at the forefront of current and future research. This approach enables UNC Lineberger to adapt to a constantly changing field and to keep building leadership and expertise in key clinical and research areas.

For example, the UCRF provides seed funds to recruit top researchers and to acquire and operate advanced technology and equipment for use by multiple faculty members. It also funds the development and operation of shared research resources and telehealth networks that give UNC Lineberger's clinician scientists the tools they need to improve patient outcomes and to collaborate with doctors and hospitals across the state. The UCRF strengthens UNC Lineberger's multidisciplinary excellence in cancer care while supporting a statewide infrastructure that brings leading-edge clinical applications and research into community practices and research institutions throughout North Carolina.

New leadership guides UNC Lineberger's bench-to-bedside work

FERRIS

As a renowned physician-scientist, **Robert Ferris, MD, PhD,** understands deeply the link between medical research and patient care. Ferris, a head and neck surgical oncologist and a leading expert in cancer immunotherapy, sees that bench-to-bedside research journey as vital to UNC Lineberger Comprehensive Cancer Center's mission.

Since he became executive director of UNC Lineberger and chief of oncology clinical services with the UNC Health System in October 2024, Ferris has taken several steps to enhance the center's translational science and amplify its impact on patient care. He created new leadership and research structures and initiated a new strategic plan to optimize UNC Lineberger's assets to better align the cancer center's research and clinical work to improve patient outcomes.

"Every time a new leader comes in, there is an opportunity for review," said Ferris, a graduate of UNC-Chapel Hill who has returned to lead at his alma mater after serving at the University of Pittsburgh as director of the Hillman Cancer Center, senior vice president for oncology programs and associate senior vice chancellor for cancer research. "The programs should reflect the center's strengths, but they should also reflect our strategic direction. That direction is to help Lineberger's programs facilitate interactions among folks with clinical experience, who understand the gaps in the field and who can take this work into the clinic."

Ferris is reconfiguring some programmatic areas within UNC Lineberger where he saw opportunities to bring more clinical perspectives and application into the research space — for example, merging clinical trials and molecular therapeutics, which focuses on developing and advancing new treatments to the clinic, into an overall cancer therapeutics program that spans preclinical research to clinical work.

Beyond leading UNC Lineberger, Ferris is working across UNC Health to build the oncology service line and coordinate clinical services at UNC Health facilities and affiliates throughout the state. UNC Lineberger's deputy directors are playing key roles in supporting this systemwide work.

> "I hope to cure a large number of people through trials, but I also want to care for them one patient at a time. That's why we all got into this profession."
>
> *– Robert Ferris, MD, PhD*

Lisa Carey, MD, ScM, FASCO, deputy director of clinical science, was appointed as executive director of Clinical Research Partners and the chief clinical research officer for UNC Health. Cancer clinical trials make up about half of UNC Health's sponsored research trials, and in her new role, Carey is focused on improving access to all clinical trials, not just cancer trials, and expanding trials to all UNC-owned hospitals and, eventually, to provider practices throughout the state.

CAREY

Jeremy Rich, MD, MHS, MBA, was named deputy director of research and chief scientific officer — a new role for UNC Lineberger, but similar to one that he held in Pittsburgh. His responsibilities at the Hillman Cancer Center in Pittsburgh include strategic planning, faculty recruitment and development, and supporting stronger research collaborations across basic, translational clinical and population sciences. He will also collaborate on making patient care more seamless across the health system.

RICH

Amid all these changes, Ferris is staying true to his physician-scientist roots. He tries to see patients every week at his clinic in Raleigh at UNC Rex while doing surgical cases at the North Carolina Basnight Cancer Hospital in Chapel Hill, and, in his NCI-funded lab, further his investigations into head and neck cancers in three RO1-funded studies he began at Pittsburgh. These activities and accomplishments have culminated in his recent election into the prestigious National Academy of Medicine. Continuing his clinical and research work keeps that bench-to-bedside link top of mind.

"It is easier to oversee research if I have a lab, and treating patients builds credibility and fosters relationships with other clinicians," he said. "I hope to cure a large number of people through trials, but I also want to care for them one patient at a time. That's why we all got into this profession."

Investigating approaches to make lung cancer screening more effective

Lung cancer is the leading cause of cancer deaths nationally and in North Carolina, with most patients diagnosed at an advanced stage when treatment is less effective. To detect the disease earlier, when it is more treatable, annual low-dose computed tomography is recommended to screen for lung cancer in high-risk patients.

But some providers are concerned that lung cancer screening may do more harm than good. For example, many patients undergo screening and receive a false positive: an abnormal lung finding that could potentially be cancerous but turns out not to be after further testing. These patients often endure additional imaging tests or invasive procedures to evaluate the abnormal finding —

> There is such a big need for more research across the lung screening care continuum as we work to address the leading cause of cancer mortality in North Carolina. – *Louise Henderson, PhD, MSPH*

which carry risks of complications and could cause anxiety or financial distress.

HENDERSON

To better understand the burdens of false-positive screenings and explore ways to mitigate them, the National Cancer Institute awarded **Louise Henderson, PhD, MSPH,** a $3.2 million grant to identify the potential harms of these false-positive results at the patient, clinician, and facility levels. The study's other lead investigators are **Angela Stover, PhD,** associate professor of health policy and management at UNC Gillings School of Global Public Health, and Patricia Rivera, MD, formerly of UNC Lineberger and now at the University of Rochester Medical Center.



STOVER

"We want to quantify the extent of this concern and see if we can identify which types of patients are more likely to experience a false positive," said Henderson, professor of radiology and co-leader of UNC Lineberger's cancer epidemiology research program. "This information may help to alleviate concerns or may be used in conversations between patients and clinicians when they discuss the screening process to help understand what to expect."

Henderson said more research in lung cancer screening is needed to evaluate how well screening actually performs in real-world populations and settings, not just in clinical trials. For example, the U.S.-based National Lung Screening Trial ensured that about 95% of participants returned every year for three years for their annual scan, but across North Carolina the return rate was only about 40%.

Increasing awareness about the importance of lung cancer screening would help improve low screening participation rates, Henderson said. In North Carolina, lung cancer screening occurs in just 10% of those who are eligible compared with breast or colorectal cancer screening, which occurs in 79% and 64%, respectively. A comprehensive database showing real-world patterns and outcomes of lung cancer screening throughout the state can help illuminate this gap and track changes over time.

The N.C. Lung Screening Registry, a UNC-based statewide partnership with community and academic sites across North Carolina, contains information from more than 40,000 patients, including demographics, comorbidities, smoking history, screening results and cancer outcomes.

"We collect and analyze data on individuals screened for lung cancer across the state to address the need for evidence on how well lung screening is working and to identify gaps where we can intervene to improve care," Henderson said. "There is such a big need for more research across the lung screening care continuum as we work to address the leading cause of cancer mortality in North Carolina."

‘If you’re trying to make a difference in cancer, you can’t go slow’

“Cancer doesn’t allow for slow,” said **Chad Pecot, MD,** professor of medicine — and he doesn’t, either.

PECOT

Pecot co-leads UNC Lineberger’s cancer therapeutics program, aiming to get discoveries made at the cancer center laboratories into the clinic; sees patients at UNC Health and runs a research lab; is founder and chief scientific officer of the Chapel Hill biotech startup EnFuego Therapeutics; and directs UNC’s RNA Discovery Center, where researchers collaborate to study ribonucleic acids (RNA) and their therapeutic potential.

“There are no RNA medicines approved for cancer treatment, partly because they’re extremely hard to deliver to tumors and also expensive to make,” Pecot said. “However, recently publishing several high-impact papers with newer RNA medicines is a sign that we’re on the right track, and it would not have been possible to engineer these molecules and get them to this point without the UCRF.”

One of these new medicines, EFTX-G12V, is undergoing toxicity studies needed for FDA approval. Pecot and **Albert Bowers, PhD,** professor of chemical biology and medicinal chemistry at UNC Eshelman, engineered this molecule to deliver therapeutic RNA interference into tumors to target a specific mutation of the KRAS oncogene, which is linked to about 25% of all cancers. They found that EFTX-G12V effectively deactivates KRAS G12V, a cancer-causing genetic mutation, to stop cancer growth while sparing non-mutated cells.

BOWERS

Pecot also created a molecule, called Chimera, that attacks cancer by simultaneously targeting KRAS and MYC, a difficult-to-drug protein. This innovative dual-targeting approach is a promising treatment strategy for multiple cancer mutations. “To my knowledge, the chimeric drug is the first tumor-directed, two-in-one oncology drug that can hit two different oncogenes at once,” Pecot said.

Although he is a pioneering physician-scientist today, Pecot initially had no interest in research; he thought it was slow and boring. He liked math and physics, and wanted to design things that could help people, so he studied biomedical engineering at the University of Miami.

His sophomore year, he was diagnosed with testicular cancer. He had surgery followed by months of chemotherapy; he was inspired by fellow patients to help people with cancer.

For his senior design project, Pecot created a medical device that could help treat cancer. But the PhD student he was paired with never tested the device, and the project stalled — feeding into Pecot’s beliefs about the drudgery of research.

Pecot then turned to a focus in oncology. He attended medical school at Miami and did his residency at Vanderbilt University, where he met researchers whose enthusiasm for their work made him start to rethink his anti-research views.

But it wasn't until Pecot was an oncologist at MD Anderson Cancer Center that everything clicked. "I'm working at one of the best cancer centers, seeing cancer patients from all over the world, and we were telling so many people we had no options left for them," he said. "I realized I couldn't be in the clinic full time; there had to be something else I could do."

Pecot gave research another try — and this time, it stuck. He spent three years training as a budding physician-scientist at MD Anderson and in 2013 was recruited to UNC Lineberger, where he thrives at the intersection of medicine, innovation and urgency.

"Once I finally got in the lab and realized that you could use your mind to help people, and that research can be exciting and move fast, I was hooked," he said. "If you're trying to make a difference in cancer, you can't go slow."

Community Advisory Board engages NC communities in the fight against cancer

About 1 in 3 North Carolinians have had cancer or know someone who has. The vast reach of North Carolina's second-leading cause of death underscores the need to raise public awareness of cancer's signs and symptoms, and to make sure cancer research reflects community needs across the state.

UNC Lineberger's Community Advisory Board works on both fronts. The 14-member board includes those who have lived with different types of cancer, represent various advocacy groups or communities within North Carolina, or have unique perspectives and expertise. Despite their different backgrounds, they share a common goal: putting patients first in UNC Lineberger's service to all 100 N.C. counties.

Stephanie Wheeler, PhD, MPH, the Michael S. O'Malley Distinguished Professor of Health Policy and Management and associate director of Community Outreach and Engagement (COE) at UNC Lineberger, works closely with the CAB and appreciates its role in connecting researchers to the real world. COE staff members Veronica Carlisle, Patty Spears and Jennifer Potter run point on coordinating and communicating with CAB members in support of their work with UNC Lineberger.

WHEELER

For example, to help shape the cancer center's research priorities. CAB members and UNC researchers jointly review the Community Health Assets and Needs Assessment (CHANA), a comprehensive resource of statewide data about cancer health needs, risk factors, incidence, mortality and survivorship experiences.

CAB members also incorporate a patient perspective in study designs and protocols, review and approve grant applications from community

organizations, and bring new research ideas from the community to the cancer center.

"CAB members review the data right alongside us and help us think through solutions to improve access to care," Wheeler said. "They're not reviewing the science — they're reflecting on the relevance of the work in terms of impact on cancer in North Carolina. They're focused on questions like, why does this matter and why is it meaningful for patients and communities?"

MAY

For **Eva May,** a marketing professional who pivoted to patient research advocacy and has been part of the CAB since its beginning, research can only be meaningful if it's reflective of the population. She assisted in the development of and participates in a training initiative that has helped more than 780 researchers learn how to incorporate community engagement into their study designs and protocols.

"Researchers have to think about the people who are going to participate in their studies," May said. "People's genetic makeup along with personal and community factors called social determinants of health can impact their risk of cancer, their diagnosis and their response to treatment. If you don't recruit enough people in key population cohorts for your research, you won't know whether your approach is going to work."

SMITH

CAB member **Jim Smith,** a retired psychiatrist and businessman, began his cancer advocacy journey in 1990 upon learning that North Carolina had the nation's highest mortality rate for prostate cancer among African Americans. He helped start the NC Minority Prostate Cancer Awareness Action Team to promote cancer screenings, and although screening rates are now identical among Black and white men, the incidence of prostate cancer for Black men is still nearly double compared to white men.

"This is why the research is so critical — there is much more to find out," he said. "UNC is a state school, and that's important. The CAB gives Lineberger the opportunity to hear from all kinds of people from all kinds of socioeconomic levels, and to help organizations across North Carolina access resources, researchers and clinical trials. It makes a difference."

Board members actively spread the word about the cancer center's work, communicating within and outside of their community organizations and participating in cancer-focused events. In September, three CAB members were panelists or speakers at the 2025 Cancer Center Community Impact Forum, a national conference of community outreach and engagement offices across the country. UNC was chosen to co-host this year's conference with Duke and Wake Forest universities.

The CAB facilitates opportunities for researchers to go into the community to participate in town halls and other data-sharing events, and connects with communities that are unique to North Carolina, including its military bases, American Indian tribes, the state's large Spanish-speaking population, and largely rural areas in both western and eastern North Carolina.

JONES

But to be truly patient-centered, cancer research must go beyond geographic, socioeconomic or other categorical differences and focus on the individual, said CAB member and cancer survivor **Matt Jones,** who served on the advisory board for UNC Lineberger's Adolescent and Young Adult (AYA) cancer program before joining the CAB.

"If you think about AYA cancer, the age range is 13–39, a pretty broad age range. I went through cancer at age 34 with a 2-year-old child and a professional life — my challenges were a lot different than a teenager's," he said. "When researchers are putting together studies or grant applications, I try to bring the perspective that it's not a one-size-fits-all kind of approach."

JOHNSON-THOMPSON

For **Marian Johnson-Thompson,** successful community engagement requires open communication that goes both ways. Serving on the CAB allows her to raise awareness about UNC Lineberger's work and to take concerns and perspectives she hears from community members back to Chapel Hill.

"Education is so important when it comes to cancer. People need to understand the signs and symptoms of cancer, because early detection works in almost all cancers — if it's not diagnosed early, there are real costs to the workforce, to families and to communities," said Johnson-Thompson, a former breast cancer researcher and longtime breast cancer advocate with Susan G. Komen. "The CAB engages the community in the process of trying to understand cancer and in working together toward addressing it. It's all about collaboration."

PRIORITY 1: GENETICS IN CANCER CAUSATION AND TREATMENT

Adaptive whole-genome sequencing could transform childhood leukemia diagnosis

UNC Lineberger researchers have demonstrated a faster, more cost-effective approach to analyzing the genetic makeup of pediatric acute leukemia. Determining a cancer's genomic classification is critical to developing a more effective treatment plan tailored to a patient's tumor. Their findings were published in the journal Leukemia.

The study enrolled 57 pediatric patients diagnosed with either B-cell acute lymphoblastic leukemia (B-ALL) or acute myeloid leukemia (AML). The researchers used nanopore DNA sequencing technology to identify the specific genetic alterations in all cases within 48 hours — and in some cases, within 15 minutes. This breakthrough could significantly speed up diagnoses, reduce costs and help doctors start targeted treatments more quickly, improving care for children with leukemia.



ALEXANDER

WANG

Thomas Alexander, MD, MPH, assistant professor of pediatrics, and **Jeremy Wang, PhD,** associate professor of

pathology and laboratory medicine and genetics, are the paper's corresponding authors. **Julie Geyer, PhD,** a postdoctoral research assistant in the Wang lab, is the first author.

GEYER

"Genomic classification of leukemia is not available for most patients in the world due to a lack of trained workforce and insufficient resources. Even in high-income countries, the process is labor-intensive, expensive and often incomplete," Alexander said. "Our driving motivation is to develop a diagnostic test that is accessible to most of the world to close the diagnostic testing gap."

The researchers demonstrated they can identify clinical genomic information for children with acute leukemia using adaptive sampling, a technique that uses nanopore sequencing to target specific genetic regions. This approach is more flexible, scalable and cost-effective than current methods for determining a cancer's genomic classification.

"Adaptive sampling can be easily adjusted and updated with new targets or for different purposes without relying on new supply chains or wet lab validation," Wang said. "On the same assay without additional wet lab work or sequencing, we also demonstrated the potential for identifying pharmacogenomic variants, with implications for treatment."

This simpler, less expensive, more comprehensive approach has significant implications in low-resource settings where clinical genomic classification is unavailable or incomplete. In high-income countries, it has the potential to simplify molecular pathology for acute leukemia, improve turnaround time and provide more comprehensive clinical findings.

New drug combination shows promise for older adults with acute myeloid leukemia

A new treatment combining the recently approved drug revumenib with the current standard of care has shown encouraging results for people newly diagnosed with acute myeloid leukemia (AML). Findings from the early-phase clinical trial, which was led by UNC Lineberger and conducted at 12 sites nationwide, were published in the Journal of Clinical Oncology and presented in June at the European Hematology Association Congress in Milan.

AML is a complex blood cancer with many genetic subtypes, requiring personalized treatment. This study focused on patients whose leukemia had one of two specific gene changes — NPM1m or KMT2Ar — which occur in about one-third and 5% of AML patients, respectively. Revumenib, an oral drug known as a menin inhibitor, targets these mutations and is already approved for relapsed AML with a KMT2Ar change.

In the trial, 43 older adults received a combination of revumenib and two standard AML drugs, azacitidine and venetoclax. The results were notable:

- 88% of patients had no detectable leukemia after treatment;
- 67% achieved complete remission with normal blood counts;
- 63% were still alive one year later; and
- These rates are higher than typically seen with current treatments alone.

"The promising results from this early study have led to a larger, Phase 3 trial to see if adding revumenib improves overall survival,"

said **Joshua F. Zeidner, MD,** associate professor of medicine and chief of leukemia research at UNC Lineberger, who will lead the U.S. arm of the next trial. "This approach could change how we treat AML with these specific genetic alterations."

ZEIDNER

Using AI, researchers launch database to predict cancer DNA anomalies

UNC-Chapel Hill researchers have launched CytoCellDB, a database that addresses a major gap in cancer research by identifying extrachromosomal DNA (ecDNA) in cancer cell lines.

BRUNK

"CytoCellDB provides researchers with an invaluable tool to determine which cancer cell lines contain ecDNA and other chromosomal abnormalities," said **Elizabeth Brunk, PhD,** assistant professor of pharmacology and chemistry. "It's a significant step toward understanding ecDNA, paving the way for more effective treatments and improved outcomes for the 15% of cancers that harbor ecDNA."

The researchers reported on the rationale for developing the database in the journal NAR Cancer.

EcDNA enables cancer cells to amplify key genes outside of chromosomes, altering how those genes are regulated, replicated and divided. Found in 14–20% of tumors, ecDNA is a marker of malignancy and genome instability, contributing to cancer growth, drug resistance and epigenetic changes. However, its biological role has been difficult to study because too few cell-line models clearly show whether ecDNA is present.

While extensive genome sequencing data exist for many cell lines, distinguishing ecDNA from chromosomal DNA requires microscopic imaging. CytoCellDB bridges this gap by combining experimental data and computational predictions across hundreds of publicly available cell lines with multi-omics data.

"By consolidating these data in one place, CytoCellDB lets researchers study how chromosomal abnormalities and ecDNA influence key cellular processes," Brunk said. "The database includes detailed information on 577 cell lines, expanding available ecDNA data by more than 400%."

The researchers used CytoCellDB with the Broad Institute's Dependency Map data to analyze gene expression, gene dependency and drug response in cell lines with and without ecDNA. The resource also improves machine learning algorithms that predict ecDNA from sequencing data, achieving more than 85% accuracy, the highest to date.

"Understanding the impact of ecDNA is an urgent, unmet need that will transform how we analyze genomics data, develop drug screens, and study drug resistance," Brunk said. "This project's success reflects the collaboration of undergraduates, graduate students and senior scientists across disciplines."

By expanding knowledge of ecDNA, CytoCellDB offers a foundation for studying genome function, cancer cell fitness, therapeutic response and drug resistance. "CytoCellDB represents the most comprehensive cytogenetic resource for cancer cell lines," Brunk said. "It provides a foundation for groundbreaking research and future therapeutic innovation."

PRIORITY 2: DEVELOPING NOVEL THERAPEUTICS

Priming the pump for new cancer treatments

Cancer genes and tumors can evolve to resist treatment, making the ongoing discovery of new therapies essential in the fight against cancer. UNC Eshelman School of Pharmacy's Chemical Biology and Medicinal Chemistry Division is a central hub for cancer therapeutics. Its faculty — more than half are UNC Lineberger members — are studying the chemical and biological mechanisms that promote cancer growth and persistence.

DAVIS

"We need better therapies," said **Ian Davis, MD, PhD,** the Stuart H. Gold Distinguished Professor and chief of the Division of Pediatric Hematology-Oncology. "We need to prime the pump with fundamental discoveries and then keep our foot on the gas to keep them moving forward in the pipeline toward clinical trials."

UCRF resources are vital to this work. The Fund helps support the Center for Integrative Chemical Biology and Drug Discovery at UNC, where staff members make proteins and help with compound management for multiple research labs. The UCRF also helped acquire some of the technologies in UNC's high-throughput sequencing core, including state-of-the-art liquid handling platforms and genetic sequencers that are key resources for data-intensive research.

These technologies are used to read the genetic information in cancer cells for UNC and for outside research institutions, said **Samantha Pattenden, PhD,** associate professor of chemical biology and medicinal chemistry and the sequencing core's managing director. She and Davis are using the sequencers as part of their longstanding collaboration on Ewing sarcoma, a rare but aggressive cancer that mostly affects bones and tissue of children and teenagers. Surgery, chemotherapy and radiation are standard in the treatment of Ewing sarcoma. But chemotherapy's toxic side effects are significant, and Ewing sarcoma often becomes resistant to treatment, leading to low survival rates.

PATTENDEN

Davis and Pattenden have invented an accelerated screening process that can simultaneously test thousands of potential compounds for efficacy against Ewing sarcoma. As part of the National Cancer Institute's Experimental Therapeutics Program, and in collaboration with the National Center for Advancing Translational Studies, they are using this process on more than 120,000 molecules to identify compounds that affect the way that proteins and DNA interact, a key factor in Ewing sarcoma.

The main protein that drives Ewing sarcoma, EWS-FLI1, is hard to directly target with drugs, so studies seek to indirectly counteract its activity. Davis and Pattenden take advantage of the precise pattern of how DNA tightly or loosely interacts with proteins, a feature called chromatin accessibility. EWS-FLI1 fuels cancer growth by creating a characteristic pattern in DNA-protein interactions.

"Since we can't target the oncoprotein, we are targeting chromatin accessibility," Pattenden said, adding that compounds that show potential will undergo further study. "If we find a compound that closes the gap, we have a winner."

DREWRY

The Davis lab also collaborates with the lab of **David Drewry, PhD,** professor at UNC Eshelman, to develop a compound that could activate destruction of the EWS-FLI1 protein in the tumor cells. Taking a related approach, UNC Lineberger researchers are taking advantage of another potential weakness in Ewing sarcoma's armor: ETV6, a protein that plays a role in cancer growth. **Pengda Liu, PhD,** associate professor of biochemistry and biophysics, and colleagues used custom-made DNA strands to develop a molecule that degrades ETV6 and suppresses Ewing sarcoma growth. Further studies will examine their molecule's potential against other ETV6-driven cancers, such as leukemia and lymphoma.

LIU

NSD2, another cancer-driving protein, is implicated in several cancer types including pancreatic cancer, prostate cancer and multiple myeloma. **Lindsey James, PhD,** associate professor of chemical biology and medicinal chemistry, and colleagues have developed a promising new compound called UNC8732 that effectively degrades this protein, suppresses cancer cell growth, induces cell death and, in certain contexts, reverses drug resistance.

JAMES

Protein degradation is a natural cellular process that breaks down damaged or misfolded proteins. Researchers used UNC8732 to hijack this process to enable degradation of NSD2 by recruiting a protein called FBXO22, an E3 ligase used to mark NSD2 for degradation.

Most protein degraders use two E3 ligases called VHL and CRBN, which somewhat limits the scope of protein degradation because some cancer cells don't express these E3 ligases. UNC8732 is the first compound to recruit the FBXO22 E3 ligase, offering potential for more types of oncoproteins to be degraded.

"The more E3 ligases we know how to recruit, the more broadly applicable this therapeutic strategy is going to be, and the more cancer targets we can go after," James said. "We are excited that companies have been inspired by our work and are using their vast resources to take what we've learned and move it closer to the clinic."

Through the discovery of new cancer dependencies that can be therapeutically exploited, supporting critical equipment and technology, and fueling collaborations, UCRF helps open the spigot of new and innovative treatments for cancer.

Immunotherapy and targeted therapy combination proves effective against metastatic colorectal cancer

UNC Lineberger researchers have demonstrated that combining two immunotherapy drugs with a targeted therapy drug proved effective in treating the most common form of metastatic colorectal cancer. In some cases, it produced a durable response, even in patients whose cancer had spread to the liver. Their findings were published in JCO Oncology Advances.

Hanna Sanoff, MD, MPH, professor of medicine and gastrointestinal cancer section chief at UNC School of Medicine, is the study's corresponding author. **Ashwin Somasundaram, MD,** assistant professor of medicine, is the first author.

SANOFF

SOMASUNDARAM

"Our research provides the rationale for better combination trials in the future for our many patients with colorectal cancer," Sanoff said. "We hope some of these studies can keep their disease at bay for many years."

In the Phase 2 clinical trial, researchers enrolled 56 patients to evaluate whether a three-drug regimen — ipilimumab, nivolumab, and panitumumab — would be effective against microsatellite stable metastatic colorectal cancer. The primary goal was to assess overall response to treatment after 12 weeks.

The combination therapy shrank the tumors in 32.1% (18 of 56) patients and produced a median survival of 17.4 months. Four patients, including two with liver metastases, experienced no cancer progression nearly 44 months after starting the trial. Seven withdrew from the study after their cancer progressed.

"Even patients with liver metastatic disease, which traditionally have not had durable responses, responded well to the intervention," Somasundaram said. "This is a really promising sign that this combination might be more effective than immunotherapy combinations alone."

Panitumumab, a monoclonal antibody that targets and blocks EGFR, a cellular growth protein, has been the standard therapy for microsatellite stable metastatic colorectal cancer. Unfortunately, it has been only modestly effective when used alone. However, tumors responding to EGFR inhibitors have increased T-cell infiltration and higher levels of CTLA-4 and PD-L1, immune checkpoint proteins.

Prior studies have shown that CTLA-4 and PD-L1 prevent the immune system from overreacting and targeting healthy tissues. These proteins can also disrupt immune T-cells from attacking cancer cells. Ipilimumab and nivolumab block CTLA-4 and PD-L1, respectively, releasing the immune system's "brakes" and enabling T-cells to target cancer cells.

Somasundaram and his colleagues hypothesized that combining panitumumab with ipilimumab and nivolumab would be an effective treatment regimen. Findings from their trial support the hypothesis.

"Most patients with this disease do not experience responses that last for years," Somasundaram said. "But our study showed that a small number did — and without this approach, they likely would not have had that benefit. These findings support further studies using similar combinations across the country."

Combination immunotherapy before surgery may increase survival in people with head and neck cancer

Researchers conducting a clinical trial of immunotherapy drugs for head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two immunotherapies than to a single drug. The scientists also analyzed immune cells in each person's tumor after one month of treatment to see which were activated to fight cancer, suggesting these cells and targets could help personalize therapy.

The findings were published in Cancer Cell.

HNSCCs, which develop in the oral cavity, pharynx, larynx, nasal cavity and salivary glands, are the seventh most common cancer worldwide, causing an estimated 890,000 new cases and 450,000 deaths annually.

Current treatments can be disfiguring and affect quality of life. Shrinking tumors before surgery increases the likelihood of preserving the tongue and voice box, which are essential for speaking, breathing, and swallowing.

"My group has conducted pre-operative trials in head and neck cancers for more than 15 years, and the ability to shrink tumors with existing drugs has been disappointing. While single-drug immunotherapy can help, it works for only a small number of patients," said Robert L. Ferris, MD, PhD, executive director of UNC Lineberger and chief of oncology clinical services for UNC Health.

"In our trial, we compared two immunotherapy combinations with a single drug and found that both combinations doubled or tripled the response rate and improved survival. Up to one-third of patients who received two drugs saw more than 50% tumor shrinkage after just one month of treatment."

Ferris began the research at UPMC Hillman Cancer Center in Pittsburgh and completed it after joining UNC Lineberger and UNC Health in June 2024.

The study enrolled 42 patients (one withdrew) who were randomly assigned to three treatment arms: nivolumab alone, nivolumab plus ipilimumab, or nivolumab plus relatlimab. Both combinations performed similarly, likely by activating tumor-specific T lymphocytes that recognize and attack cancer cells. Even after tumor removal, these T cells remained active, providing ongoing immune surveillance that may improve long-term survival.

"We identified biological signatures that helped determine which combination was most effective," Ferris said. "The Lymphocyte Activation Gene-3 (LAG-3) protein was a good marker for some patients, while CTLA-4 was for others. A patient's immune profile at diagnosis could help guide the best treatment. Because of this marker's potential, we have filed a patent for our diagnostic approach."

Based on the similar success of both combinations, the team has expanded the trial to include 40 additional patients and is testing a higher dose of relatlimab, aiming for stronger responses and longer survival.

PRIORITY 3: OUTCOMES

Building tools to help doctors better track patient symptoms, improve outcomes

Digital reporting technologies created by UNC Lineberger researchers are now being used in North Carolina and across the country to improve care and outcomes for cancer patients.

Research led by **Ethan Basch, MD, MSc, FASCO,** the Richard M. Goldberg Distinguished Professor in Medical Oncology, chief of oncology at UNC School of Medicine and co-leader of UNC Lineberger's Cancer Prevention and Control

BASCH

Research Program, sparked the creation of electronic patient-reported outcomes (PRO) tools that patients can use at home to self-report on symptoms and side effects.

Work by his research team over more than 20 years has led to changes in how the FDA advises pharmaceutical companies to study drugs, how data systems in hospitals function and how billing codes are used in cancer care clinics — all have become more patient centered, which is the mission of Basch and his team.

Their early studies showed that cancer patients often suffer from symptoms and side effects between doctors' visits that go undetected and under-addressed. To remedy this, Basch and his colleagues, with support from the UCRF and other funding sources, built new digital tools to collect symptom and side-effect information directly from patients, and then to convey concerning patient-reported symptoms to care teams to prompt timely management.

They developed these tools here in North Carolina and then tested them nationally in 52 community oncology practices across 26 states and found they improved clinicians' awareness of patient symptoms and accelerated care — leading to better symptom control, improved quality of life, fewer hospitalizations and even longer survival for cancer patients.

PRO tools based directly on the UNC work are now widely available in both the United States and Europe through electronic health record systems like Epic and are being used in global clinical trials to develop new cancer drugs in a more patient-centered way. In recognition of their work, Basch and his UNC Lineberger colleagues received the prestigious 2025 Clinical Innovation Award from the medical information platform Healio and City of Hope, one of the nation's largest cancer care and research organizations.

"Patients experience many of their side effects between visits. Using electronic tools so we can understand how they are feeling and intervene quickly when needed is becoming a standard of care in high-quality cancer care," Basch said. "It is gratifying to see the impact of our work here at UNC. There are multiple researchers here focused on ways to make cancer care more focused on the patient and their family, which is one of the striking qualities of research at UNC and support from the UCRF."

To make these resources more widely available, UNC Lineberger is now leading a national initiative called OncoPRO to provide health systems with training guidance, patient education materials, knowledge on billing codes and technical support. Through this program, and in partnership with the American Society of Clinical Oncology and the American Cancer Society, more than 20 health systems around the country — including UNC Health, East Carolina University, Wake Forest University and Duke University — are implementing PROs, with more coming online this year.

"It's an exciting time for PROs," Basch said, "and UNC is leading the way."

Home testing kits and coordinated outreach substantially improve colorectal cancer screening rates

A new study by UNC Lineberger researchers found that mailing at-home colorectal cancer screening kits and coordinating follow-up care tripled screening rates among patients at federally qualified health centers (FQHCs). Findings were published in JAMA Network Open.

Colorectal cancer screening is a proven way to detect the disease early, when it's most treatable, but remains underused among patients served by FQHCs, which provide care to 1 in 11 people in the United States. These small, grant-funded centers often face resource challenges that limit access to preventive services.

"Reaching a largely unscreened, predominantly low-income population using centralized mailed screening kits and patient navigation can substantially increase colorectal cancer screening in federally qualified health centers," said the study's corresponding author, **Daniel Reuland, MD, MPH,** the Robert A. Ingram Distinguished Professor at UNC School of Medicine and co-director of the UNC Lineberger Carolina Cancer Screening Initiative (CCSI).

REULAND

The Scaling Colorectal Cancer Screening through Outreach, Referral and Engagement (SCORE) study enrolled 4,002 adults aged 50–75 who were not current with screening guidelines at two North Carolina FQHCs: Blue Ridge Health in Hendersonville and Roanoke Chowan Community Health Center in Ahoskie.

Half of the participants received usual care. The other half received usual care plus a mailed fecal immunochemical test (FIT) kit and navigation services for follow-up colonoscopy if the FIT was positive.

Within six months, 30% of participants in the intervention group completed screening, compared with 9.7% in the control group. By 12 months, completion rates rose to 34.6% vs. 16.6%. Among those with a positive FIT, 68.8% of the intervention group completed a colonoscopy, compared with 44.4% of the control group.

"Mailed FIT is an excellent complement to usual care," said **Alison Brenner, PhD, MPH,** CCSI deputy director and associate professor of medicine. "It reaches patients who aren't getting screened otherwise and relieves pressure on both under-resourced FQHCs and busy primary care providers."

BRENNER

Colorectal cancer is the second-leading cause of cancer death in the United States. The National Cancer Institute estimates 152,000 new diagnoses and 53,000 deaths this year. While rates are declining among older adults, incidence and mortality in people under 50 have been rising since 1990.

Reuland said the next step is to assess program costs and explore statewide expansion. "FIT testing is inexpensive, so this approach could be a cost-effective way to improve screening at the population level," he said. "We're also working with North Carolina Medicaid to explore how a FIT-based outreach strategy could help expand screening while making the best use of limited colonoscopy capacity."

E-cigarette warnings lower vaping interest and raise quit intentions

Electronic-cigarette warnings are effective in discouraging vaping, with harm-specific warnings generally more effective than warnings about addiction, according to a meta-analysis of 24 studies conducted by UNC Lineberger researchers and their colleagues. The researchers also found no unintended negative consequences of e-cigarette warnings, such as encouraging people to smoke cigarettes instead

of vaping. The results were published in JAMA Internal Medicine.

NOAR

"This is the first meta-analysis that has tested the effectiveness of e-cigarette warnings that appear on packages and advertising," said **Seth M. Noar, PhD,** the James Howard and Hallie McLean Parker Distinguished Professor and director of the Communicating for Health Impact Lab at the Hussman School of Journalism and Media. "The results are very promising and highlight the importance of communicating the risks and harms of e-cigarette use to tobacco users and to the public."

The U.S. Food and Drug Administration mandates only a single addiction warning on vaping products. The authors note that effective warning policies should use multiple, rotating warnings, since tobacco product use can result in more than a single harm. Countries such as Canada have rotating warnings on advertising, including a health harms warning on e-cigarette products that states, "WARNING: Vaping products release chemicals that may harm your health."

The warnings examined in this analysis were published in studies between 2007 and 2024 and used text only.

JANG

"Part of the novelty of our findings is that we found that warnings that use only text can serve an important role in informing about tobacco product risk for e-cigarettes," said **Youjin Jang, PhD,** a postdoctoral researcher in Noar's lab and first author of the article. "Expanding text-only warnings on packages and advertisements to include potential health hazards and harms of using e-cigarettes — such as exposure to harmful chemicals — is the next important step for e-cigarette warning policies."

The researchers found that, compared to the control group, e-cigarette warnings increased the perceptions of vaping as both harmful and addictive. Health harm warnings had a greater impact than addiction warnings on most measures, including intentions to quit vaping.

"A crucial finding of this meta-analysis is that these warnings do not increase the false belief that e-cigarettes are more harmful than cigarettes," Noar said. "This is profoundly important because we want these warnings to discourage use without creating misperceptions about tobacco product risk."

FACULTY IMPACT: RESEARCH AND SCIENCE

ARPA-H funding supports adaptive clinical trial for metastatic breast cancer

UNC Lineberger Comprehensive Cancer Center has received up to $28 million from the Advanced Research Projects Agency for Health (ARPA-H) to lead a next-generation clinical trial for metastatic breast cancer. The study will use real-time data to track how tumors evolve and adjust treatment accordingly.

The Translational Breast Cancer Research Consortium (TBCRC) Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) will draw on the expertise of UNC Lineberger and 14 other TBCRC member institutions — National Cancer Institute-designated centers committed to accelerating lab discoveries into new treatments.

CAREY

Lisa Carey, MD, ScM, FASCO, the L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research and UNC Lineberger's deputy director of clinical science, is the study's lead investigator.

"Despite progress in breast cancer treatment, we still lack curative therapies for metastatic disease," Carey said. "EVOLVE takes a new approach by using real-time biomarker data to adapt treatment as the tumor changes."

The trial will enroll up to 700 patients with metastatic breast cancer. Researchers will analyze tumor biopsies, blood samples, imaging, and medical records, along with circulating tumor DNA (ctDNA), to detect resistance and guide therapy in real time.

EVOLVE is part of ARPA-H's $142 million Advanced Analysis for Precision Cancer Therapy (ADAPT) program, which funds 10 projects aimed at transforming personalized cancer care. ADAPT's goals include integrating diverse patient data to predict drug response, designing adaptive clinical trials and creating a shared research platform for real-time collaboration.

"We don't yet have strong predictive biomarkers for metastatic breast cancer, and we've largely failed to combine genomic, clinical and imaging data in a meaningful way," Carey said. "This trial will let us intervene earlier — before symptoms return — to give patients more time and better quality of life."

Advanced Cellular Therapeutics Facility earns accreditation

The Foundation for the Accreditation of Cellular Therapy (FACT) awarded accreditation without any deficiency citations to UNC Lineberger's Advanced Cellular Therapeutics Facility.

The cancer center established the Advanced Cellular Therapeutics Facility in 2015 to support clinical trials requiring human cellular therapy products. Cellular therapy products are generated and expanded in this facility for patients receiving adoptive cell therapy for the treatment of cancer, including chimeric antigen receptor T-cell, or CAR-T, therapy.

SERODY

"Earning FACT accreditation is a major milestone for any manufacturing facility and underscores our commitment to the highest standards in cellular therapy," said **Jonathan Serody, MD,** the Elizabeth Thomas Professor of Medicine, Microbiology and Immunology and chief of the Division of Hematology at UNC School of Medicine. "This recognition reflects the

dedication of our faculty and staff, as well as the rigor of our processes and procedures, which meet or exceed FACT's stringent standards and governmental regulations."

This was the first time the Advanced Cellular Therapeutics Facility underwent FACT review. "Achieving accreditation without a single issue identified by FACT inspectors is an extraordinary accomplishment," Serody said. "It's a testament to the outstanding work of our team and our unwavering commitment to providing the highest quality of care to our patients."

Cancer center members recognized for highly cited research

Eight UNC Lineberger members published some of the most influential scientific papers during the past decade, according to an independent analysis.

Clarivate's 2024 Highly Cited Researchers™ list recognizes scientists from 59 countries and regions who published papers ranked in the top 1% of cited publications in their field between 2013–2023. UNC-Chapel Hill ranked 35th among universities worldwide, with 33 faculty named to the list.

UNC Lineberger members named to the 2024 Highly Cited Researchers list are:

- **Noel T. Brewer, PhD**
- **Gianpietro Dotti, MD**
- **Katherine A. Hoadley, PhD**
- **Barry M. Popkin, PhD, MS**
- **Scott Randell, PhD**
- **Bryan L. Roth, MD, PhD**
- **Jenny P.Y. Ting, PhD**
- **David van Duin, MD, PhD**


BREWER


DOTTI


HOADLEY


POPKIN


RANDELL


ROTH


TING


VAN DUIN

FACULTY IMPACT: RESEARCH AND SCIENCE

Troester elected chair of the AACR Populations Sciences Working Group

Melissa Troester, PhD, MPH, was elected the next chair of the American Association for Cancer Research Populations Sciences Working Group.

TROESTER

She will serve as chair-elect for the 2025–2026 term and will assume the role of chair for the 2026–2028 term at the 2026 AACR Annual Meeting.

"During a time of scientific flux, it is both a privilege and an important responsibility to help set the collaborative agenda for AACR population sciences research," said Troester, associate director of the UNC Lineberger Population Sciences Program, professor of epidemiology at UNC Gillings School of Global Public Health and a professor of pathology and laboratory medicine at UNC School of Medicine. "Ensuring that all cancer patients receive optimized prevention and treatment must be an enduring priority."

Rushing receives NCI grant to create the Human Cancer Metabolome Atlas

Blake Rushing, PhD, was awarded a five-year, $3.9 million National Cancer Institute grant to support the development of the Human Cancer Metabolome Atlas. The project aims to map the complex metabolic processes that drive cancer's progression and resistance to treatment.

RUSHING

The Human Cancer Metabolome Atlas will catalog how cancer cells alter their metabolism to survive and thrive. Previous research has shown there can be significant metabolic diversity among tumors, even within the same diagnosis. This detailed metabolic profile of various cancers will help researchers identify new targets for therapies and improve the understanding of cancer biology.

"This goal of this research is to undertake a large-scale, pan-cancer metabolomics analysis and then generate a publicly available resource that all cancer researchers can use to study the landscape of tumor metabolism," said Rushing, assistant professor of nutrition and pathology and laboratory medicine. "Cancer metabolism has gained tremendous traction as a source of potential therapeutic targets. The Human Cancer Metabolome Atlas will help to identify these targets, the subpopulations of individuals who would best respond to these approaches and potentially lead to more effective treatments and ultimately improve outcomes for individuals with cancer."

UNC team awarded federal funding to harness data science for faster, more precise cancer care

A team of UNC-Chapel Hill researchers has been awarded up to $10 million in Advanced Research Projects Agency for Health (ARPA-H) funding to develop the Cancer Identification and Precision Oncology Center (CIPOC). The project is designed to improve cancer diagnosis and support personalized treatments by quickly aggregating and analyzing a wide range of health data, including electronic health records, histopathological and radiological images, insurance claims and geographic information.

Specifically, CIPOC will facilitate the development of an oncology health learning system that utilizes AI-ready data to generate real-time

identification of new cancer cases, support patient recruitment for research, recommend precision cancer care, and help improve cancer care equity and quality. It also will create an accessible, adaptable system for health providers across diverse locations and resources.

The project is led by four principal investigators across Carolina:

- **Ashok Krishnamurthy, PhD,** director of the Renaissance Computing Institute (RENCI) and data science core lead.
- **Jennifer Elston Lafata, PhD,** professor in the Division of Pharmaceutical Outcomes and Policy at UNC Eshelman School of Pharmacy and innovation and optimization partners lead.
- **Caroline Thompson, PhD, MPH,** associate professor of epidemiology at UNC Gillings School of Global Public Health and rapid identification core lead.
- **Melissa Troester, PhD, MPH,** professor of epidemiology at UNC Gillings and precision oncology core lead.

The project will organize and facilitate collaborative research conducted by faculty, staff and trainees from more than 12 schools, centers, departments and programs at UNC-Chapel Hill with a shared vision to create cutting-edge data tools researchers and practitioners can use at UNC — and in time across North Carolina and the United States — to improve the diagnosis and treatment of cancer.

"While precision oncology has made major advances in recent years, translation of these innovations to practice has lagged behind, as has our ability to monitor, track, and therefore understand and plan for needed cancer-related services," Thompson said. "By accelerating the identification of cancer cases and developing innovative informatics tools to make improved, precision recommendations for care, this project can advance the provision of equitable care services and delivery."


KRISHNAMURTHY


LAFATA


THOMPSON


TROESTER

Marks to receive the American Society for Therapeutic Radiology and Oncology's highest honor


MARKS

The American Society for Therapeutic Radiology and Oncology (ASTRO) presented its highest honor — the Gold Medal — to **Lawrence B. Marks, MD, FASTRO.** The Gold Medal recognizes individuals who have made outstanding contributions to the field of radiation oncology through research, clinical care, teaching and service.

Marks is the Sidney K. Simon Distinguished Professor of Oncology Research at UNC School of Medicine. He chaired the Department of

Radiation Oncology from 2009 to 2023, leading a period of significant growth and innovation.

"I'm indebted to my wonderful mentors, colleagues, trainees, friends and family who have assisted me in my career," Marks said. "It is a great privilege to be able to combine my interests in physics, math and engineering to help people with serious diseases such as cancer."

During his tenure, Marks spearheaded the creation of the Division of Healthcare Engineering, which applies lean management principles, behavioral science and systems engineering to improve the efficiency, safety and quality of radiation therapy. The department also expanded its clinical footprint, providing radiation oncology services at nine UNC Health locations across North Carolina.

DOD grant funds AI tool linking pancreatic cancer patients to clinical trials

Naim Rashid, PhD, assistant professor of biostatistics at UNC Gillings School of Global Public Health, received a two-year, $311,000 Department of Defense Pancreatic Cancer Research Program award to develop an artificial intelligence (AI) tool that provides personalized clinical trial recommendations for patients with pancreatic ductal adenocarcinoma (PDAC).

RASHID

Using data from PDAC patients treated at UNC Health, Rashid will link patient information to listings on ClinicalTrials.gov to build an AI-powered system that helps patients identify and discuss relevant trials with their care teams. The goal is to improve awareness and access and boost enrollment in pancreatic cancer trials.

While new treatments from clinical trials have doubled the five-year survival rate for pancreatic cancer over the past two decades, many patients still face barriers to trial access. The growing number and complexity of PDAC trials make it increasingly difficult for patients and physicians to find suitable options.

Rashid's team will fine-tune a large language model using UNC patient data and trial listings to create a personalized recommendation system that functions like an AI chatbot. The tool will rank trials by relevance and integrate with a mobile health app to make the process simple and accessible for patients and providers.

"Our AI mHealth app aims to remove the guesswork from clinical trial searches, empowering PDAC patients to self-advocate and explore more opportunities for treatment," Rashid said. "In the future, we hope to expand this approach to other cancer types."

INFRASTRUCTURE AND SHARED RESOURCES

INFRASTRUCTURE AND SHARED RESOURCES

In addition to supporting the research and clinical work of UNC's cancer experts, the UCRF invests and underwrites critical core infrastructure and shared resources that benefit patients and health care providers across the state. Imaging, informatics and other research equipment and technology are essential tools for advancing cancer research and improving patient care. Virtual tumor boards, telemedicine, partnerships with health care providers, and robust community outreach and engagement efforts have helped UNC Lineberger serve patients and clinical practices in all 100 of North Carolina's counties.

Continuing education: Providing continuing education to health care professionals across the state is a significant part of UNC Lineberger's mission as an academic institution. The credits they earn can go toward re-licensure, re-certification and renewal of hospital privileges. The UNC Lineberger Cancer Network (UNCLCN), supported by the UCRF, allows UNC faculty to deliver live, interactive medical and nursing lectures that reach physicians, nurses and allied health professionals all over the state.

The Network is one of the major sources of continuing education for North Carolina oncology professionals. The lecture series enables practitioners to access timely, evidence-based oncology therapeutic updates from the convenience of their own practice. Between live webinars and self-paced, online courses through the Cancer Network, medical professionals earned more than 4,978 credit hours this year, including:

- 74 American Medical Association Continuing Medical Education credits;
- 3,559 American Nurses Credentialing Center credits;
- 339 American Society of Radiologic Technologist credits;
- 875 Accreditation Council for Pharmacy Education credits; and
- 131 Oncology Data Specialist credits.

Tumor boards: UCRF-funded infrastructure facilitates collaboration between UNC cancer experts and oncologists and patients across the state, through virtual "tumor boards" — in-depth reviews of a particular patient's case with a team of doctors — and consultations in specialties that are not available in rural communities. This year 803 virtual tumor boards, across 24 different disciplines, helped connect community-based medical professionals with UNC oncology experts and served as another source for continuing education.

INFRASTRUCTURE AND SHARED RESOURCES

Telehealth: UNC Lineberger uses the UCRF-supported telehealth network to connect with health care providers in real time to discuss best practices for patient care and cutting-edge research, and to hold community education events aiming to raise patient awareness of issues related to cancer. UNC Lineberger hosted 30 telehealth live webinars this year with more than 3,100 participants such as nurses, doctors, physician assistants, nurse practitioners, pharmacists, social workers, nutritionists and clinic managers in 45 oncology practices across the state.

To support care providers and caregivers, the UNCLCN assisted with 33 Palliative Care Grand Rounds lectures, which cover topics that impact the practice of palliative medicine, and 6 Schwartz Rounds, which focus on issues related to the emotional impacts of patient care.

These rounds, along with lectures, webinars and videos, are part of UNCLCN's video library, which contains 1,509 oncology videos, including 109 Patient Centered Care webinars, 104 Research to Practice webinars, 42 Advanced Practice Provider webinars, 12 Southeastern American Indian Cancer Health Equity Partnership webinars, 206 Palliative Care Grand Rounds, 233 Didactic Fellows Lectures, 51 Exploring Cancer Lectures, and 60 Introduction to the Pathology of Disease lectures. UNCLCN's YouTube channel contains more than 310 videos that are readily available to health professionals and to the public.

The UNCLCN also provided various levels of planning and support this year for numerous other activities, including but not limited to:

- Community College Oncology. A series of webinars and recordings created in coordination with the North Carolina Community College System;
- Exploring Cancer. A series of lectures and recordings created in coordination with North Carolina Central University (NCCU) and North Carolina Agricultural and Technical State University (N.C. A&T);
- Support and recording for three Southeastern American Indian Cancer Health Equity Partnership webinars in coordination with Duke Cancer Institute and Wake Forest School of Medicine; and
- The Pathology of Disease. A pathology course with classes taught online to students at N.C. A&T and NCCU.

Using real-world data to understand complicated issues tied to North Carolina cancer outcomes

In addition to the outreach and education activities the UCRF supports through the UNC Lineberger Cancer Network, its funding has been used to build and maintain vital foundational infrastructure for population-based research.

The Cancer Information & Population Health Resource (CIPHR) is a rich data resource that gives researchers and policymakers alike a deeper understanding of the complicated issues tied to North Carolina cancer outcomes. CIPHR integrates large data sets from multiple public and private sources, allowing researchers to analyze real-world information about real-world patients.

With information on 1.1 million cancer patients in the state, this unique research tool connects data on cancer incidence, mortality and burden in North Carolina to individual and aggregate data sources describing health care, economic, social, behavioral and environmental patterns. CIPHR is used in several population-based studies aiming to improve our understanding of cancer burdens across the state and to design interventions that help improve access and quality of cancer care.

1.1 million *Cancer cases, 2003–2021*

86% *Linked to claims data*

12.2 million *Claims data for NC residents between 2003–2021*

84 *Principal investigators*

172 *Projects*

175 *Manuscripts*

Recruitment and Retention



Total for all years: 431 | Recruitment: 350 | Retention: 81

Faculty Recruitment

Clinical Infrastructure

Yash Agrawal, MD
Assistant Professor
UNC School of Medicine
Department of Medicine
Breast cancer, genomics
University of North Carolina at Chapel Hill

Catherine Fahey, MD
Assistant Professor
UNC School of Medicine
Department of Medicine
GU/renal cell cancers
Vanderbilt University

Laura Ferris, MD, PhD
UNC School of Medicine
Chair and Clayton E. Wheeler, Jr.
Distinguished Professor
Department of Dermatology
Melanoma, clinical trials
University of Pittsburgh

Jose Martinez, MD, PhD
Assistant Professor
UNC School of Medicine
Department of Medicine
Leukemia, RNA splicing in cancer
University of North Carolina at Chapel Hill

INFRASTRUCTURE AND SHARED RESOURCES

Developing New Treatments

Felicia Cao, MD, PhD
Assistant Professor
UNC School of Medicine
Department of Medicine
Solid tumor CAR-T therapy
University of North Carolina at Chapel Hill

Robert Ferris, MD, PhD
Executive Director of UNC Lineberger
Chief of Oncology Clinical Services for UNC Health
UNC School of Medicine
Department of Otolaryngology/Head
& Neck Surgery
Immunotherapy
University of Pittsburgh

Brent Hanks, MD, PhD
Associate Professor
UNC School of Medicine
Department of Medicine
Cancer immunology, melanoma, GI cancers
Duke University

Samuel Young, PhD
Professor
UNC School of Medicine
Department of Pediatrics/Genetics
& Metabolism
Gene Therapy Center
University of Iowa

Genomics

Michael Iglesia, MD, PhD
Associate Professor
UNC School of Medicine
Department of Medicine
GI cancers, bioinformatics, genetics
Washington University St. Louis

Opportunity

Jeremy Rich, MD, MHS, MBA
Professor
UNC School of Medicine
Department of Neurology/Neuro-Oncology
Neuro-oncology, glioblastoma, UNC Lineberger
Deputy Director
University of Pittsburgh

Tigist Tamir, PhD
Assistant Professor
UNC School of Medicine
Department of Biochemistry
& Biophysics, Nutrition
Cancer signaling, proteomics, metabolomics
Massachusetts Institute of Technology

Optimizing NC Outcomes

Tamryn Gray, PhD, RN, MPH, MSN
Assistant Professor
UNC School of Nursing
Department of Nursing
Cancer survivorship, palliative care
Dana-Farber/Brigham and Women's Hospital

Meghan O'Leary, PhD
Assistant Professor
UNC Gillings of Global Public Health
Department of Health Policy & Management
Health services, health outcomes
University of North Carolina at Chapel Hill

Kea Turner, PhD, MPH
Associate Professor
UNC School of Nursing
Department of Nursing
Cancer cachexia, nutrition
Moffitt Cancer Center

Faculty Retention

Genomics

William Kim, MD
Rush S. Dickson Distinguished Professor
of Medicine
UNC School of Medicine
Department of Medicine
Bladder cancer, genetics, therapy

Developing New Treatments

Jen Jen Yeh, MD
Professor and Assistant Dean for
Translational Research
UNC School of Medicine
Department of Surgery, Pharmacology
Surgical oncology, pancreatic cancer



BUDGET AND EXPENDITURE INFORMATION

BUDGET AND EXPENDITURE INFORMATION

When it was initially established in 2007, the UCRF had three sources of revenue: tobacco settlement funds, taxes on other (non-cigarette) tobacco products (OTP) such as snuff, and state appropriations. In the 2013–14 budget, the General Assembly consolidated all tobacco settlement funds into the State's General Fund, eliminating tobacco settlement funds as a source of UCRF support. As of July 1, 2024, the UCRF is supported by an annual appropriation from the North Carolina General Assembly.

This report and its charts reflect anticipated and actual revenue for Fiscal Year 2025, and the fund balance after considering carryover and expenditure.

Fiscal Year 2025 Anticipated and Actual Fund Revenue

Anticipated	**Amount***
State Appropriation	$59,520,000
Total	**$59,520,000**
Actual	
State Appropriation	$59,520,000
Actual OTP Tax Receipts	$0
Total	**$59,520,000**

* Rounded to the nearest dollar

Fiscal Year 2025 Budget and Expenditures

Anticipated Budget	**Amount***
Revenue	$59,520,000
Carryover from Fiscal Year 24	($14,876)
Total	**$59,505,124**
Actual Budget	
Revenue	$59,520,000
Carryover from Fiscal Year 24	($14,876)
Total	**$59,505,124**
Expenditures	$59,577,164
Balance	($72,040)

* Rounded to the nearest dollar

Restrictions on the Use of UCRF Monies

G.S. 116-29.1 established the UCRF as a special revenue fund and created the Cancer Research Fund Committee to provide accountability and oversight. As the Cancer Research Fund Committee developed the UCRF strategic plan, each potential use of UCRF resources was evaluated according to the following questions:

- Will it address North Carolina's needs in terms of the goal of reducing the cancer burden in the state?
- Can we be world class at it? (Does it build on existing strengths, and is there an opportunity to lead?)
- Is there a strong economic model/justification for UCRF investment?

Based on these questions, the Committee developed a clear set of rules to guide how UCRF funds would be best spent. The Committee determined that UCRF funds should focus major resources on a limited set of opportunities to have the greatest impact; fund initiatives where UNC has the opportunity to establish a leadership position; be self-sustaining and provide leverage for additional extramural funding; build fundamental cancer-related research capabilities that benefit UNC research programs; and enhance North Carolina's economy by creating jobs, intellectual property, and startup companies.

To maximize the effectiveness of the state's investment and to ensure wise and responsible use of the funding, the strategic plan imposed additional restrictions on the use of these funds, instructing that UCRF funds should not:

- Invest broadly in an effort to make incremental improvements everywhere;
- Provide funding that would limit future flexibility;
- Undermine faculty innovation and competitiveness by eliminating the need for extramural grant funding;
- Substitute for existing university or health system funding or new philanthropy;
- Make expenditures based upon institutional or other needs outside cancer research; or
- Negatively impact other research on campus, for example by appropriating shared research infrastructure or resources.

Conclusion

The University Cancer Research Fund is a nation-leading investment whose positive impacts have grown every year since its creation in 2007. As this report demonstrates, the UCRF continues to benefit North Carolina by creating jobs, generating outside grant funds and tax revenues, and sustaining vital resources that help UNC Lineberger serve patients in all 100 counties and continue as a global leader in advancing cancer research and care.

The UCRF lays a strong foundation for the patient-centered clinical work and innovative research of our world-class cancer experts, not to mention their partnerships with health care providers and communities statewide — for the ultimate benefit of patients and families affected by cancer both throughout and beyond North Carolina. On behalf of those patients and families, and the researchers and clinicians who serve them, thank you for your continued support of this incredible investment.



APPENDIX

CANCER RESEARCH FUND COMMITTEE

The legislatively established Cancer Research Fund Committee oversees the University Cancer Research Fund and is chaired by Lee Roberts, chancellor of the University of North Carolina at Chapel Hill. The seven-member committee, which includes five ex-officio members designated by the legislation, elects two at-large members. The at-large members are to be leaders at nationally prominent cancer programs. Currently, the two are Edward Benz, MD, (president and CEO emeritus, Dana-Farber Cancer Institute) and Gary Gilliland, MD, PhD (president and director emeritus, Fred Hutchinson Cancer Center).

Lee H. Roberts
Chair
Chancellor
The University of North Carolina at Chapel Hill



Edward J. Benz, MD
President and Chief Executive Officer, Emeritus
Dana-Farber Cancer Institute



A. Wesley Burks, MD, MPH
Dean, UNC School of Medicine
CEO, UNC Health
The University of North Carolina at Chapel Hill



Robert Ferris, MD, PhD
Executive Director
UNC Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill



Gary Gilliland, MD, PhD
President and Director Emeritus
Fred Hutchinson Cancer Center

Angela Kashuba, BScPhm, PharmD, DABCP, FCP
Dean
UNC Eshelman School of Pharmacy
The University of North Carolina at Chapel Hill

Nancy Messonnier, MD
Dean
UNC Gillings School of Global Public Health
The University of North Carolina at Chapel Hill

APPENDIX

ESTABLISHING LEGISLATION

§ 116-29.1. University Cancer Research Fund (as modified by SL 2013-360)

(a) Fund. – The University Cancer Research Fund is established as a special revenue fund in the Office of the President of The University of North Carolina. Allocations from the fund shall be made in the discretion of the Cancer Research Fund Committee and shall be used only for the purpose of cancer research under UNC Hospitals, the Lineberger Comprehensive Cancer Center, or both.

(b) Effective July 1 of each calendar year, the funds remitted to the University Cancer Research Fund by the Secretary of Revenue from the tax on tobacco products other than cigarettes pursuant to G.S. 105 113.40A is appropriated for this purpose are appropriated for this purpose.

(c) Cancer Research Fund Committee. – The Cancer Research Fund Committee shall consist of five ex officio members and two appointed members. The five ex officio members shall consist of the following: (i) one member shall be the Chancellor of the University of North Carolina at Chapel Hill, (ii) one member shall be the Director of the Lineberger Comprehensive Cancer Center, (iii) one member shall be the Dean of the School of Medicine at The University of North Carolina, (iv) one member shall be the Dean of the School of Pharmacy at The University of North Carolina, and (v) one member shall be the Dean of the School of Public Health at The University of North Carolina. The remaining two members shall be appointed by a majority vote of the standing members of the Committee and shall be selected from persons holding a leadership position in a nationally prominent cancer program. If any of the specified positions cease to exist, then the successor position shall be deemed to be substituted in the place of the former one, and the person holding the successor position shall become an ex officio member of the Committee.

(d) Chair. – The chair shall be the Chancellor of the University of North Carolina at Chapel Hill.

(e) Quorum. – A majority of the members shall constitute a quorum for the transaction of business.

(f) Meetings. – The Committee shall meet at least once in each quarter and may hold special meetings at any time and place at the call of the chair or upon the written request of at least a majority of its members. (2007-323, s. 6.23(b); 2009-451, s. 27A.5(e); 2010-31, s. 9.12.)

(g) Report. – By November 1 of each year, the Cancer Research Fund Committee shall provide to the Joint Legislative Education Oversight Committee and to the Office of State Budget and Management an annual financial report which shall include the following components:

(1) Accounting of expenditures of State funds related to strategic initiatives, development of infrastructure, and ongoing administrative functions.

(2) Accounting of expenditures of extramural funds related to strategic initiatives, development of infrastructure, and ongoing administrative functions.

(3) Measures of impact to the State's economy in the creation of jobs, intellectual property, and start-up companies.

(4) Other performance measures directly related to the investment of State funds.

(5) Accounting of any fund balances retained by the Fund, along with information about any restrictions on the use of these funds.

UNC | LINEBERGER COMPREHENSIVE CANCER CENTER

THE ECONOMIC IMPACT OF UNIVERSITY CANCER RESEARCH FUND

Current economic, employment, government revenue, and generated research funds that assist with the recruiting and retaining of local research talent due to the UCRF at University of North Carolina Lineberger Comprehensive Cancer Center



EXECUTIVE SUMMARY

In 2007, North Carolina's state leaders established the University Cancer Research Fund (UCRF) to support and advance cancer research at the UNC Lineberger Comprehensive Cancer Center. The initial $25 million investment has grown to **$59.5 million** in FY 2025, and according to an analysis by Tripp Umbach, this year's funding alone played a key role in generating **$807.7 million** in economic impact. This sustained support has fueled innovation in cancer detection, treatment, and prevention—positioning UNC Lineberger as one of the nation's leading public comprehensive cancer centers.

UNC Lineberger is one of only 57 National Cancer Institute–designated comprehensive cancer centers and the only public cancer center in North Carolina. It serves as a leading hub for groundbreaking research and clinical care, bringing together some of the country's top physicians and scientists to advance prevention, early detection, and treatment strategies. From lab research to clinical trials to community outreach, UNC Lineberger faculty are driving discoveries that shape the future of cancer care. Investment in the UCRF ensures that North Carolinians have access to world-class treatments while reinforcing the state's long-term commitment to public health.

The UCRF's strength lies in its focus on people and collaboration. The fund supports talented researchers and expert clinicians whose work translates into real-world treatments and cures. At UNC-Chapel Hill, collaboration is embedded in the culture—both across disciplines within the university and with external partners—helping transform research discoveries into tangible progress against cancer.

Beyond advancing cancer science and care, the UCRF generates broad economic benefits. It drives job creation, supports North Carolina's biomedical sector, and multiplies dollars throughout the state's economy. This report highlights both the current-year impact of UCRF investments and the cumulative benefits since the fund's inception, including expanding the state economy, creating jobs, generating tax revenue, fostering scientific collaboration, and attracting federal research dollars. Together, these investments strengthen North Carolina's position as a national leader in biomedical research and innovation, while enhancing the health and well-being of its residents.

KEY FINDINGS



EXPANDING THE STATE'S ECONOMY

In FY 2025, the UCRF generated a total economic impact of **$807.7 million** in North Carolina. This impact includes direct spending of more than $407.9 million within the state, with a significant portion of this amount coming from national grants secured through research activities, totaling $253.7 million. The ripple effect of this in-state spending contributed an additional $399.8 million in economic activity, reflecting the downstream spending by employees, vendors, and contractors involved with the UCRF. These economic benefits extend far beyond the initial investments, driving growth across multiple sectors and enhancing the state's overall financial landscape.

CREATING JOBS

The UCRF has been a critical driver of employment in North Carolina, directly supporting 1,556 jobs in FY 2025. Beyond this, the indirect and induced impacts of those jobs, as well as the spending generated by the UCRF, contributed to the creation of an additional 2,312 jobs across the state. In total, the fund supported **3,868 jobs** in FY 2025, spanning sectors such as healthcare, research, construction, and administrative services. The employment opportunities generated by the UCRF have not only strengthened the state's workforce but also fostered professional growth and skill development in North Carolina's biomedical sector.

GENERATING TAX REVENUE

In addition to job creation and economic growth, the UCRF provided significant fiscal benefits to the state. Tripp Umbach estimates that the UCRF generated **$25.4 million** in local and state tax revenue in FY 2025. This tax revenue helps fund essential public services, including education, infrastructure, and healthcare, reinforcing the long-term value of the UCRF's economic contributions to North Carolina.

ENCOURAGING SCIENTIFIC COLLABORATION AND LEVERAGING FEDERAL RESEARCH FUNDS

One of the UCRF's most profound impacts has been its ability to foster scientific collaboration and attract competitive federal research funding. By encouraging recipient institutions to work together, the UCRF has enabled researchers to secure highly competitive federal grants. In FY 2025 alone, UCRF recipients leveraged **$210.8 million** in federal research grants, contributing to more than **$253.7 million** in external funding. This level of success would not have been possible without the UCRF's foundational support, which has helped elevate UNC Lineberger to the top ranks of cancer research institutions nationwide. The ability to attract federal dollars has not only amplified the fund's research capabilities but also reinforced North Carolina's leadership in biomedical innovation.

IMPACTS OF THE UCRF IN FY 2025

State research funds deliver economic benefits that ripple across North Carolina's economy—immediately and for years to come. In the immediate future, these impacts include capital and non-capital investments, job creation, and the influx of new federal research funding, all of which contribute to expanding North Carolina's economy. In the longer term, these investments enhance the state's ability to compete nationally for additional funding, attract world-class scientists, and drive economic growth through the commercialization of medical research and innovation. These investments, in turn, lead to the development of new products, services, and employment opportunities. Additionally, innovation in healthcare leads to cost savings for the state by improving outcomes and reducing the overall burden on healthcare systems (see Figure 1).

Figure 1: Research Return on Investment Timeline



ECONOMIC IMPACT OF FUNDING

In FY 2025, UCRF investments in research contributed to a **$807.7 million** expansion of North Carolina's economy. Tripp Umbach's economic impact analysis reveals that even in the program's early years (2007-2011), investments in capital and human resources yielded a return of more than three dollars for every dollar invested. By FY 2025, this return has grown substantially, with nearly **$13.57 generated for every dollar invested**. The economic impact of UCRF spending is divided into two categories: direct and indirect/induced impacts.

Direct impacts include institutional spending on capital improvements, goods, and services, as well as expenditures by researchers, staff, subcontractors, and visitors attending conferences and meetings at these institutions. Indirect impacts stem from the income generated by these direct expenditures, which is recirculated through the state's economy as businesses and individuals spend their earnings, creating successive rounds of economic activity. The result is a multiplied economic effect, directly tied to the state's strategic investment in research. The cumulative impacts of the UCRF over the past 17 years are detailed in the chart below.



IMPACT OF UCRF DOLLARS ON EMPLOYMENT

Tripp Umbach estimates that in FY 2025, UCRF funding for healthcare research created and sustained **3,868 high-paying research-related jobs** across North Carolina. These jobs include 1,556 high-paying jobs directly tied to UNC, as well as an additional 2,312 indirect and induced jobs supported throughout the state. The economic growth driven by UCRF allocations has generated increased demand for employment across various sectors of the state's economy. As a result, the employment impact continues to expand, providing North Carolina with a growing number of high-paying, research-driven opportunities.



TAX IMPACTS

Tripp Umbach estimates that FY 2025 UCRF funds generated **$25.4 million** in tax revenue for the state of North Carolina. This revenue is driven by in-state spending from recipient organizations and the expenditures of out-of-state visitors, which significantly contribute to the state's tax base. As early-stage research transitions into commercial applications, the resulting economic activity is expected to boost tax revenues further. Over the past decade, these tax impacts have steadily increased, offering a growing return on the state's investment in research and development.



IMPACTS ASSOCIATED WITH LEVERAGED FEDERAL MEDICAL RESEARCH FUNDS

These state funds have measurably enhanced the North Carolina academic medical industry and growing life sciences industry. Federal medical research funding helps fuel clinical enterprises. These funds from the state's UCRF have encouraged researchers at the recipient organization to collaborate on applying for and winning highly competitive federal grants. These funds have enabled recipients of UCRF dollars to leverage federal research funds amounting to $210.8 million, bringing the total to **$253.7 million** in external funding in 2025 alone.

COMMERCIALIZATION

Additional impacts that will be realized due to the UCRF are the levels of commercialization that occur when clusters of research professionals collaborate on a specific area of research. Looking at the projected commercialization impact in 2032, Tripp Umbach estimates **$807.7 million** at a conservative level of growth scenario, and more than **$1.4 billion** using an aggressive level of growth, which includes additional economic activity within North Carolina. These activities will also create an additional 4,148 (conservative estimate) to 7,631 (aggressive estimate) high-paying jobs. These additional economic and employment impacts will translate into an additional state and local tax impact of $27.6 million to $49.5 million.

It is essential to note that these commercialization impacts are in addition to the annual operational impacts of the UCRF, and they will continue to grow as the research fund remains successful. These impacts are realized after years of research, once breakthroughs or discoveries have been made, and the discoveries begin to reach the marketplace. Examples of successful spinoff businesses supported by UNC Lineberger include Meryx, G1 Therapeutics, GeneCentric, EpiCypher, Epizyme, and Liquidia, among many others. Since 2009, UNC Lineberger startup companies have raised more than **$300 million** in non-dilutive financing from the NIH, angel investors, and venture capitalists.

APPENDIX A: DEFINITION OF TERMS

STUDY YEAR

Fiscal Year 2025

TOTAL IMPACT

The total impact of an organization is a compilation of its direct impact, indirect impact, and induced impact on the economy.

DIRECT IMPACT

Direct impact encompasses all direct effects that the organization has on the regional area due to its organizational operations. These items include direct employee expenses, organizational expenditures, employee expenditures, and expenditures by patients and visitors to the organization.

INDIRECT IMPACT

The indirect impact encompasses the effect of local industries purchasing goods and services from other local industries. The cycle of spending works its way backward through the supply chain until all money leaks out of the local economy, either through imports or through payments for value added. The impacts are calculated by applying direct effects to the Type I Multipliers.

INDUCED IMPACT

The response by an economy to an initial change (direct effect) that occurs through re-spending of income received by a component of value added. IMPLAN's default multiplier recognizes that labor income (including employee compensation and proprietor income components of value added) is not considered leakage to the regional economy. This money is recirculated through the household spending patterns, causing further local economic activity.

MULTIPLIER EFFECT

The multiplier effect refers to the additional economic impact generated as a result of an organization's direct economic impact. Local companies that provide goods and services to an organization increase their purchasing power by creating a multiplier effect.



APPENDIX B: METHODOLOGY

To measure the impact of UCRF funding on UNC Lineberger's operations across North Carolina, Tripp Umbach applied a rigorous and conservative methodology designed to ensure accuracy and reproducibility for future studies.

The analysis used the IMPLAN economic impact model, a nationally recognized tool for quantifying the direct, indirect, and induced effects of economic activity. Direct impacts reflect jobs and spending directly tied to operations; indirect impacts capture activity generated through vendors and suppliers; and induced impacts result from household spending by employees. IMPLAN was selected for its independence, reliability, and widespread use in economic impact research.

Employment and operational data were collected from UNC Lineberger and validated to ensure accuracy, then modeled using the most recent IMPLAN datasets (2022). These datasets offer detailed coverage of hundreds of industries, adhering to the conventions of the U.S. Bureau of Economic Analysis and the United Nations for input/output modeling.

This approach enabled Tripp Umbach to deliver a comprehensive and credible estimate of UCRF's economic contribution at the state level, while ensuring consistency with best practices in economic impact analysis.



APPENDIX C: TRIPP UMBACH QUALIFICATIONS

Tripp Umbach is the national leader in providing economic impact analysis to leading healthcare organizations and academic health centers. The firm has completed over 500 economic impact studies for clients such as the Mayo Clinic Rochester, The Cleveland Clinic, University of Florida Shands HealthCare, and the Ohio State University Wexner Medical Center.

Besides completing similar studies for UNC Lineberger over the last 25 years, Tripp Umbach has also completed economic impact studies for cancer centers such as the The Wistar Institute, Ohio State University's James Cancer Hospital and Solove Research Institute, Ohio State University's Comprehensive Cancer Center, Milton S. Hershey Medical Center's Cancer Institute, Mayo Clinic/Allegheny General Hospital Cancer Services planning, UPMC Hillman Cancer Center, University of Pennsylvania projected economic impact of the Cancer Center as a component of the Civic Center project, and University of Florida Shands HealthCare economic impact projections.

Tripp Umbach
Turning Ideas Into Action

FISCAL YEAR 2025 EXPENDITURES

Expenditures of State Funds Invested in the UCRF

G.S. 116-29.1 established the UCRF as a special revenue fund and created the Cancer Research Fund Committee to provide accountability and oversight. The Cancer Research Fund Committee developed the UCRF strategic plan to guide the responsible, strategic use of UCRF resources. The plan included three major research themes, an Opportunity Fund that allows UNC Lineberger to remain nimble and seize opportunities as they arise in a quickly changing field, and a focus on shared infrastructure to support clinical excellence and outreach.

Strategy	Annual Budget	Year to Date Actual*	Cash Balance*
Theme 1: Optimizing NC Cancer Outcomes	$10,905,000	$10,908,668	($3,668)
Theme 2: Understanding Genetics in Cancer — Basic Approaches and Clinical Applications	$9,550,000	$9,495,399	$54,601
Theme 3: Developing New Cancer Treatments	$9,590,000	$9,825,962	($235,962)
Tier 2: Opportunity Fund	$9,500,000	$8,050,536	($144,041)
Tier 3: Infrastructure — Clinical Excellence and Outreach	$8,250,000	$8,509,077	$199,464
Infrastructure	$11,725,000	$11,652,557	$72,443
Grand Total	**$59,520,000**	**$59,577,164**	**($57,164)**

* Rounded to the nearest dollar

FY 2025 EXPENDITURES

Total Expenses

Expense Category	Year To Date Actual*	Expense to Total Expenditure
Faculty Salaries	$20,220,901	33.9%
EPA Student Salaries	$3,502,336	5.9%
Staff Salaries	$7,664,763	12.9%
Other Staff	$577,916	1.0%
Benefits	$10,013,126	16.8%
Physician Benefits	$265,690	0.4%
Other Staff Benefits	$198,179	0.3%
Transit Tax	$106,112	0.2%
Consultants/Contracted Services	$627,679	1.1%
Employee Education	$32,240	0.1%
Repairs and Maintenance	$31,990	0.1%
Other Current Services	$4,711,335	7.9%
Supplies, Other	$4,371,753	7.3%
Travel	$801,667	1.3%
Advertising	$13,839	0.0%
Meetings and Amenities	($71,166)	-0.1%
Printing and Binding	$88,714	0.1%
Communication	$140,983	0.2%
Computer Services	$593,403	1.0%
Rental/Lease Facilities	$1,142,732	1.9%
Equipment	$2,287,711	3.8%
Study Subjects and Expenses	$248,656	0.4%
Health care system Residents	$714,392	1.2%
Insurance	$29,728	0.0%
Student Support	$1,261,991	2.1%
Legal Fees	$494	0.0%
Grand Total	**$59,577,164**	**100.0%**

* Rounded to the nearest dollar

UCRF Funding by Strategy and Expense

Theme 1: Optimizing NC Cancer Outcomes	Year to Date Actual
Faculty Salaries	$3,708,519
EPA Student Salaries	$378,914
Staff Salaries	$2,042,556
Other Staff	$186,760
Benefits	$2,148,948
Physician Benefits	$10,678
Other Staff Benefits	$49,964
Transit Tax	$21,195
Consultants/Contracted Services	$80,558
Employee Education	$14,034
Repairs and Maintenance	$514
Other Current Services	$795,729
Supplies, Other	$121,835
Travel	$286,056
Advertising	$730
Meetings and Amenities	$1,505
Printing and Binding	$41,836
Communication	$47,332
Computer Services	$40,174
Rental/Lease Facilities	$489,198
Equipment	$18,488
Study Subjects and Expenses	$170,064
Insurance	$15,414
Student Support	$233,057
Legal Fees	$4,609
Theme 1: Optimizing NC Cancer Outcomes Total	**$10,908,668**

* Rounded to the nearest dollar

FY 2025 EXPENDITURES

Theme 2: Understanding Genetics in Cancer — Basic Approaches and Clinical Applications	Year to Date Actual*
Faculty Salaries	$3,444,419
EPA Student Salaries	$383,901
Staff Salaries	$1,075,768
Other Staff	$64,934
Benefits	$1,675,376
Physician Benefits	$16,525
Other Staff Benefits	$32,240
Transit Tax	$16,540
Consultants/Contracted Services	$3,493
Employee Education	$3,976
Repairs and Maintenance	$1,305
Other Current Services	$845,021
Supplies, Other	$1,358,719
Travel	$33,954
Advertising	$7,168
Printing and Binding	$1,079
Communication	$3,661
Computer Services	$272,346
Equipment	$120,080
Study Subjects and Expenses	$5,206
Insurance	$1,540
Student Support	$132,069
Legal Fees	($3,920)
Theme 2: Understanding Genetics in Cancer — Basic Approaches and Clinical Applications Total	**$9,495,399**

* Rounded to the nearest dollar

Theme 3: Developing New Cancer Treatment	Year to Date Actual*
Faculty Salaries	$2,389,359
EPA Student Salaries	$350,338
Staff Salaries	$1,248,096
Other Staff	$119,604
Benefits	$1,368,474
Physician Benefits	$1,965
Other Staff Benefits	$27,809
Transit Tax	$13,592
Consultants/Contracted Services	$84,616
Employee Education	$275
Repairs and Maintenance	$10,851
Other Current Services	$1,369,091
Supplies, Other	$1,411,701
Travel	$87,438
Advertising	$725
Printing and Binding	$4,410
Communication	$6,578
Computer Services	$24,647
Rental/Lease Facilities	$624,465
Equipment	$393,799
Insurance	$8,421
Student Support	$114,241
Health care system Residents	$165,468
Theme 3: Developing New Cancer Treatment Total	**$9,825,962**

* Rounded to the nearest dollar

FY 2025 EXPENDITURES

Tier 2: Opportunity Fund	Year to Date Actual*
Faculty Salaries	$1,632,044
EPA Student Salaries	$980,613
Staff Salaries	$1,067,303
Other Staff	$178,195
Benefits	$1,129,877
Physician Benefits	$13,208
Other Staff Benefits	$21,724
Transit Tax	$12,854
Consultants/Contracted Services	$5,474
Employee Education	$3,100
Repairs and Maintenance	$18,162
Other Current Services	$1,172,711
Supplies, Other	$1,047,034
Travel	$320,701
Advertising	$14,923
Meetings and Amenities	$144
Printing and Binding	$38,991
Communication	$18,586
Computer Services	$207,481
Rental/Lease Facilities	$28,170
Equipment	$1,532,231
Study Subjects and Expenses	$30,421
Insurance	$661
Student Support	$169,630
Legal Fees	($195)
Tier 2: Opportunity Fund Total	**$9,644,041**

* Rounded to the nearest dollar

FY 2025 EXPENDITURES

Tier 3: Infrastructure — Clinical Excellence and Outreach	Year to Date Actual*
Faculty Salaries	$5,527,146
Staff Salaries	$390,969
Other Staff	$28,424
Benefits	$1,512,385
Physician Benefits	$220,438
Other Staff Benefits	$12,774
Transit Tax	$19,684
Consultants/Contracted Services	$66,247
Employee Education	$10,795
Repairs and Maintenance	($3,462)
Other Current Services	$25,172
Supplies, Other	$88,227
Travel	$1,271
Advertising	$764
Meetings and Amenities	$7,051
Communication	$2,374
Computer Services	$5,700
Study Subjects and Expenses	$850
Health care system Residents	$133,179
Student Support	$549.45
Tier 3: Infrastructure — Clinical Excellence and Outreach Total	**$8,050,536**

* Rounded to the nearest dollar

FY 2025 EXPENDITURES

Infrastructure	Year to Date Actual*
Faculty Salaries	$3,519,415
EPA Student Salaries	$1,408,570
Staff Salaries	$1,840,071
Benefits	$2,178,066
Physician Benefits	$2,877
Other Staff Benefits	$53,668
Transit Tax	$22,248
Consultants/Contracted Services	$387,291
Employee Education	$60
Repairs and Maintenance	$4,619
Other Current Services	$503,611
Supplies, Other	$344,236
Travel	$72,248
Advertising	($10,471)
Meetings and Amenities	($79,867)
Printing and Binding	$2,397
Communication	$62,452
Computer Services	$43,056
Rental/Lease Facilities	$900
Equipment	$223,112
Insurance	$3,693
Study Subjects and Expenses	$42,116
Health care system Residents	$415,745
Student Support	$612,444.94
Infrastructure Total	$11,652,557
Grand Total	**$59,577,164**

* Rounded to the nearest dollar

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Retention	Abdou	Yara	VCU Medical College of Virginia		10/16/23	1/15/26	PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in Triple Negative Breast Cancer with Residual Disease	$80,000
Retention	Abdou	Yara	Gilead Sciences, Inc.	GS-US-595-6184	3/12/24	3/27/34	A Randomized, Open-Label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy	$25,322
Retention	Abdou	Yara	Blueprint Medicines Corporation	BLU-222-1101	3/12/24	3/26/34	A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors	$90,439
Retention	Abdou	Yara	University of Texas Southwestern Medical Center	230405	1/1/24	12/31/26	Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer	$14,000
Retention	Abdou	Yara	Johns Hopkins University	TBCRC059	9/13/24	9/12/34	TBCRC-059 / DF-HCC-22-225: ETHAN: A phase II study comparing different Endocrine THerapies for mAle breast caNcer	$25,895
Retention	Abdou	Yara	Conquer Cancer Foundation		10/1/24	9/30/27	Molecular Residual Disease in Triple Negative Breast Cancer: Detection and Therapeutic Interception	$66,667
Retention	Abdou	Yara	Memorial Sloan-Kettering Cancer Center	TBCRC-058	12/3/24	12/3/29	A randomized, phase II study of enzalutamide, enzalutamide with mifepristone and treatment of physician's choice in patients with AR+ metastatic triple-negative or ER-low breast cancer	$21,290
Retention	Abdou	Yara	Johns Hopkins University	TBCRC 2024 2006482705	7/1/24	6/30/25	TBCRC 2024 - Infrastructure Support Task Order	$28,000
Retention	Abdou	Yara	Johns Hopkins University	TBCRC 2024 2006467310	7/1/24	6/30/25	TBCRC 2024 - Infrastructure Support Task Order	$28,000
Investment (HTSF)	Ahmed	Shawn	NIH National Institute of Environmental Health Sciences	5-R01-ES035777-01-02	3/15/24	2/28/29	Telomere uncapping epigenetically reprograms a stress response and longevity pathway	$487,001
Investment (CC)	Ainslie	Kristie	NIH National Institute of Allergy and Infectious Diseases	5R01AI167099-03	1/3/23	12/31/27	Mechanistic Evaluation of Mast Cell Agonists Combined with TLR, NOD and STING Agonists	$612,113
Recruitment	Akulian	Jason	Biodesix		10/24/19	12/31/25	(INSIGHT): An Observational Study Assessing the Clinical Effectiveness of VeriStrat® and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer BDX00146	$25,892
Recruitment	Akulian	Jason	Veracyte, Inc.	NIGHTINGALE	10/30/23	10/31/27	Clinical Utility of Management of Patients with CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier - with familiarization (NIGHTINGALE)	$14,302
Recruitment	Akulian	Jason	Tempus Labs, Inc	TP-CA-002	7/6/23	10/31/28	Tempus NSCLC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer Using Comprehensive Next-Generation Sequencing Assays	$20,480
Recruitment	Akulian	Jason	Tempus Labs, Inc	TP-CA-003	7/12/23	10/31/28	A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small CellLung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays	$22,336
Recruitment	Akulian	Jason	Pleural Dynamics, Inc.	CL2301	4/12/24	5/31/27	A Post-Market Study Evaluating Fluid Shunting Using the Automatic Continuous Effusion Management System (ACES™) in Patients with Symptomatic Aseptic Pleural Effusion: The ACES Study	$58,332
Recruitment	Aleman	Maria	Sanofi US Services, Inc.	24-0279	9/12/24	7/24/27	Fibrin Formation Assays to Test Procoagulant Activity	$24,825
Recruitment	Alexander	Thomas	Public Health Institute	AR68422	8/1/23	7/31/25	COG NCORP Per Case Reimbursement (5UG1CA189955-10)	$32,750
Recruitment	Alexander	Thomas	Public Health Institute	ATR67200	7/1/23	6/30/26	APEC14B1 Project: Every Child (PEC) A Registry, Eligibility Screening, Biology and Outcome Study	$9,500

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Andermann	Tessa	NIH National Institute of Allergy and Infectious Diseases	5-K23-AI163365-01-04	9/10/21	8/31/26	Precision characterization of antimicrobial resistance gene dynamics in bloodstream infection risk after hematopoietic stem cell transplantation	$202,619
Theme Investment	Anton	Eva	NIH National Institute of Neurological Disorders and Stroke	5-R35-NS116859-06	5/1/20	4/30/28	Defining mechanisms of progenitor balance and neuronal connectivity	$544,250
Theme Investment	Anton	Eva	NIH National Institute of Mental Health	5-R01-MH132710-01-03	8/19/22	5/31/27	Primary Cilia: A Novel Signaling Gateway To Neural Circuit Modulation	$1,094,968
Theme Investment	Anton	Eva	The Brain and Behavior Research Foundation	33063	3/15/25	3/14/26	Decoding the Communications of Neuronal Antennae Essential for Neural Circuit Function	$100,000
Investment (Protocol)	Armistead	Paul	Ohio State University	SPC-1000013903 GR137375	9/1/24	6/30/25	The Ohio State Blood and Marrow Transplant Research Consortium	$19,596
Recruitment	Arthur	Janelle	Wake Forest University Health Sciences	2045-45110-11000001883	6/14/23	5/31/28	Mechanisms of Klebsiella pneumoniae gastrointestinal colonization	$14,399
Investment (Training)	Aubé	Jeff	NIH National Institute of General Medical Sciences	5-T32-GM135122-04	7/1/21	6/30/26	UNC Chemical Biology Interface Training Program	$281,364
Recruitment	Aubé	Jeff	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI155510-01-04	7/13/21	6/30/25	Discovery of Phospopantetheinyl Transferse Inhibitors Against Mycobacterium tuberculosis	$770,597
Recruitment	Aubé	Jeff	University of Florida	SUB00004841	4/15/25	2/28/30	Novel Probes of the Kappa Opioid Receptor: Chemistry, Pharmacology, and Biology	$204,577
Retention	Bae-Jump	Victoria	University of Washington	UWSC12682/PO#55965	4/1/21	8/31/25	Social Interventions for Support during Treatment for Endometrial Cancer and Recurrence: SISTER Study	$16,800
Retention	Bae-Jump	Victoria	NIH National Cancer Institute	5-R21-CA267584-01-02	8/1/22	7/31/25	Impact of Obesity on Immuno-Oncology Agents in Endometrial Cancer	$172,653
Retention	Bae-Jump	Victoria	Magee-Womens Research Institute Foundation	6843	1/1/25	12/31/27	EGFL6: A Link Between Obesity, High Risk Endometrial Cancer, and Racial Disparities	$153,134
Retention	Bae-Jump	Victoria	Department of Defense	HT94252411024	8/15/24	8/14/27	Targeting Obesity Via Diet and Drugs for the Treatment of Endometrial Cancer	$518,333
Recruitment	Baker	Rick	NIH National Institute of General Medical Sciences	5-R35-GM150960-01-02	9/20/23	7/31/28	Molecular mechanisms of endocytic initiation and cargo selection	$388,750
Recruitment	Baker	Rick	NIH National Institute of Dental and Craniofacial Research	1-F31-DE034311-01	9/1/24	8/31/27	Fellow: D Sloan Molecular mechanism of CCDC32 in Cardiofacioneurodevelopmental syndrome	$37,346
Theme Investment	Baric	Ralph	NIH National Institute of Allergy and Infectious Diseases	HHSN272201700036I 75N93022F00001	7/14/17	9/30/26	Animal Models II Umbrella	$1,201,020
Theme Investment	Baric	Ralph	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI110700-06-10	4/20/15	8/31/25	Cell entry, cross-species transmission and pathogenesis of novel coronavirus from Wuhan	$748,081
Theme Investment	Baric	Ralph	Washington University in Saint Louis	WU-21-206/PO#ST00000215	9/15/20	8/31/25	Human Anti-body based countermeasures against the Wuhan Coronavirus SARS-CoV-2	$383,802
Investment (Training)	Baric	Ralph	NIH National Institute of Allergy and Infectious Diseases	5-F30-AI160898-04	7/1/21	6/30/26	Fellow: D Zhu Age in dengue antibody response and risk after primary natural infection	$53,787
Theme Investment	Baric	Ralph	International Vaccine Institute	23-5358	4/25/24	4/24/29	SARS-CoV-2 VLP-forming mRNA Vaccine: Broadly protective against SARS-CoV-2, variants, and sarbecoviruses with crossover potential into humans	$170,159
Theme Investment	Baric	Ralph	SK bioscience	24-0961	6/1/24	5/31/25	SK Bioscience Service Agreement	$1,020,689

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Theme Investment	Baric	Ralph	NIH National Institute of Allergy and Infectious Diseases	5R01AI148260-05	3/5/20	2/28/26	Antibody Landscape Following Human Norovirus Infection and Vaccination	$73,247
Investment (CC)	Baric	Ralph	NIH National Cancer Institute	3-U54-CA260543-02	9/30/20	8/31/25	North Carolina SeroNet Center of Excellence	$403,614
Investment (CC)	Baric	Ralph	NIH National Cancer Institute	3-U54-CA260543-02S1	9/1/23	8/31/25	North Carolina SeroNet Center of Excellence-Supplement	$1,475,028
Theme Investment	Baric	Ralph	NIH National Cancer Institute	3-U54-CA260543-02S2	9/30/20	8/31/25	North Carolina SeroNet Center of Excellence-Supplement	$820,801
Theme Investment	Baric	Ralph	International AIDS Vaccine Initiative	A12522	5/20/25	8/31/25	Mini binder Supplemental Proposal 2	$108,106
Recruitment	Baron	John	Medical University of South Carolina	A21-0071-S002	9/1/20	8/31/25	The immune contexture of colorectal adenomas and serrated polyps	$42,144
Investment (HTSF)	Bartlelt	Luther	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI151214-01-05	9/1/20	8/31/26	Interactions of dietary protein intake and intestinal resident microbiota affecting susceptibility to persistent Giardia infection and Giardia-mediated enteropathy	$600,193
Retention	Basch	Ethan	University of Alabama at Birmingham	000527573-SC001	5/4/21	2/28/26	Evaluating the implementation and impact of navigator-delivered ePRO home symptom monitoring and management	$169,439
Investment (Training)	Basch	Ethan	NIH National Cancer Institute	5-T32-CA116339-17	7/1/05	7/31/28	Cancer Care Quality Training Program (CCQTP T32)	$392,446
Retention	Basch	Ethan	Patient-Centered Outcomes Research Institute	DI-2023C1-31283	3/1/24	2/28/30	Implementation of Symptom Monitoring with Electronic Patient-Reported Outcomes (ePROs) during Cancer Treatment: The OncoPRO Initiative	$652,458
Retention	Basch	Ethan	Johns Hopkins University	2006636808 YACS-24-1416263-01	10/1/24	9/30/26	Improving the equity, actionability, and effectiveness of electronic patient-reported outcomes for clinical cancer care	$17,706
Innovation Award	Bautch	Victoria	NIH National Heart, Lung, and Blood Institute	5-R35-HL139950-07	1/1/18	12/31/25	Molecular and cellular control of angiogenesis	$73,783
Innovation Award	Bautch	Victoria	American Heart Association	25POST1377401	1/1/25	12/31/26	LINC complex function in endothelial cell during vascular development, function and in disease	$156,640
Retention	Bear	James	NIH National Institute of General Medical Sciences	5-R35-GM130312-06-07	2/1/19	4/30/29	Systematic Analysis of the Actin Cytoskeleton and Directed Cell Migration	$588,330
Recruitment	Bell	Ronny	University of Miami	SPC-003698 OS00001332	8/15/23	6/30/25	Native Alzheimer's Disease Resource Center for Minority Aging Research (NAD-RCMAR)	$18,290
Recruitment	Bennett	Antonia	Boston University Board of Trustees	4500000000	7/1/18	6/30/25	Access to and Value of Treatment Innovation Study	$85,654
Recruitment/ Theme Investment	Berg	Jonathan	NIH National Human Genome Research Institute	3-U24-HG009650-08S1	9/12/17	6/30/26	The Clinical Genome Resource - Advancing genomic medicine through biocuration and expert assessment of genes and variants at scale	$4,980,872
Recruitment/ Theme Investment	Berg	Jonathan	NIH National Human Genome Research Institute	3-R01-HG012271-03S1	9/14/22	6/30/27	Age-based genomic screening in newborns, infants, and children: a novel paradigm in public health genomics	$969,413
Recruitment	Bjurlin	Marc	Janssen Research & Development, LLC	WO# 56021927PCR3011	6/21/19	12/31/27	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy	$49,444
Recruitment	Bjurlin	Marc	enGene, Inc.	EG-70-101	7/1/22	4/30/26	A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment	$11,719
Recruitment	Bowers	Albert	National Science Foundation	CHE-2204094	6/1/22	5/31/25	Controlling protein post-translational modification by separating affinity and catalysis in designer enzymes	$165,000
Recruitment	Bowers	Albert	NIH National Institute of General Medical Sciences	5-R35-GM125005-06-08	9/5/17	8/31/27	Chemoenzymatic Synthesis, Mode of Action and Evolution of Natural Product-based Macrocycles	$389,341
Recruitment	Bowers	Albert	NIH National Institute of General Medical Sciences	1-F32-GM157944-01	12/1/24	11/30/27	Fellow: J Elllis Engineering and application of modular chimeric tRNA synthetases in mRNA display	$73,828
Recruitment	Bowers	Albert	Eindura Therapeutics, Inc.	25-4202	6/1/25	5/31/26	mRNA Display Selections Against Eindura Targets	$260,060
Recruitment	Branca	Rosa	University of Massachusetts Medical School	SUB00000106-UNC/WA0118039	8/15/21	8/14/25	Advancement of CRISPR-based Adipose Therapeutics for Type 2 Diabetes to Non-human Primates	$293,285

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Brenner	Alison	Drexel University		7/1/23	6/30/25	Assessing Equity in Shared Decision Making, Utilization, and Outcomes of Lung Cancer Screening	$42,000
Recruitment	Brenner	Alison	NIH National Cancer Institute	5-R01-CA279010-01-02	2/1/24	1/31/29	Expanding access to colorectal cancer screening through community pharmacies: The PharmFIT study	$584,334
Recruitment	Brewer	Noel	NIH National Institute on Drug Abuse	5-R01-DA048390-01-05	7/1/20	4/30/26	Informing ENDS policies: Studying the impact of e-cigarette warnings on behavior	$522,726
Recruitment	Brewer	Noel	NIH National Cancer Institute	5-P01-CA250989-01-04	9/23/21	8/31/26	Program Project - Improving Provider Announcement Communication Training (IMPACT)	$2,273,914
Recruitment	Brown	Nicholas	American Heart Association	23IPA1048749	7/1/23	6/30/25	Dissecting Macromolecular Complexes of Protein Quality Control in the Heart	$100,000
Recruitment	Brown	Nicholas	NIH National Institute of General Medical Sciences	5-R35-GM128855-06-07	8/1/18	7/31/28	Spindle Assembly Checkpoint Silencing	$454,118
Recruitment	Brown	Nicholas	Amgen, Inc.	20231200000	12/12/23	11/30/25	Uncovering New Interactions to a Vast Set of Ubiquitin Ligases	$250,355
Recruitment	Brown	Nicholas	University of California at San Diego	707092	7/5/24	6/30/26	Recognition and Ubiqutination of neurodevelopmental chromatin regulators	$113,171
Recruitment	Brown	Nicholas	National Ataxia Foundation	25-2479	3/1/25	2/28/26	Deciphering the link between mRNA regulation and protein degradation in PUM1-related ataxias, PADDAS and PRCA	$50,000
Investment (HTSF)	Browne	Edward	NIH National Institute on Drug Abuse	5-R61-DA059918-01-02	9/30/23	7/31/25	Defining the impact of cannabinoids on the HIV reservoir in humanized mice	$519,071
Investment (HTSF)	Browne	Edward	NIH National Institute on Drug Abuse	4-R33-DA053599-04	7/1/21	6/30/26	Defining the impact of cannabinoids on the latent HIV reservoir through multi-omic analysis	$730,078
Investment (HTSF)	Browne	Edward	NIH National Institute of Allergy and Infectious Diseases	2-R56-AI143381-05	7/16/19	7/31/26	Regulation of HIV Latency by Host Cell Transcriptional and Epigenetic Networks	$415,427
Recruitment	Brudno	Yevgeny	North Carolina Biotechnology Center	2024-TRG-0018	1/15/24	1/14/26	Implantable Bio factories For Rapid and More Potent CAR T Cell Therapy	$100,000
Recruitment	Brudno	Yevgeny	NIH National Cancer Institute	7-R21-CA277018-02	6/1/24	5/31/25	Biomaterial Scaffolds for In Vivo CAR T Cell Manufacture	$199,164
Recruitment	Brudno	Yevgeny	NIH National Cancer Institute	5-R01-CA278961-02-03	8/27/24	2/28/29	Bioinstructive Scaffolds for Potent and Affordable CAR-T Cell Therapy Against Brain Tumors	$634,205
Recruitment	Brudno	Yevgeny	NIH National Cancer Institute	5-R37-CA260223-05-06	7/2/24	3/31/26	Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production	$344,389
Recruitment	Brudno	Yevgeny	NIH National Cancer Institute	7-R33-CA281875-02	8/17/23	7/31/27	MASTER Scaffolds for Rapid, Single-Step Manufacture and Prototyping of CAR-T cells	$276,536
Recruitment	Brudno	Yevgeny	Persistence Therapeutics	25-2413	3/1/25	2/28/26	Persistence - Translating SynthNode materials to the clinic.	$300,132
Recruitment	Brudno	Yevgeny	NIH National Cancer Institute	1-F31-CA290823-01A1	7/1/25	6/30/27	Fellow: M Vanblunk Potent and Affordable GD2-Specific CAR T Cell Therapy for Glioblastoma Treatment Using Biomaterials	$40,752
Recruitment	Brunk	Elizabeth	Pharmaceutical Research and Manufacturers of America	25-0780	1/1/25	12/31/25	Controlling Rapid and Reversible DNA Adaptations Through Epigenetic Remodel	$100,000
Recruitment	Bryant	Ashley	NIH National Cancer Institute	5-K00-CA253762-03-06	5/17/22	4/30/26	Understanding Quality of Life and Physical Activity in Black Breast Cancer Survivors	$91,112
Recruitment	Bryant	Kirsten	NIH National Cancer Institute	5-R37-CA251877-01-05	7/1/20	6/30/25	Mechanistic dissection and inhibitor targeting of autophagy in RAS driven cancers	$306,070
Recruitment	Bryant	Kirsten	Department of Defense	W81XWH2110693	9/1/21	8/31/25	Targeting KRAS-dysregulated metabolism for novel therapeutic approaches	$164,467
Recruitment	Bryant	Kirsten	Washington University in Saint Louis	WU-24-0142	4/1/23	3/31/28	Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer.	$138,194
Recruitment	Bryant	Kirsten	NIH National Cancer Institute	1-F31-CA284869-01A1	7/1/24	6/30/27	Mechanistic examination and inhibitor targeting of nutrient scavenging for the treatment of pancreatic cancer	$40,064

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Investment (GeriOnc)	Busby-Whitehead	Jan	Hebrew Rehabilitation Center	90108	6/1/21	2/28/26	NIDUS II: Advanced-Stage Development and Utilization of the NIDUS Research Infrastructure to Advance Interdisciplinary Aging Research in Delirium	$19,046
Investment (GeriOnc)	Busby-Whitehead	Jan	American Geriatrics Society		10/1/23	9/30/27	Geriatrics Workforce Enhancement Program Coordinating Center	$64,650
Investment (GeriOnc)	Busby-Whitehead	Jan	HRSA Bureau of Health Workforce	1-U1Q-HP53061-01	7/1/24	6/30/29	Carolina Geriatric Workforce Enhancement Program	$1,000,000
Recruitment	Calabrese	Mauro	National Science Foundation	DBI-2228805	5/1/23	4/30/26	A computational approach to identify non-linear sequence similarity between lncRNAs	$220,877
Recruitment	Calabrese	Mauro	NIH National Institute of Child Health and Human Development	5-F31-HD111292-03	3/1/23	2/28/26	Fellow: M Murvin Dissecting mechanisms of gene silencing by the lncRNA Kcnq1ot1 in mouse trophoblast stem cells	$42,798
Recruitment	Calabrese	Mauro	NIH National Institute of General Medical Sciences	5-R35-GM153293-02	4/1/24	3/31/29	Mechanisms of gene regulation by long noncoding RNAs	$624,197
Recruitment	Calabrese	Mauro	NIH National Institute of Child Health and Human Development	1-F31-HD114456-01A1	11/1/24	10/31/26	Fellow: E Abrash Decoding Repression: Recruitment of epigenetic silencers by RNA binding proteins and long non-coding RNAs	$40,064
Recruitment	Calabrese	Mauro	Duke University	313000145	9/30/24	9/29/25	Targeting the Macro lncRNA KCNQ1OT1 in Rhabdomyosarcoma Tumorigenesis	$42,000
Recruitment	Calhoun	Ben	Dana-Farber Cancer Institute	6444400	7/1/23	6/30/26	Endocrine therapies for male breast cancer	$28,460
Recruitment	Cameron	Craig	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI045818-22-25	9/1/19	6/30/26	RNA-dependent RNA Polymerase	$404,270
Recruitment	Cameron	Craig	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI169462-01-04	4/13/22	3/31/27	Enteroviral 2C protein as a therapeutic target	$747,931
Recruitment	Cameron	Craig	Leland Stanford Junior University	63054089-242682	5/16/22	4/30/25	Development of outpatient antiviral cocktails against SARS-CoV-2 and other potential pandemic RNA viruses	$816,375
Recruitment	Cameron	Craig	NIH National Institute of Allergy and Infectious Diseases	5-R37-AI053531-20-22	2/1/23	1/31/28	Picornavirus Genome Replication	$534,015
Retention	Campbell	Sharon	NIH National Cancer Institute	5-R01-CA281295-01-03	3/1/23	2/29/28	KRAS G12C: Kinetic and Redox Characterization of Covalent Inhibition	$569,072
Retention	Campbell	Sharon	Ohio State University	SPC-1000013748 GR137338	7/1/24	6/30/29	Molecular mechanism of allele specific NRAS signaling and tumorigenesis	$319,727
Retention	Campbell	Sharon	NIH National Institute of General Medical Sciences	2-R35-GM134962-06	2/1/20	1/31/30	Structure and Mechanism of G-proteins and cell adhesion proteins in regulation of cell growth and motility	$602,153
Investment (Protocol)	Carey	Lisa	Syndax Pharmaceuticals, Inc.		12/15/17	8/20/25	LCCC 1639: A non-randomized, non-comparative, open-label, window trial of entinostat in patients with TNBC (Part 1) or entinostat with or without exemestane in patients with newly diagnosed, Stage I-IIIC, hormone receptor - positive (HR+) breast cancer (Part 2)	$55,472
Investment (Protocol)	Carey	Lisa	NIH National Cancer Institute	3-UG1-CA233373-06S1	5/1/19	2/28/26	UNC Lead Academic Participating Site	$303,121
Investment (Protocol)	Carey	Lisa	Dana-Farber Cancer Institute	DF-HCC 20-166	7/22/21	6/2/31	DF-HCC 20-166: Saci-IO TNBC: Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in PD-L1-negative metastatic triple negative breast cancer (TNBC)	$27,074
Investment (Protocol)	Carey	Lisa	Dana-Farber Mass General Brigham Cancer Care Inc.	20-153	5/18/22	9/30/31	DF-HCC-20-153: Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC)	$19,343
Investment (Protocol)	Carey	Lisa	SOLTI	SOLTI-2101 / LEE011A2303R	11/2/23	5/14/33	A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA trial	$13,712

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Investment (Protocol)	Carey	Lisa	Susan G Komen for the Cure	SAB232144	10/9/23	10/8/26	Understanding antibody-drug conjugate (ADC) sensitivity and resistance in breast cancer.	$200,000
Investment (Protocol)	Carey	Lisa	Dana-Farber Mass General Brigham Cancer Care Inc.	20-347	8/8/23	8/8/33	DF-HCC-20-347-ADEPT: A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor- positive, HER2-positive breast cancer (ADEPT)	$14,940
Investment (Protocol)	Carey	Lisa	Breast Cancer Research Foundation	BCRF-24-023	10/1/24	9/30/25	Clinical implications of metastatic subtype, microenvironment, and organ of involvement	$225,000
Investment (Protocol)	Carey	Lisa	Johns Hopkins University	2006524155	10/1/24	9/30/25	AURORA US: PROspective Biospecimen Repository in Metastatic Breast Cancer: Tissue Source Site.	$28,988
Investment (Protocol)	Carey	Lisa	NIH Advanced Research Projects Agency for Health	140D042590009	5/20/25	5/19/31	TBCRC Evolutionary Clinical Trial for Novel Biomarker-driven Therapies (EVOLVE_BDT)	$4,430,837
Investment (HTSF)	Cohan	Todd	NIH National Institute on Aging	5-R01-AG087877-01-02	8/15/24	4/30/29	Environmental risk factors linked to TDP-43 proteinopathies	$772,621
Investment (HTSF)	Cohan	Todd	NIH National Institute of Neurological Disorders and	1-R61-NS140724-01	12/24/24	11/30/26	The translational potential of next-generation sporadic mouse and human models of ALS/FTD	$374,349
Investment (Training)	Caron	Kathleen	NIH National Institute of General Medical Sciences	5-T32-GM133364-05	7/1/20	6/30/25	Training Program in Cellular Systems and Integrative Physiology	$217,676
Innovation Award	Caron	Kathleen	NIH National Heart, Lung, and Blood Institute	5-F31-HL163885-03	9/1/22	8/31/25	Elucidating the GPCR protein networks that drive lymphatic growth	$43,481
Innovation Award	Caron	Kathleen	NIH National Institute of Child Health and Human Development	5-R01-HD060860-11-13	4/1/09	1/31/28	Adrenomedullin Signaling at the Maternal-Fetal Interface	$419,055
Investment (CC)	Caron	Kathleen	NIH National Heart, Lung, and Blood Institute	5R01HL129086-08	6/8/23	6/30/25	Cardiac Lymphatics in Development and Repair	$583,072
Investment (CC)	Caron	Kathleen	NIH National Heart, Lung, and Blood Institute	5R01HL129086-08S1	6/27/23	6/30/25	Cardiac Lymphatics in Development and Repair - Supplement	$252,485
Innovation Award	Caron	Kathleen	American Heart Association	24POST1188946	7/1/24	6/30/26	Role of ACKR3 in postpartum cardiomyopathy	$144,580
Innovation Award	Caron	Kathleen	VentureWell (National Collegiate Inventors and Innovators Alliance)	SWH-16	10/23/24	10/22/26	FLyGT: Female Lymphatic GPCR Therapeutics for Migraine Treatment	$1,514,040
Recruitment	Casey	Dana	Johns Hopkins University	TBCRC053-M-60030	6/30/22	5/25/32	TBCRC053-M-60030: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer	$29,824
Recruitment	Casey	Dana	Johns Hopkins University	TBCRC053-M-59105/PO 2005665856	8/7/22	5/25/32	TBCRC053-M-59105: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer	$14,313
Recruitment	Charlot	Marjory	Conquer Cancer Foundation		7/1/21	12/31/24	A User-centered Mobile Health App to Promote Participation of Black Women in Breast Cancer Clinical Trials	$150,000
Investment (Protocol)	Coghill	James	Sanofi US Services, Inc.	EFC17757	5/23/24	5/23/34	A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)	$53,597
Retention	Cook	Jean	NIH National Institute of General Medical Sciences	5-R35-GM141833-01-04	7/1/21	6/30/26	Cell Cycle Dynamics that ensure Genome Maintenance	$575,320

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Coombs	Lorinda	AcademyHealth	350-04-10847	11/15/23	8/31/25	Characterizing Delays in Cancer Diagnosis for Underserved Populations in North Carolina	$57,681
Investment (HTSF)	Crowley	James	NIH National Institute of Mental Health	5-R01-MH124675-01-05	12/15/20	10/31/25	2/2 Rare Genetic Variation and Risk for Obsessive Compulsive Disorder	$198,263
Investment (HTSF)	Crowley	James	NIH National Institute of Mental Health	5-U01-MH125050-04	9/1/21	6/30/26	1/2 Trans-ancestry genomic analysis of obsessive-compulsive disorder	$362,266
Investment (HTSF)	Crowley	James	Karolinska Institute		3/15/23	2/28/26	Saving lives: Constructing a nationwide cohort with multimodal data to improve precision in prediction and prevention of suicide	$563,897
Investment (HTSF)	Crowley	James	NIH National Institute of Mental Health	1-R13-MH133380-01A1	6/1/24	5/31/25	Annual Latin American Congress on OCD	$20,000
Investment (HTSF)	Crowley	James	Icahn School of Medicine at Mount Sinai	0255-J201-4609	5/10/24	2/28/29	Phenotypic and genetic architecture of OCD in African Americans	$91,787
Retention	Damania	Blossom	NIH National Cancer Institute	5-U54-CA254564-05	8/13/20	7/31/25	Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa	$1,094,228
Retention	Damania	Blossom	NIH National Cancer Institute	5-P01-CA019014-42-44	5/1/97	6/30/27	Viral Oncogenesis, Latency and Replication	$1,936,921
Retention	Damania	Blossom	Leukemia and Lymphoma Society	5653-24	7/1/23	6/30/26	Elucidating the role of FAM72A in EBV-driven B cell lymphomagenesis	$70,000
Retention	Damania	Blossom	American Cancer Society	PF-23-1031420-01-CDP	7/1/23	12/31/25	Inhibition of NEK2 as a novel therapy for viral lymphomas	$73,750
Retention	Damania	Blossom	NIH National Cancer Institute	1-R01-CA291437-01A1	9/1/24	8/31/29	Therapy for Non-Hodgkin lympoma	$435,506
Retention	Damania	Blossom	NIH National Cancer Institute	1-U01-CA294800-01	9/10/24	8/31/29	Targeting EBV-associated lymphomas	$645,012
Retention	Damania	Blossom	Lymphoma Research Foundation of		7/1/25	6/30/28	Novel therapy for EBV-positive lymphomas	$65,000
Theme Investment	Dangl	Jeff	Brookhaven Science Associates, LLC	436421	11/17/23	9/30/26	Unlocking the Molecular Basis of Plant-Pathogen Interactions to Create Resilient Bioenergy Crops	$225,000
Theme Investment	Dangl	Jeff	National Science Foundation	IOS-2416244	9/1/24	8/31/27	Mechanisms of microbiota detente with the plant immune system.	$139,664
Investment (HTSF)	Darville	Lee Antoinette	NIH National Institute of Allergy and Infectious Diseases	5-U01-AI182180-01-02	5/10/24	3/31/29	Development of a recombinant protein vaccine for Chlamydia trachomatis	$1,925,693
Investment (Genomics)	Davis	Ian	V Foundation for Cancer Research	T2020-003	11/1/20	11/1/24	Combining Cellular and Epigenetic Therapies to Treat Pediatric Solid Tumors	$150,000
Investment (Genomics)	Davis	Ian	National Pediatric Cancer Foundation	22-3605	4/1/22	6/30/26	Enhancing immunotherapy for pediatric solid tumors through epigenetic modulation	$25,000
Investment (Genomics)	Davis	Ian	V Foundation for Cancer Research	AST2023-003	3/1/23	3/1/28	Novel mechanisms to improve CAR-T cell therapy for pediatric solid tumors	$200,000
Investment (Genomics)	Davis	Ian	NIH National Cancer Institute	5-R01-CA276663-01-03	1/1/23	12/31/27	Developmental control of chromatin states in cancer	$424,710
Retention	Dayton	Paul	NIH National Cancer Institute	3-R01-CA189479-08S1	9/4/14	8/31/26	Academic-Industrial Partnership for Translation of Acoustic Angiography	$576,707
Retention	Dayton	Paul	Vanderbilt University Medical Center	VUMC110935	2/1/23	12/31/27	Next generation transcranial ultrasound brain therapies using phase change nanoemulsions	$195,565
Retention	Dayton	Paul	North Carolina State University	500768	6/15/23	5/31/28	Quantitative assessment of angiogenesis using ultrasound multiple scattering	$255,895
Retention	Dayton	Paul	NIH National Cancer Institute	5-R21-CA286897-01-02	1/1/24	12/31/25	Novel approaches to enrich CAR-T cell Therapy in brain tumors using focused ultrasound	$211,773
Retention	Dayton	Paul	California Institute of Technology	S633472	1/1/24	12/31/27	Biogenic Gas Nanostructures as Molecular Imaging Reporters for Ultrasound	$80,200
Retention	Dayton	Paul	North Carolina State University	501628	5/15/24	3/31/28	Integrated Dual-frequency Ultrasound Catheter for Accelerated Sonothrombolysis (iDUCAS)	$157,551
Retention	Dayton	Paul	North Carolina State University	501752	4/1/25	3/31/27	Duplex dual-frequency CMUT array for acoustic angiography	$18,000

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Retention	Dees	Claire	Vanderbilt University Medical Center	VICC BRE 15136	8/20/18	8/19/28	A Phase II trial of Atezolizumab (anti-PDL1) with Carboplatin in Patients with Metastatic Triple Negative Breast Cancer	$26,240
Retention	Dees	Claire	Johns Hopkins University	2004353955	9/25/20	3/29/30	TBCRC-050: A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer	$29,607
Retention	Dees	Claire	Ohio State University	SPC-1000012759/GR134326	3/1/23	2/28/25	OSU ETCTN supplement to add UNC	$162,871
Retention	Dees	Claire	Ohio State University	SPC-1000014209 GR138040	3/1/24	2/28/25	The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network	$44,877
Retention	Dees	Claire	Duality Biologics	DB-1303-O-3002	9/24/24	10/17/34	DB-1303-O-3002: A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)	$58,019
Retention	Dees	Claire	Daiichi Sankyo, Inc	DS3201-324	1/7/25	1/7/30	A Phase 1B, Multicenter, open-label study of Valemetostat Tosylate in combination with DXd ADCs in subjects with solid tumors	$58,492
Recruitment	Denby-Brinson	Ramona	Duke Endowment	2131-SP	5/2/23	4/30/28	Children with Disabilities: Increasing Kinship Caregivers' Capacity and Improving Child Outcomes	$339,600
Recruitment	Denby-Brinson	Ramona	Blue Cross Blue Shield of North Carolina Foundation		7/14/25	7/14/28	Public Sector Leadership and Workforce Development Program, BCBSNC	$400,000
Investment (Proteomics)	Der	Channing	NIH National Cancer Institute	5-R35-CA232113-07	9/1/18	8/31/25	Targeting undruggable RAS for cancer treatment	$865,656
Investment (Proteomics)	Der	Channing	Department of Defense	W81XWH2110692 0011663366	9/1/21	8/31/25	Targeting KRAS-dysregulated metabolism for novel therapeutic approaches	$82,769
Investment (Proteomics)	Der	Channing	Revolution Medicines, Inc.	22-4651	6/21/22	6/20/25	Evaluation of KRAS inhibitors in pancreatic cancer	$74,070
Investment (Proteomics)	Der	Channing	American Cancer Society	PF-22-066-01	7/1/22	6/30/25	Targeting mitochondrial function as a therapeutic strategy for pancreatic cancer	$70,167
Investment (Proteomics)	Der	Channing	Pancreatic Cancer Action Network	22-WG-DERB	7/1/22	6/30/25	Determination of novel RAF/MEK and/or FAK inhibitor combinations in KRAS-mutant PDAC	$113,333
Investment (Training)	Der	Channing	NIH National Cancer Institute	5-T32-CA071341-27	9/30/96	6/30/28	Cancer Cell Biology Training Program	$332,856
Investment (Proteomics)	Der	Channing	NIH National Cancer Institute	5-K99-CA276700-01-02	7/1/23	11/30/24	Mechanistic Basis for ERK in driving KRAS-dependent pancreatic cancer	$111,438
Investment (Proteomics)	Der	Channing	American Cancer Society	PF-23-1072348-01-CDP	1/1/24	12/31/26	Overcoming resistance to KRASG12D inhibitors in KRASG12D mutant pancreatic cancer	$108,750
Theme Investment	Deshmukh	Mohanish	NIH National Institute of Neurological Disorders and Stroke	5-R01-NS122399-01-05	6/3/21	3/31/26	Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning	$344,560
Theme Investment	Deshmukh	Mohanish	NIH National Institute on Aging	5-R01-AG082140-01-03	4/1/23	12/31/27	miR-29: A brain homeostasis molecule for Alzheimer's disease prevention	$570,149
Theme Investment	Deshmukh	Mohanish	NIH National Institute of Neurological Disorders and Stroke	5-R01-NS117133-02-03	2/1/21	1/31/26	Unexpected Function of Inflammasomes in Axon Pruning: Focus on NLRP1	$492,776
Investment (Training)	Deshmukh	Mohanish	NIH National Institute of General Medical Sciences	3-T32-GM152316-01S1	7/1/24	6/30/29	UNC Medical Scientist Training Program	$1,378,526
Retention	Dittmer	Dirk	EMMES Corporation	13992	9/1/20	8/31/25	AIDS Malignancy Consortium (AMC)	$216,027
Retention	Dittmer	Dirk	NIH National Cancer Institute	5-R01-CA163217-11-13	9/1/11	6/30/27	Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma	$400,103

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Retention	Dittmer	Dirk	NIH National Institute of Dental and Craniofacial Research	1-U01-DE034179-01	9/20/24	6/30/28	Concentration and single virion analysis of the virome	$233,250
Recruitment	Dittus	Christopher	Seattle Genetics, Inc		10/18/17	1/1/27	Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the treatment of Adult T-Cell Leukemia/Lymphoma: A Phase II Trial of the Rare Lymphoma Working Group	$138,523
Recruitment	Dittus	Christopher	AstraZeneca Pharmaceuticals LP		3/3/20	3/2/30	A Phase II Trial of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas	$172,092
Investment (Training)	Doerschuk	Claire	NIH National Heart, Lung, and Blood Institute	5-T32-HL166141-02	7/1/23	6/30/28	UNC Research Training Program in Respiratory Diseases and Critical Care	$563,600
Recruitment	Doerschuk	Claire	NIH National Institute of Environmental Health Sciences	1-R21-ES035981-01A1	9/17/24	8/31/26	The pulmonary immune response induced by single and multiple exposures to combustion products of burn pit constituents	$427,625
Recruitment	Doerschuk	Claire	NIH National Heart, Lung, and Blood Institute	1-R01-HL171598-01A1	8/26/24	5/31/28	Uncovering and understanding the many functions of ICAM-1 in the lungs during homeostasis and innate immune responses	$759,025
Recruitment	Doerschuk	Claire	NIH National Heart, Lung, and Blood Institute	1-R01-HL175463-01A1	5/15/25	2/28/29	Migration and resolution, lung microenvironment and mechanisms: examining the diverse responses of neutrophils during S. pneumoniae pneumonia and acute lung injury	$759,983
Investment (Chair Package)	Dohlman	Henrik	NIH National Institute of General Medical Sciences	5-R35-GM118105-06-10	5/1/21	4/30/26	Negative and positive feedback in cell signaling	$659,119
Recruitment	Dominguez	Daniel	NIH National Institute of General Medical Sciences	5-R35-GM142864-01-04	8/1/21	7/31/26	Protein Disorder as a Mechanism of RNA Binding and Regulation	$388,750
Recruitment	Dominguez	Daniel	Yale University	CON-80004061 (GR118142)	9/21/22	8/31/27	RNA Splicing Defects as Oncogenic Events and Targets in Pancreatic Cancer	$43,931
Recruitment	Dotti	Gianpietro	NIH National Cancer Institute	5-R01-CA247436-01-05	1/1/21	12/31/25	Tuning CAR-T Cell Functions.	$447,292
Recruitment	Dotti	Gianpietro	NIH National Cancer Institute	5-R01-CA256898-01-05	2/1/21	1/31/27	Targeting B7-H3 in ovarian cancer.	$597,170
Recruitment	Dotti	Gianpietro	V Foundation for Cancer Research	D2024-013	8/15/24	8/15/27	B7H3 CAR T Therapy of Therapeutically Resistant Pancreatic Cancer	$116,667
Recruitment	Dotti	Gianpietro	Boston Children's Hospital	GENFD0002650935	7/3/24	6/30/29	Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia	$97,253
Recruitment	Dowen	Jill	NIH National Institute of General Medical Sciences	5-R35-GM152103-01-02	1/1/24	12/31/28	The role of genome folding in regulating gene expression and chromatin state	$373,010
Recruitment	Dowen	Rob	NIH National Center for Complementary and Integrative Health	5-F31-AT012138-02	8/1/23	7/31/25	Fellow: R Dumez Elucidating the Host Metabolic Response to Consumption of Kombucha-associated Microorganisms	$40,064
Recruitment	Dowen	Rob	NIH National Institute of General Medical Sciences	2-R35-GM137985-06	7/1/20	4/30/30	Developmental and nutritional regulation of lipid metabolism	$422,076
Investment (Protocol)	Downs-Canner	Stephanie	Johns Hopkins University	TBCRC042/PO#2004261049	6/26/19	6/25/29	(TBCRC042) A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions	$2,266
Theme Investment	Earp	Shelton	NIH National Cancer Institute	5-R01-CA270792-01-03	12/1/22	11/30/27	Divergent Roles of MerTK, Tyro3, and Axl in Pancreatic Cancer and Metastasis	$537,271
Theme Investment	Earp	Shelton	Breast Cancer Research Foundation	BCRF-24-041	10/1/24	9/30/25	Receptor Tyrosine Kinases and Breast Cancer Progression	$225,000
Recruitment	Elmore	Shekinah	American Society of Clinical Oncology		7/1/23	6/30/26	Adapting and implementing a telehealth-enhanced navigator program to improve breast cancer care adherence and clinical outcomes in Malawi	$66,667
Recruitment	Elston	Timothy	NIH National Institute of General Medical Sciences	5-R35-GM127145-06-07	7/1/18	6/30/28	Mathematical modeling of cellular signaling systems	$466,907
Recruitment	Elston Lafata	Jennifer	American Cancer Society	84266	7/1/22	6/30/25	Implementing Navigation Decision Support to Enhance Oncology Care Equity	$100,000

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Investment (Training)	Emanuele	Michael	NIH National Institute of General Medical Sciences	5-T32-GM135095-05	7/1/20	6/30/25	Pharmacological Sciences Training Program	$549,359
Recruitment	Emanuele	Michael	University of California at Irvine	2023-2008 49476	7/1/23	6/30/25	Harnessing the ubiquitin system as a therapeutic approach in SCLC	$40,000
Recruitment	Emanuele	Michael	NIH National Institute of General Medical Sciences	5-R35-GM153250-01-02	4/1/24	3/31/29	Proteostasis signaling in cell cycle control	$770,656
Recruitment	Emanuele	Michael	NIH National Cancer Institute	1-F31-CA288070-01	8/15/24	8/14/27	Regulation of the retinoblastoma (Rb) tumor suppressor by the ubiquitin-proteasome system	$40,188
Investment (Training)	Emanuele	Michael	NIH National Institute of General Medical Sciences	2-T32-GM135095-06	7/1/20	6/30/30	Pharmacological Sciences Training Program	$534,450
Recruitment	Engel	Larry	NIH National Institute of Environmental Health Sciences	2479801	9/27/24	9/26/26	IPA for Lawrence Engel to the NIEHS	$150,343
Recruitment	Enyioha	Chineme	NIH National Institute on Drug Abuse	5-K23-DA057416-01-03	9/30/22	8/31/27	Development of a prototype for a mobile health intervention for smoking cessation with features culturally adapted for African American smokers	$201,315
Recruitment	Fenton	Owen	NIH National Institute of Biomedical Imaging and Bioengineering	5-R21-EB034942-01-02	8/1/23	7/31/26	Optimization of Tannic Acid Lipid Nanoparticles for a Therapeutic mRNA Vaccine Against Melanoma	$226,293
Recruitment	Fenton	Owen	NIH National Institute of General Medical Sciences	1-R35-GM157060-01	1/1/25	11/30/29	Investigating and Manipulating Cells in Low Oxygen Environments Using Lipid Nanoparticles	$381,995
Investment (CC)	Ferris	Robert	NIH National Institute of Allergy and Infectious Diseases	1P01AI181898-01	8/20/24	5/31/29	Systems Genetics of Tuberculosis	$326,550
Investment (CC)	Ferris	Robert	NIH National Institute of Allergy and Infectious Diseases	5R21AI175987-02	11/1/24	10/31/25	The Impact of IL-4 and IL-4-Producing Cells on Protective Immunity to Tuberculosis	$62,536
Recruitment	Ferris	Robert	NIH National Cancer Institute	5-P30-CA016086-45-49	6/1/97	11/30/25	Cancer Center Support Grant	$7,402,429
Recruitment	Ferris	Robert	University of Pittsburgh	AWD00007794 139360-1	10/1/24	6/30/28	Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes	$34,417
Recruitment	Flick	Matthew	NIH National Heart, Lung, and Blood Institute	5-R01-HL160046-01-04	9/1/21	7/31/25	Mechanisms linking the plasminogen/fibrinogen axis to the pathogenesis of COVID-19	$531,940
Recruitment	Flick	Matthew	Michigan State University	RC115226UNC	5/11/23	2/28/27	Novel proteolytic mechanisms driving pathologic hepatic congestion in drug-induced hepatotoxicity	$66,227
Recruitment	Flick	Matthew	NIH National Heart, Lung, and Blood Institute	5-R01-HL168009-01-02	2/15/25	1/31/28	Novel mechanisms to limit thrombosis by decreasing fibrinogen or suppressing fibrin matrix formation.	$648,218
Recruitment	Flick	Matthew	Canadian Institutes of Health Research	510504	6/1/24	5/31/27	Dissecting the fibrin(ogen)-platelet forces driving arterial and venous thrombosis	$50,000
Recruitment	Flick	Matthew	The University of Texas Health Science Center at Houston	SA0003464	1/10/24	12/31/27	On the Basis of Sex: The Role of Sex chromosomal complement in AtrialFibrillation and Dementia	$37,848
Recruitment	Flick	Matthew	University of Illinois at Urbana-Champaign	118511-20106	2/20/24	8/31/27	Reprogramming to PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment	$446,892
Recruitment	Flick	Matthew	Versiti Wisconsin, Inc. aka Versiti Blood Center of Wisconsin	2002656-UNC	9/1/24	8/31/26	Controlling Thromboembolism After Polytrauma with an RNA Therapy Against Excess Fibrinogen	$203,580
Recruitment	Frerichs	Leah	Avera Health	R01DA050696-S2UNC	10/1/20	5/31/25	Community Based System Dynamics Models of Alcohol and Substance Exposed Pregnancy in Northern Plains American Indian Women.	$30,823
Recruitment	Frerichs	Leah	Robert Wood Johnson Foundation	79640	4/15/22	1/15/26	Assessing and promoting equity in mental health systems of care for adolescent youth in a rural community in North Carolina	$90,253

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Frerichs	Leah	NIH National Cancer Institute	5-R01-CA273331-01-02	8/1/23	7/31/28	Evaluating a remotely delivered, digital health CRC screening intervention among racially diverse patients of a community health center	$577,297
Recruitment	Frerichs	Leah	Avera Health	U54HD113179-1001	8/17/23	7/31/25	Maternal American-Indian Rural Community Health (M.A.R.C.H.)	$83,558
Recruitment	Frerichs	Leah	William T Grant Foundation	203876	6/1/24	5/31/28	Improving the use of research evidence to reduce child and youth opioid-related trauma: developing and testing a reflective decision analysis tool	$241,342
Recruitment	Frerichs	Leah	NIH National Institute of Child Health and Human Development	1-F30-HD116454-01	8/21/24	8/20/29	Fellow: C Smith Helping clinicians address digital information about contraception with adolescents	$41,241
Recruitment	Frerichs	Leah	Klingenstein Third Generation Foundation		7/1/25	6/30/27	Preventing serious mental illness among rural Black youth by integrating appealing and culturally relevant mind-body interventions into physical education	$200,000
Retention	Fry	Rebecca	NIH National Institute of Environmental Health Sciences	5-P42-ES031007-05	2/20/20	1/31/25	The UNC Chapel Hill Superfund Research Program (UNC-SRP)	$236,190
Investment (Training)	Fry	Rebecca	NIH National Institute of Environmental Health Sciences	5-T32-ES007018-48	7/1/77	6/30/27	Biostatistics for Research in Environmental Health	$1,387,182
Retention	Fry	Rebecca	NIH National Institute of Environmental Health Sciences	2-P42-ES031007-06	9/11/20	1/31/30	The UNC Chapel Hill Superfund Research Program (UNC-SRP)	$2,586,206
Recruitment	Frye	Stephen	NIH National Institute of General Medical Sciences	5-R35-GM139514-01-05	4/1/21	1/31/26	PROBING ALLOSTERY IN METHYL-LYSINE READER DOMAINS	$383,255
Recruitment	Furey	Terry	NIH National Institute of Diabetes, Digestive, and Kidney Diseases	5-R01-DK138462-01-02	3/1/24	2/29/28	Multi-omic characterization of genetic variants in IBD risk loci	$413,948
Recruitment	Furey	Terry	NIH National Institute of Diabetes, Digestive, and Kidney Diseases	5-F31-DK137574-02	3/1/24	2/28/26	Fellow: Nishiyama Using molecular quantitative trait loci mapping approaches to determine candidate gene regulatory mechanisms of functional variants within inflammatory bowel disease GWAS loci.	$42,574
Retention	Gallagher	Kristalyn	Mayo Clinic in Jacksonville	THE-294275-03 P002197575	2/1/23	1/31/27	Targeted Prevention of Postpartum-Related Breast Cancer	$178,395
Recruitment	Gilkey	Melissa	University of Alabama at Birmingham	000526841-SC002	9/18/20	8/31/25	Provider-Focused Multi-Component Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors receiving Follow-Up Care in Pediatric Oncology Practices	$25,830
Recruitment	Gilkey	Melissa	Kaiser Foundation Research Institute	RNG211477-UNC-03	7/15/21	6/30/26	Effectiveness and mechanisms of multilevel implementation strategies to improve provider recommendation and advance HPV vaccination: a cluster randomized trial	$10,876
Investment (HTSF)	Giudice	Jimema	NIH National Institute of General Medical Sciences	5-R35-GM152426-01-02	7/9/24	4/30/29	When alternative splicing meets cytoskeleton organization, local translation, and transcription regulation	$383,755
Innovation Award	Goldstein	Bob	American Cancer Society	PF-23-1152831-01-CCB	1/1/24	12/31/26	Understanding how developmental patterning coordinates cell shape changes	$108,750
Innovation Award	Goldstein	Bob	NIH National Institute of General Medical Sciences	5-R35-GM134838-06-07	1/1/20	12/31/28	C. elegans gastrulation: A model for understanding apical constriction mechanisms	$663,771
Recruitment	Greenberg	Caprice	Agency for Healthcare Research and Quality	7-R01-HS025989-06	9/1/18	6/30/25	Video-based Collaborative Learning to Improve Ventral Hernia Repair	$151,205
Recruitment	Grover	Natalie	Celgene Corporation	JCAR017-EAP-001	1/15/21	12/22/30	Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene maraleucel that is Nonconforming for Commercial Release	$16,506
Recruitment	Grover	Natalie	Kite Pharma, Inc.	KT-US-471-0140	11/30/23	7/5/34	Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel	$36,584

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Grover	Natalie	Kite Pharma, Inc.	KT-US-472-0141	11/30/23	7/5/34	Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleuce	$24,056
Recruitment	Grover	Natalie	Regeneron Pharmaceuticals Inc.	R1979-HM-2298	3/8/24	3/10/34	R1979-HM-2298: A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anit-CD3 Bispecific Antibody, Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMIPA-1)	$85,589
Recruitment	Grover	Natalie	Poseida Therapeutics, Inc.	P-CD19CD20-ALLO1-001	6/10/24	6/5/34	Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B cell Malignancies	$64,737
Recruitment	Grover	Natalie	American Society of Hematology		7/1/24	6/30/26	CD30 Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma	$75,000
Recruitment	Grover	Natalie	Affimed GmbH	AFM13-203	7/18/24	7/22/34	Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-2	$63,117
Retention	Gupta	Gaorav	Merck Sharp Dohme LLC	60963	7/6/22	12/31/25	Correlative Biomarker Analysis of P-RAD: A Randomized Study of Preoperative Pembrolizumab and No, Low or High Dose Radiation in Node-Positive, Triple Negative Breast Cancer	$333,237
Retention	Gupta	Gaorav	Department of Defense	HT94252310961 0011956625	9/1/23	8/31/27	Spatial Reprogramming of Tumor Immune Microenvironments by Preoperative Radiotherapy and Immune Checkpoint Inhibition in HER2-negative Breast Cancer	$1,125,991
Retention	Gupta	Gaorav	NIH National Cancer Institute	5-R37-CA227837-06-07	12/1/18	11/30/25	Mre 11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis	$422,092
Retention	Gupta	Gaorav	NIH National Cancer Institute	7-R01-CA274254-02	7/3/23	3/31/29	Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer	$355,463
Retention	Gupta	Gaorav	Breast Cancer Research Foundation	BCRF-24-214	10/1/24	9/30/25	Immune sensing of DNA damage in breast cancer	$225,000
Recruitment	Gupton	Stephanie	NIH National Institute of General Medical Sciences	5-R35-GM135160-01-05	12/1/19	1/16/25	Coordinated Cytoskeletal Dynamics and Membrane Remodeling in Cellular Shape Change	$38,027
Recruitment	Gupton	Stephanie	NIH National Institute on Aging	1-R21-AG077827-01	5/15/22	4/30/25	Exploring The Brain Enriched E3 Ubiquitin Ligase TRIM9 in Alzheimer's Disease	$142,542
Recruitment	Gupton	Stephanie	NIH National Cancer Institute	3-F99-CA294269-01S1	9/1/24	8/31/26	The interface of neurons and cancer	$41,079
Recruitment	Gupton	Stephanie	NIH National Institute of General Medical Sciences	2-R35-GM135160-06	12/1/19	11/30/29	Coordinated Cytoskeletal Dynamics and Membrane Remodeling in Cellular Shape Change	$443,311
Retention	Hahn	Klaus	University of Texas Southwestern Medical Center	GMO 210601 PO 0000002343	5/1/21	4/30/26	Integrated visualization, control, and analysis of GEF - GTPase networks in living cells	$256,574
Retention	Hahn	Klaus	NIH National Institute of General Medical Sciences	5-R35-GM122596-06-09	4/1/17	3/31/27	Dissecting signaling in vivo via precise control and visualization of protein activity	$810,270
Retention	Hahn	Klaus	University of Texas Southwestern Medical Center	PO 000002859B GMO231206	9/17/22	6/30/27	UTSW-UNC Center for Cell Signaling Analysis	$332,184
Retention	Hahn	Klaus	Duke University	383002051	12/1/23	11/30/25	Revealing the Hidden Topologies of the Human Kinome	$333,333
Recruitment	Hall	Marissa	NIH National Institute on Alcohol Abuse and Alcoholism	5-R01-AA030548-01-02	7/20/23	6/30/28	Informing alcohol policy: The impact of evidence-based alcohol warnings on consumption	$582,475
Recruitment	Hall	Marissa	NIH National Institute of Diabetes, Digestive, and Kidney Diseases	5-R01-DK135743-01-02	4/4/24	1/31/29	Evaluating the impact of sugar warnings on beverage purchases in Hispanic populations	$587,694
Recruitment	Han	Zongchao	BrightFocus Foundation	M2022001F	7/1/22	8/31/24	Nanoceria-Coated Melanin Nanoparticle as a Novel Antioxidant for Age-Related Macular Degeneration	$100,000

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Han	Zongchao	North Carolina Biotechnology Center	2024-FLG-0059	7/1/24	6/30/25	Transforming Viral Vectors into Nonviral Solutions in AMD Gene Therapy	$20,000
Recruitment	Hanks	Brent	NIH National Cancer Institute	7-R01-CA251136-05	7/20/21	12/31/26	Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities	$263,831
Recruitment	Hanks	Brent	Melanoma Research Foundation		2/1/25	9/29/25	Role of the Gli2 Pathway in Melanoma Immunotherapy Resistance	$104,091
Innovation Award	Hanson	Laura	NIH National Institute on Aging	5-R01-AG065394-01-05	9/10/20	5/31/26	Palliative Care for Persons with Late-stage Alzheimer's and Related Dementias and their Caregivers: a Randomized Clinical Trial	$524,104
Innovation Award	Hanson	Laura	University of Pittsburgh	AWD00008316 (139521-1)	9/30/23	5/31/28	Improving Primary Care Clinicians' Advance Care Planning for Alzheimer's Disease and Related Dementias	$554,622
Innovation Award	Hanson	Laura	Massachusetts General Hospital		4/16/24	1/1/30	Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia - SCOPE-Leukemia	$171,220
Recruitment	Hathaway	Nate	Georgia Institute of Technology	AWD-002151-G1	3/1/21	2/28/25	Reposition and Optimization of Deferiprone for Breast Cancer Therapy	$41,583
Recruitment	Hathaway	Nate	NIH National Institute of General Medical Sciences	5-R35-GM148365-01-03	6/1/23	5/31/28	Illumination of Chromatin Regulation via Chemical Controlled Proximity	$440,289
Recruitment	Hathaway	Nate	NIH National Institute of Allergy and Infectious Diseases	1-F31-AI179044-01A1	8/12/24	8/11/26	Fellow: S Wassernan Dose control of recombinant adeno-associated virus with Chemical Epigenetic Modifiers	$40,277
Theme Investment (CC)	Heise	Mark	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI157253-01-05	9/25/20	8/31/25	Genetic Analysis of COVID-19 Susceptibility and Resistance Determinants in the Collaborative Cross	$766,144
Theme Investment (CC)	Heise	Mark	Oregon Health and Science University	COA#4 1022269_UNC	11/1/22	10/31/27	Development of a Novel 2-Pyrimidone (SRI-42718) as a Potent Inhibitor of Chikungya Virus Infection and Disease	$162,281
Investment (Training)	Heise	Mark	NIH National Institute of Allergy and Infectious Diseases	5-T32-AI007419-32	9/1/93	8/31/28	Molecular Biology of Viral Diseases Predoctoral Training Grant	$198,475
Retention	Henderson	Louise	Virginia Commonwealth University	FP00015652_SA002	2/1/22	1/31/26	South Eastern Consortium for Lung Cancer Health Equity	$491,853
Retention	Henderson	Louise	NIH National Cancer Institute	5-R01-CA212014-06-07	9/20/17	5/31/28	Evaluating Lung Cancer Screening Patterns and Outcomes in Diverse Populations and Settings	$507,725
Retention	Henderson	Louise	NIH National Cancer Institute	1-R01-CA285976-01A1	7/18/24	6/30/29	Lung Cancer Screening: Cumulative Risk and Multilevel Impact of False Positive Findings	$657,536
Retention	Henderson	Louise	NIH National Cancer Institute	1-R01-CA298002-01	1/1/25	12/31/29	OPTimizing surveillance in lung cancer survivors with novel IMAging biomarkers and deep-Learning (OPTIMAL)	$968,999
Recruitment	Hingtgen	Shawn	NIH National Cancer Institute	5-R01-CA269974-01-04	2/1/22	1/31/27	Harnessing Continuous Liquid Interface 3D Printing to Improve Tumor-homing Stem Cell Therapy for Post-surgical Brain Cancer	$430,654
Recruitment	Hingtgen	Shawn	NIH National Institute of Neurological Disorders and Stroke	5-F31-NS134198-02	9/1/23	8/31/25	Fellow: L Kass Novel Bioprinted Neural Stem Cell-Embedded Hydrogel Matrices forEnhanced Treatment of Glioblastoma	$40,492
Recruitment	Hirschey	Rachel	NIH National Institute on Minority Health and Health Disparities	5-K23-MD015719-01-05	5/3/21	1/31/26	Physical activity intervention co-created and pilot tested with African American Colorectal Cancer Survivors	$158,736
Recruitment	Hirschey	Rachel	NIH National Institute of Nursing Research	5-F31-NR021241-02	5/1/24	1/31/26	Fellow: Xu Jingle The processes through which prostate cancer survivors and their partners adopt and maintain a healthy diet during prostate cancer survivorship	$31,699
Recruitment	Hoadley	Katherine	Scimentis, LLC	SMS0002267B	5/9/22	9/30/25	Bioinformatics and Computational Biology Subject Matter Expertise in Support of Human Research Program SpaceRadiation Element	$113,333
Recruitment	Hoadley	Katherine	NIH National Cancer Institute	5-U24-CA264021-04	9/1/21	8/31/26	Specialized RNA analysis center for integrative genomic analyses	$344,352

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Hoadley	Katherine	Duke University	383000605	6/8/22	6/7/25	Ancestry-related RNA Splicing and Immune Expression in Metastatic Breast Cancer	$53,605
Recruitment	Hoadley	Katherine	Johns Hopkins University	2006533752	7/1/24	9/30/25	AURORA US: PROspective Biospecimen Repository in Metastatic Breast Cancer: Clinical Data Coordinating Center	$111,398
Recruitment	Hood-Pishchany	Indriati	Bill and Melinda Gates Foundation	INV-072197	10/28/24	11/20/25	VMRC Bacterial Community Co-culture Preclinical Studies	$499,886
Recruitment	Howard	Valerie	American Association of Retired Persons Andrus		7/1/24	6/30/25	Promoting Healthy Work Environments and Confronting Workplace Violence Through Simulation Training	$25,000
Recruitment	Hucks	George	Department of Defense	W81XWH2010889	9/15/20	9/14/25	Phase I Study of Autologous Activated T-cells Transduced With a 3rd Generation GD2 Chimeric Antigen Receptor, Co-expression of IL-15 and iCaspase9 Safety Switch	$159,828
Investment (HTSF)	Hunter	Senyene	Kennedy Krieger Institute	9000166	7/1/23	6/30/26	Child Neurologist Career Development Program	$206,221
Recruitment	Hursting	Stephen	University of Utah	U000527486 10058539-01-UNC	9/23/21	8/30/26	Adipose tissue-colorectal tumor cross-talk: new targets for breaking the obesity-cancer link	$33,423
Recruitment	Hursting	Stephen	Purdue University	11001401-029	12/28/22	11/30/27	Impact of hypoxia on lipid metabolism in obesity-driven breast cancer progression	$145,197
Recruitment	Hursting	Stephen	NIH National Cancer Institute	5-F31-CA275336-02	9/12/23	9/11/25	Fellow: E Devericks Evaluating the impact of obesity-associated fatty acid metabolic dysregulation on breast cancer sensitivity to ferroptosis	$35,988
Recruitment	Hursting	Stephen	Breast Cancer Research Foundation	BCRF-24-073	10/1/24	9/30/25	Preclinical Investigations into Next Generation Incretin Therapy for Preventing Obesity-Associated Breast Cancer	$225,000
Investment (Training)	Ibrahim	Joseph	NIH National Cancer Institute	5-T32-CA106209-19	5/1/04	7/31/26	Biostatistics for Research in Genomics and Cancer	$257,213
Retention	Ibrahim	Joseph	GlaxoSmithKline, Inc.	AGR-6303	12/7/23	12/6/26	Bayesian Non-parametric Statistics Methodology Collaboration	$87,846
Retention	Ibrahim	Joseph	Amgen Pharmaceuticals	7300800000	1/1/25	12/31/25	Scientific Collaboration Agreement with Amgen	$249,000
Retention	Ibrahim	Joseph	Merck Sharp Dohme LLC	25-2459	12/5/24	12/4/26	Research Agreement with Merck	$300,000
Theme Investment (CC)	Jackson	Klarissa	NIH National Institute of General Medical Sciences	5-R35-GM143044-01-04	7/1/21	6/30/26	Interindividual Variability in Drug Metabolism in Ethnically Diverse Populations	$381,394
Theme Investment	James	Lindsey	NIH National Cancer Institute	5-R01-CA242305-01-06	8/23/19	7/31/25	Discovery of First-in-Class NSD2 Degraders for Cancer Therapy	$138,700
Investment (Protocol)	Jamieson	Katarzyna	AbbVie, Inc.	M19-063	5/25/21	12/1/31	A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax incombination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute MyeloidLeukemia (AML) (VIALE-T)	$29,040
Investment (Protocol)	Jamieson	Katarzyna	National Marrow Donor Program	ACCESS	8/17/21	12/31/27	ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies	$12,500
Investment (Protocol)	Jensen	Christopher	American Society of Clinical Oncology		7/1/24	6/30/27	Combating Cancer-Related Fatigue for Patients with Indolent Lymphoma: An Integrated Supportive Care Program	$66,667
Investment (Protocol)	Jensen	Christopher	CLL Society		7/1/24	6/30/26	Combating Cancer-Related Fatigue: A Personalized Supportive Care Program	$50,000
Investment (HTSF)	Jiang	Guochun	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI186609-01-02	6/10/24	4/30/29	Histone decrotonylation uniquely regulates HIV latency	$733,530
Investment (HTSF)	Jiang	Guochun	NIH National Institute of Mental Health	5-R01-MH136852-01-02	5/6/24	3/31/29	Defining the HIV reservoir and latency mechanism in human brain myeloid cells	$623,736
Investment (Proteomics)	Johnson	Gary	University of Alabama at Birmingham	000531784-SC002	1/12/22	12/31/26	Credentialing next-generation human glioma models for precision therapeutics	$11,883
Investment (HTSF)	Jones	Corbin	National Science Foundation	IOS-2034929	6/15/21	5/31/26	Collaborative Research: Rules for Dynamic-Light Environmental Sculpting of Genomes	$242,522

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Investment (HTSF)	Jones	Corbin	NIH National Cancer Institute	75N91019D00033/ 75N9	9/8/21	9/7/26	Comprehensive total RNA, mRNA, and miRNA sequencing for OCCPR	$627,585
Investment (HTSF)	Jones	Corbin	Duke University	303-000857	6/15/22	4/30/26	Social experience dependent modification of gene regulation and circuit function	$52,340
Investment (HTSF)	Jones	Corbin	National Science Foundation	IOS-2243536	3/1/23	2/28/27	Collaborative Research: Ideas Lab: The Role of Extracellular RNA in Intercellular and Interkingdom Communication	$231,247
Recruitment	Joseph	Sarah	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI176596-01-03	3/2/23	2/29/28	Identifying Roadblocks to Antigen Expression and Enhancing Killing of HIV-Infected Cells That Are Refractory to Clearance	$1,132,909
Investment (HTSF)	Juliano	Jonathan	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI155730-01-04	8/1/21	7/31/25	Importation and transmission of malaria in Zanzibar: a case study for elimination	$753,731
Investment (HTSF)	Juliano	Jonathan	Brown University	00002016	8/5/21	7/31/25	Artemisinin Resistance in Africa: its emergence and evolution in Rwanda	$186,743
Investment (HTSF)	Juliano	Jonathan	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI165537-01-03	7/25/22	6/30/27	Relapsing malaria in Africa: mechanisms for persistence amid falciparum decline	$771,018
Investment (HTSF)	Juliano	Jonathan	NIH National Institute of Allergy and Infectious Diseases	5-K24-AI134990-06-08	1/12/18	12/31/27	Mentoring in Translational Malaria Genomics	$172,941
Investment (HTSF)	Juliano	Jonathan	Duke University	303-001853	1/25/23	6/30/25	Evolutionary dynamics of zoonotic malaria	$88,848
Investment (HTSF)	Juliano	Jonathan	University of California at San Francisco	15073SC	12/1/23	11/30/27	Surveillance to track ACT resistance trends in Ugandan malaria parasites (STARTUP)	$97,212
Investment (Training)	Kabanov	Alexander	NIH National Cancer Institute	5-T32-CA196589-10	7/1/15	6/30/25	Carolina Cancer Nanotechnology Training Program (C-CNTP)	$520,560
Recruitment	Kabanov	Alexander	University of Texas Rio Grande Valley	1R01AI147731-01A1 (01)	7/16/20	6/30/25	A targeted anti-HIV drug delivery to the GALT	$78,647
Recruitment	Kabanov	Alexander	NIH National Cancer Institute	5-R01-CA264488-01-04	8/1/21	7/31/25	Toward Translation of Nanoformulated Paclitaxel-Platinum Combination	$582,405
Recruitment	Kabanov	Alexander	St Baldricks Foundation	1052982	7/1/23	6/30/26	Naturally Targeted Exosomal TLR7/8 Agonist for Immunotherapy of Medulloblastoma	$66,667
Recruitment	Kabanov	Alexander	NIH National Institute of Neurological Disorders and	1-R21-NS135362-01	9/20/23	8/31/25	Naturally Targeted Exosomal TLR7/8 Agonist for Immunotherapy of Medulloblastoma	$213,813
Recruitment	Kabanov	Alexander	Emervax, Inc.	A24-0634-R23-5143	10/31/23	4/30/25	Safe and Effective Circular RNA Vaccines for Emerging Viruses	$283,683
Recruitment	Kabanov	Alexander	Vanderbilt University Medical Center	VUMC127499	8/20/24	7/31/27	Bunyavirus and Picornavirus Pandemic Pathogen Preparedness (BP4) Center	$229,619
Investment (CC)	Kafri	Tal	NIH National Heart, Lung, and Blood Institute	5R01HL155986-04	9/1/20	8/31/26	The Circadian Rhythm as a Lentiviral Vector Restriction factor	$240,850
Investment (CC)	Kelada	Samir	NIH National Institute of Environmental Health Sciences	5-R01-ES034260-01-04	4/18/22	2/28/27	Regulatory Genomics of Ozone Air Pollution Response in Vitro and In Vivo	$637,686
Investment (CC)	Kelada	Samir	Genentech, Inc.		12/9/22	7/1/25	Research Collaboration Agreement with Genentech, Inc.	$50,000
Investment (CC)	Kelada	Samir	NIH National Heart, Lung, and Blood Institute	1-F31-HL176167-01	9/1/24	8/31/27	Fellow: S Lester Understanding the Genetic Contributions to Variation in Ozone Exposure Response	$40,064
Investment (CC)	Kelada	Samir	NIH National Institute of Environmental Health Sciences	1-R01-ES036228-01A1	1/1/25	10/31/29	Genetic mechanisms underlying maladaptive respiratory responses to air pollution	$671,165
Recruitment	Kent	Erin	NCDHHS Division of Aging and Adult Services	00047720 NC533873	7/18/24	9/30/25	NC Department of Health and Human Services Division of Aging and Adult Services All Ages, All Stages NC Data Dashboard	$249,463
Recruitment	Kent	Erin	Agency for Healthcare Research and Quality	1-R36-HS030175-01	8/1/24	7/31/25	Financial Hardship among LGBTQ+ Cancer Survivors and Caregivers: Prevalence, Determinants, and Access to Care	$45,170

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Kent	Erin	Fred Hutchinson Cancer Center	1195451	8/15/24	6/30/29	Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia	$50,685
Recruitment	Kent	Erin	Humana Foundation		1/1/25	6/30/26	enCompass: expanding the support of family caregivers of diverse patients with cancer and diabetes	$299,998
Recruitment	Kent	Erin	Duke University	383002633	10/1/24	9/30/25	Reconceptualizing the experiences of caregiving for older adults: developing items to inform a caregiver-centered assessment survey to improve caregiver services and supports.	$19,437
Retention	Key	Nigel	uniQure Biopharma B.V		9/11/18	10/2/25	Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B	$18,154
Investment (Training)	Key	Nigel	NIH National Heart, Lung, and Blood Institute	5-T32-HL007149-48	7/1/22	6/30/27	Research Training in Hematology at UNC Chapel Hill, Reissue of PA-18-403 for due dates on or after May 25, 2020	$484,006
Retention	Key	Nigel	BioMarin Pharmaceutical, Inc.	270-401	12/18/23	12/15/48	A Long-Term Follow-Up Study in Subjects with Severe Hemophilia A Who Received BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in a Prior BioMarin Clinical Trial (BMN 270-401)	$39,832
Retention	Key	Nigel	NIH National Heart, Lung, and Blood Institute	5-R01-HL171501-01-02	2/15/24	1/31/28	Mechanisms of venous thrombosis and renal dysfunction in sickle trait	$628,149
Retention	Key	Nigel	CSL Behring	CSL222_3003	12/2/24	12/2/29	An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects with Hemophilia B	$58,565
Retention	Khairat	Saif	NIH National Center for Advancing Translational Sciences	5-RC2-TR004380-01-03	8/1/23	4/30/28	Center for Virtual Care Value and Equity (ViVE)	$749,745
Retention	Kim	Hong Jin	North Carolina State University	PAM-P23-000090-SA01	4/1/23	3/31/28	Enteric Glia is a New Biological Target to Block Drug Resistance in Colon Cancer	$12,874
Retention	Kim	William	Vanderbilt University Medical Center	VUMC108453	9/2/22	9/1/25	Academy of Kidney Cancer Investigators Dean Award	$40,954
Retention	Kim	William	NIH National Cancer Institute	5-R01-CA290597-01-02	3/12/24	2/28/29	Triggering Aberrant RNA Processing for RCC Therapy	$618,056
Retention	Kim	William	NIH National Cancer Institute	2-K12-CA120780-16	9/17/07	6/30/29	UNC Oncology K12	$756,019
Retention	Kim	William	NIH National Cancer Institute	1-F31-CA281339-01A1	7/1/24	6/30/27	Fellow: M Sturdivant The Mutagenic Effects of APOBEC3A and APOBEC3B in Urothelial Carcinoma	$35,843
Retention	Kim	William	Conquer Cancer Foundation		7/1/24	12/31/25	Multispecific T-cell engagers targeting intracellular cancer-testis antigens in urothelial carcinoma	$50,000
Retention	Kim	William	NIH National Cancer Institute	1-R01-CA292625-01A1	3/1/25	2/28/30	Targeting APOBEC3-induced squamous differentiation in bladder cancer	$514,582
Investment (HTSF)	Kim	Wonho	NIH National Institute of General Medical Sciences	5-R35-GM155096-01-02	7/1/24	4/30/29	Deciphering the Stepwise Regulatory Mechanisms of Genome Folding	$388,750
Investment (Bios/HTSF)	Kosorok	Michael	National Science Foundation	DMS-2210659	8/15/22	7/31/25	Collaborative Research: Semiparametric and Reinforcement Learning for Precision Medicine	$86,667
Investment (CC)	Kulis	M	Department of Defense	W81XWH-20-PRMRP-EA	9/30/21	9/29/25	Exploiting Inhibitory Siglecs to Combat Food Allergies	$374,916
Investment (CC)	Kulis	M	National Institute of Health	75N93022C00053	8/25/22	8/31/27	Adjuvant Comparison and Characterization - UNC subcontract	$202,660
Investment (Protocol)	Kuzmiak	Cherie	ECOG-ACRIN Cancer Research Group	EA1151	10/20/17	10/19/30	ECOG-ACRIN LAPS: Protocol EA1151, Tomosynthesis Mammographic Imaging Screening Trial (TMIST)	$392,129
Retention	Laederach	Alain	NIH National Institute of General Medical Sciences	5-R35-GM140844-01-05	6/1/21	5/31/26	Variant induced RNA structure change in human genetic disease	$483,390

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Retention	Laederach	Alain	National Science Foundation	DMS-2151859	5/1/22	4/30/26	Collaborative Research: Unraveling structural and mechanistic aspects of RNA viral frameshifting elements by graph theory and molecular modeling	$46,130
Retention	Laederach	Alain	NIH National Heart, Lung, and Blood Institute	5-R01-HL111527-11	1/1/12	8/31/27	Non-coding RNA structure change in Chronic Obstructive Pulmonary Disease	$696,520
Retention	Laederach	Alain	New York University	F2499-01	3/1/24	2/28/27	MFB: RNA modifications of frameshifting stimulators: cellular platforms to engineer gene expression by computational mutation predictions and functional experiments	$145,917
Recruitment	Lai	Sam	Oak Crest Institute of Science	UNC20-315	5/5/20	2/28/25	Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception	$15,125
Recruitment	Lai	Sam	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI165853-01-03	9/19/22	7/31/27	Engineered muco-trapping antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections	$629,240
Recruitment	Lai	Sam	Benaroya Research Institute	FY24ITN622	2/1/23	1/31/25	Measurement of anti-PEG antibodies in COVID-19-004 clinical trial	$153,508
Recruitment	Lai	Sam	NIH National Institute of Allergy and Infectious Diseases	5-R21-AI180822-01-02	1/19/24	11/30/25	Engineering a vaccine that generates antibodies with fully tunable variable domain and immunoglobulin isotype specificity based on in vivo transduction of circulating B-cells	$211,869
Recruitment	Lai	Sam	Pharmaceutical Research and Manufacturers of America Foundation	25-0948	1/1/25	12/31/26	Direct in vivo engineering of CAR-T cells for cost-effective cancer therapy	$30,000
Recruitment	Lai	Sam	Ovarian Cancer Research Fund Alliance	RPG-R-2025-2-1455356	6/1/25	5/31/27	In vivo engineering of B7-H3.CAR-T cell therapy for ovarian cancer	$75,000
Recruitment	Lai	Sam	NIH National Institute of Allergy and Infectious Diseases	1-R21-AI185808-01A1	5/13/25	4/30/27	Engineering non-replicating self-recirculating phages as platform for gene therapy of the microbiome	$233,250
Innovation Award	Lawrence	David	NIH National Heart, Lung, and Blood Institute	5-R01-HL153744-01-04	5/1/21	4/30/25	Design and Application of Photoresponsive Modules in Circulating Erythrocytes	$56,156
Innovation Award	Lawrence	David	NIH National Heart, Lung, and Blood Institute	1-R01-HL17666-01	1/15/25	12/30/28	Assembly, Dosimetry, and Assessment of a Platform Technology for the Delivery of Thrombolytics	$767,077
Recruitment	Lazear	Helen	Burroughs Wellcome Fund	1021339	7/1/21	7/1/26	Host Range Determinants of Emerging Flaviviruses	$100,000
Recruitment	Lazear	Helen	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI170625-01-03	8/5/22	7/31/26	Host Factors Controlling Neuroinvasive Flavivirus Pathogenesis	$388,750
Recruitment	Lazear	Helen	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI175708-01-03	3/13/23	2/29/28	Antiviral and immunomodulatory effects of interferon lambda in the skin	$594,722
Investment (Protocol)	Lee	Carrie	V Foundation for Cancer Research	DM2023-003	4/1/23	4/1/25	Use of Multimedia Educational Tools to Advance Equity in Cancer Clinical Trial Participation	$25,000
Recruitment	Legant	Wesley	David and Lucile Packard Foundation	2019-69652	10/15/19	11/30/27	AI-enhanced microscopy	$109,375
Recruitment	Legant	Wesley	Silicon Valley Community Foundation	2023-321164	3/1/23	8/31/25	Molecules in Context with 4Pi Lattice Light Sheet Nanoscopy	$627,554
Investment (HTSF)	Li	Feng	NIH National Institute of Child Health and Human Development	5-R01-HD101485-01-05	8/16/21	5/31/26	Benefits of nicotinamide in placental development and in preeclamsia	$410,139
Recruitment	Li	Zibo	NIH National Cancer Institute	5-R01-CA247769-01-05	7/15/20	6/30/26	The development of novel radiation-sensitizer based on ultra-small carbon dots	$474,089
Recruitment	Li	Zibo	University of Georgia Board of Regents	SUB00002554	6/1/21	5/31/25	Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer	$232,684

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Li	Zibo	NIH National Cancer Institute	5-R01-CA287184-01-02	12/5/23	11/30/27	Development of an Efficient 18F labeling technology based on tetrazine trans-cyclooctene ligation	$616,880
Recruitment	Li	Zibo	NIH National Institute of Biomedical Imaging and Bioengineering	1-K99-EB037078-01	7/1/25	6/30/27	Development of Radiofluorination Methods and Prosthetic Groups Suitable for Quick Iterative Constructions of PET Tracer Analogs in Rapid Radiopharmaceutical Development and SAR Study	$122,260
Recruitment	Lichtman	Eben	GlaxoSmithKline, Inc.	GSK 209626	2/19/21	2/7/31	GSK-209626-DREAMM12: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)	$118,634
Recruitment	Lichtman	Eben	AbbVie, Inc.	M24-108	10/12/23	10/19/33	A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma	$114,221
Recruitment	Lichtman	Eben	Juno Therapeutics	CA0881000	6/12/24	6/26/34	A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma	$42,729
Recruitment	Lichtman	Eben	AbbVie, Inc.	M22-574	11/12/24	11/12/27	A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)	$48,460
Theme Investment (BRIC)	Lin	Weili	NIH National Institute on Drug Abuse	5-U01-DA055344-04	9/30/21	6/30/26	5/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium	$2,623,446
Theme Investment (BRIC)	Lin	Weili	University of California at San Diego	705059	10/1/21	6/30/25	The Healthy Brain and Child Development National Consortium Administrative Core	$136,258
Theme Investment (BRIC)	Lin	Weili	University of Washington	UWSC16385 PO-0100153658	9/1/24	8/31/28	ADRC Consortium for Clarity in ADRD Research Through Imaging	$249,187
Theme Investment (BRIC)	Lin	Weili	Once Upon a Time Foundation		11/1/24	10/31/26	The Raynor Cerebellum Project (RCP)	$357,477
Retention	Linnan	Laura	Centers for Disease Control and Prevention	5-U19-OH012303-01-04	9/1/21	8/31/26	Carolina Center for Healthy Work Design and Worker Well-Being	$963,426
Recruitment	Liu	Pengda	NIH National Cancer Institute	5-R01-CA244825-01-05	7/7/20	6/30/26	Elucidating novel functions of cGAS in breast cancer	$337,922
Recruitment	Liu	Pengda	Department of Defense	HT94252410644 0012116536	7/1/24	6/30/28	Targeting the E3 ligase SPOP in treating Renal Cell Carcinoma	$311,000
Recruitment	Liu	Pengda	Mary Kay Ash Foundation	45954	7/1/24	6/30/26	Statins suppress breast cancer metastasis by controlling canonical and non-canonical 2'3'-cGAMP signaling	$50,000
Recruitment	Liu	Pengda	DOD DA Army Medical Research Acquisition Activity	HT94252410823 0012138754	9/1/24	8/14/27	Combination therapy to overcome chemoresistance in Ewing sarcoma	$181,417
Retention	Long	Jason	Nucleix Ltd.	Lung-RND-003	6/6/22	3/1/26	Determination and Validation of Lung EpiCheck a Multianalyte Assay for Lung Cancer Prediction. A Case-ControlStudy	$18,301
Retention	Long	Jason	Delfi Diagnostics, Inc.	AFT-63	6/13/23	3/31/26	DNA evaluation of fragments for early interception-Lung Cancer Training Study (DELFI-L101)	$23,998
Recruitment	Lund	Jennifer	NIH National Cancer Institute	3-R01-CA277756-02S1	7/1/23	6/30/28	Applying causal inference methods to improve estimation of the real-world benefits and harms of lung cancer screening	$406,375
Recruitment	Lund	Jennifer	Janssen Research Development, LLC	U01FD007937 C2025038551	9/18/23	6/1/25	Advisory Committee Consulting Agreement - Jenny LundTitle of Proposal: Development of novel methods to enable robust comparison of real-world Progression Free Survival (rwPFS) and Clinical Trial PFS in Multiple Myeloma	$37,445
Investment (HTSF)	MacIver	Nancie	NIH National Institute of Allergy and Infectious Diseases	5-R21-AI180741-01-02	11/16/23	10/31/25	Utilizing alternative dietary interventions to alter gut microbiome and improve T cell responses to viral infection in obesity	$241,877

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Investment (HTSF)	Maeda	Nobuyo	NIH National Heart, Lung, and Blood Institute	5-R01-HL049277-30-33	9/30/92	12/31/25	Animal Models for Studying the Genetics of Complex Diseases	$770,952
Theme Investment (CC)	Magnuson	Terry	NIH Office of the Director	2-U42-OD010924-26	9/30/99	2/28/30	A Carolina Center to Characterize and Maintain Mutant Mice	$1,166,141
Investment (Bios/HTSF)	Marron	James	National Science Foundation	DMS-2113404	9/1/21	8/31/25	Data Integration Via Analysis of Subspaces (DIVAS)	$125,000
Innovation Award	Matera	Greg	NIH National Institute of General Medical Sciences	5-R35-GM136435-01-05	4/1/20	3/31/25	Ribonucleoprotein Biogenesis and Epigenetic Gene Regulation	$65,232
Innovation Award	Matera	Greg	NIH National Institute of General Medical Sciences	2-R35-GM136435-06	4/1/20	3/31/30	Role of histone PTMs in epigenetic control of metazoan transcription and RNA processing	$725,271
Investment (Protocol)	Mcclure	Elizabeth	University of Kentucky Research Foundation	3210002492-25-255 7800007927	9/30/24	9/29/25	Improving Documentation of Occupational Heat Related Injuries in North Carolina to Inform Worker Protections	$15,000
Recruitment	McGinty	Robert	NIH National Institute of General Medical Sciences	5-R35-GM133498-07	8/1/19	5/31/29	Molecular Mechanisms of Chromatin Recognition	$461,304
Investment (HTSF)	McKay	Daniel	NIH National Institute of General Medical Sciences	5-R35-GM128851-06-08	8/1/18	5/31/28	Genetic and epigenetic mechanisms of developmental gene regulation	$457,926
Investment (HTSF)	Merker	Jason	NIH National Cancer Institute	3-UG1-CA233333-06S1	3/13/19	2/28/26	UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation Center	$438,001
Investment (HTSF)	Merker	Jason	Redbud Labs		7/1/24	6/30/25	SBIR: Improving extraction success of FFPE samples with automated and reliable microfluidic sample preparation	$163,175
Recruitment	Miller	Brian	NIH National Cancer Institute	5-K08-CA248960-03-06	7/1/20	6/30/25	Targeting Unique Meyloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations	$286,658
Recruitment	Miller	Brian	Burroughs Wellcome Fund	1021540	1/1/22	8/31/26	Targeting Myeloid Cells as a Personalized Immunotherapy Approach to Cancer	$175,000
Recruitment	Miller	Brian	Melanoma Research Alliance	1255560	6/1/24	5/31/27	Targeting suppressive macrophages to overcome resistance to immunotherapy	$85,000
Recruitment	Miller	Brian	V Foundation for Cancer Research	V2024-021	10/1/24	10/1/27	Dissecting metabolic vulnerabilities of tumor-associated macrophages to improve the efficacy of immunotherapy	$200,000
Recruitment	Milner	Justin	V Foundation for Cancer Research	V2022-019	10/1/22	10/1/24	Reprogramming T cells for effective and durable responses against pancreatic cancer	$200,000
Recruitment	Milner	Justin	Mary Kay Ash Foundation	45861	7/1/23	6/30/26	Tailoring CAR-T Cell Responses for Triple Negative Breast Cancer	$33,333
Recruitment	Milner	Justin	Lung Cancer Initiative of North Carolina		1/1/24	12/31/25	Engineering durable and effective T cell responses against lung cancer	$75,000
Recruitment	Milner	Justin	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI177864-01-02	6/18/24	4/30/29	Epigenetic regulation of T cell differentiation during infection	$559,331
Recruitment	Milner	Justin	Brown University	2556	5/21/24	3/31/26	Interrogating mucosal resident memory CD8 T cell biology with 3D organoids	$129,466
Recruitment	Milowsky	Matthew	Seattle Genetics, Inc		4/20/18	4/30/28	A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer	$18,586
Recruitment	Milowsky	Matthew	ALX Oncology, Inc.	AT148007	2/7/23	3/1/33	A Phase 1, Open-label, Multicenter, Safety, Pharmacokinetic, Pharmacodynamic Study of ALX148 in Combination with Enfortumab Vedotin and/or Other Anticancer Therapies in Subjects with Urothelial Carcinoma (ASPEN-07)	$65,685
Recruitment	Milowsky	Matthew	Loxo Oncology, Inc.	LOXO-FG3-22001	4/28/23	5/11/33	An Open-label, Multicenter Study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies with FGFR3 Gene Alterations	$88,784
Recruitment	Milowsky	Matthew	Flare Therapeutics, Inc.	FX-909-CLINPRO-1	10/3/23	10/10/33	A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma	$167,416

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Milowsky	Matthew	Seagen, Inc.	RC48G001	11/22/24	11/22/29	A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2	$63,421
Investment (CC)	Mock	Jason	NIH National Heart, Lung, and Blood Institute	1R01HL173765-01A1	2/1/25	11/30/29	The Effect of Endogenous and Exogenous Glucocorticoids Acting Through Regulatory T Cells on Resolution of ALI and the Contribution of Host nGenetic Variability	$775,992
Recruitment	Mody	Gita	NIH National Heart, Lung, and Blood Institute	5-K23-HL157765-01-04	1/1/22	12/31/26	Improving Thoracic Surgical Care using electronic Patient-Reported Outcomes (ePROs)	$202,157
Investment (HTSF)	Mohlke	Karen	NIH National Institute of Diabetes, Digestive, and Kidney Diseases	5-R01-DK072193-14-18	9/1/05	7/31/25	Targeted Genetic Analysis of T2D and Quantitative Traits	$568,529
Investment (HTSF)	Mohlke	Karen	NIH National Institute of Diabetes, Digestive, and Kidney Diseases	5-UM1-DK126185-05	8/20/20	6/30/26	Bridging the gap between type 2 diabetes GWAS and therapeutic targets	$1,767,978
Investment (HTSF)	Mohlke	Karen	University of California at Los Angeles	1.44E+13	5/1/22	4/30/26	Genetics of adipose cell-type expression and cardiometabolic traits	$171,656
Investment (HTSF)	Mohlke	Karen	Foundation for the National Institutes of Health		3/3/23	9/3/25	Single nucleus-RNA and metabolomics in subcutaneous adipose tissue	$488,880
Investment (HTSF)	Mohlke	Karen	NIH National Institute of Diabetes, Digestive, and Kidney	5-R01-DK093757-11-12	9/5/11	2/29/28	Genetic epidemiology of rare and regulatory variants for metabolic traits	$562,388
Investment (HTSF)	Mohlke	Karen	Broad Institute	879-5500003202	1/1/25	12/31/25	Regulatory variants and effector genes at T2D-associated loci	$177,109
Recruitment	Moody	Cary	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI173039-01-03	5/18/23	4/30/28	Interplay between the cellular DNA damage response and the HPV life cycle	$403,970
Recruitment	Moon	Andrew	Cepheid	293C	1/24/24	1/31/25	Clinical Evaluation of Xpert® HCV Test on the GeneXpert® Xpress System in a CLIA-Waived Environment	$169,447
Recruitment	Moon	Andrew	University of Texas Southwestern Medical Center	GMO 251110 PO0000003584	8/1/24	7/31/27	National Liver Cancer Screening Trial	$146,693
Recruitment	Moorman	Nathaniel	Research Triangle Institute	66818L	4/1/22	3/31/27	Rapidly Emerging Antiviral Drug Development Initiative	$700,000
Recruitment	Moorman	Nathaniel	Evotec International GmbH	EVT87671	12/20/23	12/19/28	Development of innovative RNA-targeting antivirals against Henipaviruses	$37,245
Recruitment	Moorman	Nathaniel	Battelle Memorial Institute	884661	12/5/23	12/31/26	Rapidly Emerging Antiviral Drug Development Initiative	$620,268
Retention	Morrison	Kaitlin	DHHS Food and Drug Administration	1-U01-FD008266-01	8/1/24	7/31/25	Building Hybrid Operations to Promote Equity (HOPE) and improve clinical trial access across North Carolina	$250,000
Recruitment	Moschos	Stergios	Merck Sharp and Dohme Corp.		5/6/19	5/14/29	A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial	$29,108
Recruitment	Moschos	Stergios	University of Washington	UWSC11108	10/1/19	5/31/25	A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (anti-PDL-1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases.	$20,000

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Moschos	Stergios	Merck Sharp and Dohme Corp.	V940-001-1949	3/18/24	4/7/34	A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma	$52,200
Recruitment	Mungo	Chemtai	American Association for Cancer Research	22-20-73-MUNG	9/1/22	2/28/25	Feasibility of adjuvant topical therapy for cervical precancer treatment	$68,667
Recruitment	Mungo	Chemtai	Gilead Sciences, Inc.	23-0814	1/30/23	7/29/25	Feasibility of Artemisinin as neoadjuvant or adjuvant topical therapy for cervical precancer treatment in among women living with HIV in low- and middle-income countries (LMICs)	$90,000
Recruitment	Mungo	Chemtai	NIH National Cancer Institute	5-R34-CA284983-01-02	9/6/23	8/31/26	Feasibility of artesunate to improve HPV and cervical precancer treatment outcomes among HIV positive women in LMICs	$278,390
Recruitment	Muscatell	Keely	National Science Foundation	BCS-2047344	5/1/21	4/30/26	CAREER: Bidirectional Links Between Social Experiences and the Immune System	$146,392
Recruitment	Muscatell	Keely	NIH National Heart, Lung, and Blood Institute	5-R01-HL157422-05	5/1/21	4/30/26	Neural and Molecular Mechanisms Underlying Stress-Induced Inflammatory Responses	$530,953
Recruitment	Muscatell	Keely	Robert Wood Johnson	79936	9/1/22	8/31/26	Health Policy Research Scholars Cohort Six - 2022	$31,000
Recruitment	Muss	Hy	Breast Cancer Research Foundation	BCRF-23-114	10/1/22	9/30/24	p16INK4a Expression, Chemotherapy Toxicity, and Aging in Women with Breast Cancer	$26,333
Recruitment	Muss	Hy	University of California at Los Angeles	1.559E+13	9/1/23	8/31/28	Targeting Senescence to Mitigate Chemotherapy-induced Functional Decline	$97,641
Recruitment	Muss	Hy	Breast Cancer Research Foundation	BCRF-24-114	10/1/24	9/30/25	p16INK4a Expression, Chemotherapy Toxicity, and Aging in Women with Breast Cancer	$225,000
Recruitment	Muss	Hy	Conquer Cancer Foundation		7/1/25	6/30/26	Aging and intrinsic subtype-specific intratumoral and systemic immune profiles in stage I-III hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer	$50,000
Recruitment	Nakamura	Zev	NIH National Institute on Aging	1-K23-AG086604-01	9/10/24	6/30/29	Memantine and Exercise for Chemotherapy-Related Cognitive Decline in Patients with Breast Cancer	$181,626
Investment (Chair Package)	Neal-Perry	Genevieve	NIH National Institute of Child Health and Human Development	5-K12-HD103085-05	7/23/20	6/30/25	Advancing women's health through research: the UNC WRHR Career Development Program	$340,200
Recruitment	Nichols	Hazel	Kaiser Permanente Division of	RNG211063-UNC-01	9/15/20	6/30/25	PROJECT 1 Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers	$70,470
Recruitment	Nichols	Hazel	Kaiser Permanente Division of Research	RNG211061-UNC-01	9/15/20	6/30/25	CORES A & B Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers	$34,904
Recruitment	Nichols	Hazel	University of Texas MD Anderson Cancer Center	3002230000	6/28/23	12/31/27	Health equity in fertility specialty care among cancer survivors	$22,461
Recruitment	Nichols	Hazel	NIH National Cancer Institute	5-U01-CA281026-02	3/1/24	2/28/29	The Carolina Endometrial Cancer Study: A population-based survivor cohort	$637,806
Recruitment	Nielsen	Matthew	University of Kansas Medical Center Research Institute, Inc.	AWD-003150 GR18144	4/1/24	3/31/26	NC ProCESS-2: North Carolina Prostate cancer Comparative Effectiveness and Survivorship Study	$457,178
Recruitment	Nielsen	Matthew	National Academy of Sciences	SCON-10001130	7/1/24	6/30/26	Advancing Diagnostic Excellence and Health Equity in Prostate Cancer Care through Enhanced Quality in MRI and MRI Fusion Biopsy	$35,000
Theme Investment	Niethammer	Marc	Kitware, Inc.	K003982-00-S01	6/23/23	5/31/25	Exploratory Analysis Tools for Developmental Studies of Brain Microstructure with Diffusion MRI	$88,609
Theme Investment	Niethammer	Marc	NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases	5-R01-AR082684-01-02	2/1/24	1/31/29	A comprehensive imaging genetics framework for osteoarthritis research	$649,156
Theme Investment	Niethammer	Marc	NIH National Heart, Lung, and Blood Institute	1-R21-HL172230-01A1	8/1/24	12/23/24	A Pediatric Atlas of Upper Airway Shape has completed the first phase of peer review	$109,870

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Retention	Noar	Seth	Wake Forest University Health Sciences	555-45117-100000555115	4/1/20	9/30/25	Communicating Waterpipe Tobacco Harms To Reduce Use among Young Adults	$19,092
Investment (HTSF)	Nobel	Andrew	National Science Foundation	DMS-2113676	7/1/21	6/30/25	Inference for Stationary Processes: Optimal Transport and Generalized Bayes	$74,986
Investment (HTSF)	Nobel	Andrew	National Science Foundation	DMS-2413928	8/1/24	7/31/27	Collaborative Research: Network Analysis via Optimal Transport of Markov Embeddings	$91,667
Retention	North	Kari	Fred Hutchinson Cancer Research Center	1164014	8/20/20	7/31/25	Polygenic Risk Scores for Diverse Populations - Bridging Research and Clinical Care	$127,447
Retention	North	Kari	NIH National Institute of Diabetes, Digestive, and Kidney Diseases	5-R01-DK122503-01-05	9/22/20	7/31/25	Integrative Approaches to Identifying Function and Clinical Significance of Adiposity Susceptibility Genes	$640,718
Investment (Training)	North	Kari	NIH National Heart, Lung, and Blood Institute	5-T32-HL129982-09	6/1/16	5/31/26	The Genetic Epidemiology of Heart, Lung, and Blood Traits Training Grant (GenHLB)	$354,722
Retention	North	Kari	Vanderbilt University Medical Center	VUMC114911	7/1/23	3/31/27	Hispanic Latino Lipid Consortium	$96,154
Retention	North	Kari	The University of Texas Health Science Center at Houston	SA0003255	9/1/23	5/2/25	Multi-omics for obesity-associated liver disease discovery in Hispanics/Latinos: the Cameron County Hispanic Cohort	$156,024
Retention	North	Kari	Takeda Development Center Americas, Inc.	8001500000	3/15/24	3/14/26	Epidemiology Estimates of AATD in the US.	$197,177
Retention	North	Kari	Westat, Inc.		7/30/24	8/14/24	Leveraging integrative multi-omics to disentangle molecular mechanisms for severe obesity in diverse cohorts participating in Trans-Omics for Precision Medicine (TOPMed) Program	$16,931
Retention	North	Kari	Vanderbilt University Medical Center	VUMC134234	9/1/24	4/30/25	Integrative multi-omics for discovery of molecular pathways associated with diabetic retinopathy in Hispanics/Latinos	$136,080
Retention	North	Kari	Texas Tech University	23A9CR-01	11/25/24	11/10/25	DNA Methylation in Anorexia Nervosa	$24,898
Retention	Nyante	Sarah	University of Washington	UWSC12808 BPO56485	6/1/21	5/31/26	Disparities in Breast Cancer Diagnostic Pathways and Outcomes According to Socioeconomic Characteristics	$45,515
Retention	Nyante	Sarah	University of California at Davis	A22-1534-S008	9/16/22	8/31/27	Advancing Equitable Risk-based Breast Cancer Screening and Surveillance in Community Practice	$145,998
Investment (CBCS)	Nyante	Sarah	University of Vermont	225028 AWD00001578S	9/19/23	8/31/28	Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis	$73,059
Investment (CBCS)	Nyante	Sarah	University of Washington	UWSC16274 0100156307	9/9/24	8/31/29	Evaluation of Commercial Mammography-Based Artificial Intelligence Algorithms for Breast Cancer Risk Prediction in U.S. Screening Populations	$85,502
Investment (HTSF)	O'Connell	Catherine	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI170959-01-02	1/2/24	11/30/28	Natural History of Chlamydia trachomatis genital tract infection in women	$742,607
Innovation Award	Oldenburg	Amy	NIH National Heart, Lung, and Blood Institute	5-R01-HL154429-01-05	9/1/20	7/31/25	Predicting the Need for Surgery in Pediatric Subglottic Stenosis using Airway Elastography derived from Endoscopic OCT and Intraluminal Pressure Measurement	$738,780
Innovation Award	Oldenburg	Amy	NIH National Institute of Environmental Health Sciences	5-R01-ES032730-01-05	9/28/20	6/30/26	Developing an in vitro to in vivo pipeline of mammary gland exposure-response relationships to per- and poly-fluoroalkyl substances (PFAS)	$499,609
Investment (CBCS)	Olshan	Andrew	DHHS Centers for Disease Control and Prevention	5-U01-DD001308-01-02	9/1/23	8/31/27	North Carolina Center for Birth Defects Research and Prevention (NCCBDRP)	$570,000
Recruitment	Painschab	Matthew	NIH National Cancer Institute	1-DP1-CA291150-01	7/1/24	6/30/29	Innovations in diagnosis for lymphadenopathy across HIV Centers of Excellence in Malawi	$544,250
Recruitment	Palmer	Adam	NIH National Cancer Institute	5-R01-CA279968-01-02	2/1/24	1/31/29	Modeling and analysis of curative combination therapy for Diffuse Large B-Cell Lymphoma	$344,581
Recruitment	Palmer	Adam	Merck Sharp Dohme LLC		7/9/24	7/8/26	Forecasting the efficacy of combination therapies with TIGIT immune checkpoint inhibition.	$71,018

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Investment (CC)	Pardo Manuel de Villena	Fernando	Neogen Corporation		11/15/23	11/14/26	Service Agreement for miniMUGA inbred mouse Background Analysis Report	$25,000
Investment (HTSF)	Parnell	Scott	NIH National Institute on Alcohol Abuse and Alcoholism	5-R01-AA031346-01-02	9/15/23	7/31/28	Characterizing the Genetics of FASD in Complementary Mouse and Fish Models	$545,168
Recruitment	Patel	Shetal	Lung Cancer Initiative of North Carolina		1/1/21	12/31/25	Metabolic reprogramming of the tumor microenvironment to enhance immunotherapy in lung cancer	$43,750
Recruitment	Patel	Shetal	Dracen Pharmaceuticals, Inc.	DRA-104-001	5/3/21	8/6/25	Phase 1 and Phase 2a, First-in-human Study of DRP-104, a Glutamine Antagonist, in Adult Patients with Advanced Solid Tumors	$12,535
Recruitment	Patel	Shetal	American Society of Clinical Oncology		2/22/22	4/30/31	Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	$13,000
Recruitment	Patel	Shetal	Amgen, Inc.	20200469	10/26/22	11/30/32	A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer	$119,013
Recruitment	Patel	Shetal	Loxo Oncology, Inc.	LOXO-RAS-20001	12/6/23	12/31/34	A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors	$110,129
Recruitment	Patel	Shetal	Black Diamond Therapeutics, Inc.	BDTX-4933-101	5/8/24	11/30/24	A Phase 1, Open-label Study of Oral BDTX-4933 in Patients with BRAF and Other SelectRAS/MAPK Mutation Positive Neoplasms	$49,547
Recruitment	Patel	Shetal	Genentech, Inc.	BO45217	11/14/24	11/14/29	BO45217: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer	$58,101
Investment (HTSF)	Pawlinski	Rafal	NIH National Heart, Lung, and Blood Institute	5-R01-HL157441-01-04	4/1/21	3/31/25	Mechanism of sickle cell disease-specific venous thromboembolism	$647,758
Retention	Pecot	Chad	NIH National Cancer Institute	5-R01-CA258451-01-05	3/1/21	2/28/26	Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices	$580,098
Retention	Pecot	Chad	NIH National Cancer Institute	5-R01-CA279532-01-03	4/4/23	3/31/28	Circle RNA Regulation of Lung Cancer Metastasis	$398,845
Retention	Pecot	Chad	Enfuego Therapeutics		7/5/23	6/30/25	SBIR: Ligand-Directed KRAS G12V Mutant-Specific Therapeutics	$224,522
Retention	Pecot	Chad	Lung Cancer Initiative of North Carolina		7/1/24	6/30/25	Dynamic Ablation of Circular RNAs as a Novel Target in Lung Cancer	$25,000
Investment (HTSF)	Peifer	Mark	NIH National Institute of General Medical Sciences	5-R35-GM118096-06-09	7/16/16	8/31/26	Regulating cell fate and shaping the body plan during morphogenesis and their alteration during oncogenesis	$595,169
Investment (HTSF)	Perou	Charles	Susan G Komen for the Cure	SAC160074	7/15/16	1/15/26	Identification of the Genetic Drivers of HER2-Enriched Subtype Breast Cancers	$266,667
Investment (HTSF)	Perou	Charles	Breast Cancer Research Foundation	DRC-20-004	1/15/21	1/14/25	Disentangling the anti-tumor effects from the immune effects of Abemaciclib using RB- proficient and RB-deficient breast cancer mouse models.	$100,000
Investment (HTSF)	Perou	Charles	NIH National Cancer Institute	5-R01-CA148761-11-15	3/17/10	3/31/26	Therapeutic Targeting of Breast Cancer Tumor Initiating Cells	$413,297
Investment (HTSF)	Perou	Charles	NIH National Cancer Institute	1-F31-CA290953-01	7/1/24	6/30/27	Fellow: D O'Connell Characterizing and Overcoming MHC-I-Mediated Immune Evasion in Triple-Negative Breast Cancer	$40,064
Investment (HTSF)	Perou	Charles	Breast Cancer Research Foundation	BCRF-24-127	10/1/24	9/30/25	Molecular Therapeutics for Luminal Tumor Subtypes	$225,000
Investment (HTSF)	Perou	Charles	NIH National Cancer Institute	2-P50-CA058223-29A1	8/5/97	8/31/29	SPORE in Breast Cancer	$2,268,690
Investment (HTSF)	Perou	Charles	Johns Hopkins University	2006533717	7/1/24	9/30/25	AURORA US: Prospective Genomic Characterization Center in Metastatic Breast Cancer (ProGCC)	$109,013
Investment (HTSF)	Perou	Charles	The Jayne Koskinas Ted Giovanis Foundation for Health and Policy		2/1/25	3/31/29	Identifying interactions between metastatic breast cancer tumor cells and the lung Microenvironment	$247,500

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Investment (HTSF)	Perou	Charles	Department of Defense	HT94252510107 0012232964	3/1/25	2/28/29	The Breast Cancer Cellular Atlas	$385,320
Recruitment	Pfaff	Emily	Mayo Clinic	THE-282677-03 P001833511	7/12/21	7/31/25	Subcontract with Mayo Clinic School of Medicine Jiang R01 - FHIRCat: Enabling the Semantics of FHIR and Terminologies for Clinical and Translational Research	$130,000
Recruitment	Pfaff	Emily	NYU School of Medicine	EHR-04-24	3/1/24	11/30/25	The RECOVER Post-Acute Sequelae of SARS-CoV-2 (PASC) Electronic Health Record (EHR) Cohort Study	$5,770,258
Recruitment	Pfaff	Emily	Axle Informatics, LLC	SUBK_UNC_OTSS_TO-014	9/30/24	9/29/25	Subcontract with Axle Informatics, LLC National Clinical Cohort Collaborative (N3C-Clinical) for 2024-2025	$580,476
Recruitment	Phanstiel	Douglas	NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases	5-R01-AR079538-01-03	9/20/22	8/31/27	Identifying novel osteoarthritis risk genes using GWAS, chondrocyte genomics, and genome editing	$484,189
Recruitment	Phanstiel	Douglas	NIH National Institute on Aging	5-F31-AG084224-02	8/4/23	8/3/26	Cell-type Specific Interrogation of Variant Function in Alzheimer's Disease	$40,791
Recruitment	Phanstiel	Douglas	Duke University	303002773	9/4/23	6/30/27	The role for phase separation in oncogenesis and aberrant chromatin looping formation	$286,900
Recruitment	Phanstiel	Douglas	NIH National Institute of General Medical Sciences	5-R35-GM128645-06-07	7/19/18	12/31/28	Mechanisms and impacts of chromatin looping	$410,940
Recruitment	Phanstiel	Douglas	NIH National Institute on Aging	5-K00-AG068509-03-04	9/1/20	1/31/28	Elucidating Immune and Microglial Dynamics in Alzheimer's Disease with Advanced Organoid Models	$76,502
Recruitment	Phanstiel	Douglas	Howard Hughes Medical Institute	GT16825	9/1/24	8/30/27	The role of 3D chromatin structure in response to environmental stress	$173,000
Recruitment	Phanstiel	Douglas	NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases	1-F31-AR083722-01A1	8/1/24	7/31/27	Fellow: Seyoun Byun The effect of genetic variation on mRNA splicing in chondrocytes responding to cartilage matrix damage	$40,418
Recruitment	Pinton	Gianmarco	NIH National Institute of Biomedical Imaging and Bioengineering	5-R01-EB036295-02	8/20/24	4/30/28	Ultra-high precision image-guided incisionless transcranial ultrasound surgery	$750,055
Recruitment	Pinton	Gianmarco	North Carolina State University	501517	9/17/24	6/30/28	Quantitative Ultrasound for Interstitial Lung Diseases	$74,337
Recruitment	Pinton	Gianmarco	Once Upon a Time Foundation		2/20/25	2/19/27	Ultrasound for Combined Non-invasive Functional Volumetric Imaging and Circuit-Level Neuromodulation	$125,000
Investment (HTSF)	Polacheck	William	NIH National Institute of General Medical Sciences	5-R35-GM142944-01-04	9/23/21	7/31/26	Integrative Approaches for the Study of the Fluidic Cellular Microenvironment	$375,364
Recruitment	Purvis	Jeremy	National Science Foundation	MCB-2242980	3/1/23	2/28/27	Quantitative models of reversible and irreversible cell cycle arrest	$300,000
Recruitment	Purvis	Jeremy	NIH National Cancer Institute	5-R01-CA280482-01-02	2/1/24	1/31/29	Cell cycle paths as a framework for understanding drug resistance in tumor cell subpopulations	$621,861
Retention	Pylayeva-Gupta	Yuliya	The Mark Foundation for Cancer Research		1/1/22	12/31/24	Reprogramming B cell fate and function in cancer	$375,000
Retention	Pylayeva-Gupta	Yuliya	American Cancer Society	RSG-21-103-01 IBCD	1/1/22	12/31/25	B cells as mediators of tumor eradication in pancreatic cancer	$264,000
Retention	Pylayeva-Gupta	Yuliya	NIH National Cancer Institute	5-F31-CA278589-02	7/12/23	7/11/25	Fellow: W Bell Role of Gastrokine 2 in pancreatic cancer development	$40,491
Retention	Pylayeva-Gupta	Yuliya	NIH National Cancer Institute	5-R37-CA230786-06-07	4/1/24	3/31/26	Function of IL35+ B cells in pancreatic cancer	$417,022
Recruitment	Raab	Jesse	NIH National Institute of General Medical Sciences	3-R35-GM147286-03S1	8/15/22	7/31/27	Mechanisms of SWI/SNF complex assembly and function	$471,190
Recruitment	Raab	Jesse	American Cancer Society	PF-24-1247688-01-DMC	1/1/25	12/31/27	Identification of epigenetic therapies for liver cancer	$108,750
Retention	Rashid	Naim	Johns Hopkins University	TBCRC059 STATS 2006342060	4/22/24	4/21/27	TBCRC-059_STATS / DF-HCC-22-225: ETHAN: A phase II study comparing different Endocrine THerapies for mAle breast caNcer	$23,245

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Retention	Rashid	Naim	Department of Defense	HT94252411031 0012116832	11/1/24	10/31/26	Enhancing clinical trial discovery, matching, and enrollment in PDAC using fine-tuned large language models	$155,500
Recruitment	Rauf	Yasmeen	Imvax, Inc.	14379-201	10/4/23	10/10/33	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma	$20,817
Recruitment	Ray	Emily	Conquer Cancer Foundation		7/1/21	12/31/24	Validation and usability testing in an academic comprehensive cancer center of a prognostic calculator for 30-day mortality in patients with metastatic breast cancer	$66,667
Recruitment	Ray	Emily	Lung Cancer Initiative of North Carolina	22-1942	1/1/22	12/31/24	Development of an enhanced risk stratification system for patients with hospital-diagnosed advanced lung cancer	$75,000
Recruitment	Ray	Emily	Agency for Healthcare Research and Quality	5-K08-HS028862-01-02	9/1/23	8/31/28	Evaluation of end-of-life best practices and implementation of a tool to predict near-term death among patients with metastatic breast cancer in an oncology clinic	$160,109
Innovation Award	Redinbo	Matthew	NIH National Institute of General Medical Sciences	5-R35-GM152079-01-02	3/1/24	2/28/29	Gut Microbial Enzymes and Human Disease	$482,601
Recruitment	Reeder-Hayes	Katie	Susan G Komen for the Cure	OG23872434	3/17/24	3/16/27	Capturing Patient Reported Data to Impact Disparities in Metastatic Breast Cancer	$166,666
Recruitment	Reeder-Hayes	Katie	American Cancer Society	PASD-TEAM-23-1076363-01-PASD	1/1/24	12/31/28	Geographic Small Area Estimation of Cancer Screening Rates: Precision Approaches to Inform Screening Equity, Outreach, and Interventions	$300,000
Recruitment	Reeder-Hayes	Katie	Pfizer Inc. (Connecticut)	88230111	11/15/23	8/31/25	Promoting Resilience in Stress Management for Metastatic Breast Cancer (PRISM-MBC)	$249,988
Recruitment	Reeder-Hayes	Katie	Alliance Foundation Trials,		7/1/23	6/30/28	AFT-25 COMET study service agreement for patient survey data collection	$429,672
Recruitment	Reeves	Brandi	Janssen Research & Development, LLC		8/29/19	2/3/26	A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant.	$13,007
Recruitment	Reeves	Brandi	PharmaEssentia USA	A22-301	7/25/23	7/9/33	A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability ofRopeginterferon alfa-2b-njft (P1101) in Adult Patients with EssentialThrombocythemia	$392,767
Recruitment	Reeves	Brandi	NIH National Heart, Lung, and Blood Institute	5-K08-HL163485-01-02	8/1/23	7/31/28	Hypoxia-Inducible Factors and Neutrophil Heterogeneity in Myeloproliferative Neoplasm-Associated Venous Thrombosis	$141,211
Recruitment	Reeves	Brandi	PharmaEssentia Corporation	A22-203	1/31/24	12/15/33	A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Polycythemia Vera (PV)	$139,523
Recruitment	Reeves	Brandi	MPN Research Foundation		8/15/24	8/14/26	Chronic Kidney Disease in Myeloproliferative Neoplasms	$100,000
Retention	Reuland	Dan	Wake Forest University	497-32751-10000550124	1/1/20	6/30/25	A Personalized Digital Outreach Intervention for Lung Cancer Screening	$166,053
Retention	Reuland	Dan	NIH National Cancer Institute	3-UG1-CA286949-02S1	2/15/24	12/31/27	Cancer Screening Research Network - North Carolina Hub (CSRN-NC HUB)	$1,331,844
Retention	Ribisl	Kurt	Cumberland County Department of	25000708	7/1/24	5/31/25	Fort Bragg Tobacco Control: Military Health and Readiness Initiative	$31,077
Investment (Training)	Ribisl	Kurt	NIH National Cancer Institute	5-T32-CA057726-33	7/1/17	6/30/27	Cancer Control Education Program	$369,409
Retention	Ribisl	Kurt	NIH National Institute on Drug Abuse	5-U54-DA060049-02	9/30/23	8/31/28	Advancing Tobacco Regulatory Science to Reduce Health Disparities	$3,855,746
Retention	Ribisl	Kurt	Cumberland County Department of	25001055 2025606	1/1/25	5/30/25	WIC CIAO Contract with Cumberand County	$14,991

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Richardson	Daniel	American Society of Hematology		7/1/23	6/30/26	Developing a patient-reported measure to identify treatment priorities of patients with advanced blood cancers	$50,000
Recruitment	Richardson	Daniel	NIH National Cancer Institute	5-K08-CA273684-01-02	6/11/24	5/31/29	Developing a Values Elicitation Tool to Improve Treatment Decision-Making in Acute Myeloid Leukemia	$285,049
Recruitment	Roberson	Mya	American Association for Cancer Research	22-20-73-ROBE	3/1/23	2/28/25	Centering Equity in HBOC Genetic Testing: A Mixed Methods Study	$97,734
Recruitment	Roberson	Mya	Prevent Cancer Foundation		1/15/24	1/14/26	We Got Us: Promoting Cancer Family History Sharing Among Black Americans	$50,000
Recruitment	Roberts	Megan	University of Texas Southwestern Medical Center	0000002723 220726	8/15/21	8/14/25	Familial hypercholesterolemia in the United States: evaluating a centralized cascade screening model to improve early diagnosis	$24,821
Recruitment	Roberts	Megan	NIH National Cancer Institute	5-R13-CA261073-02-03	7/16/21	5/31/26	Transdisciplinary Conference for Future Leaders in Precision Public Health	$33,000
Recruitment	Roberts	Megan	NIH National Human Genome Research Institute	1-R21-HG013417-01	9/20/24	8/31/26	Let's Talk: Overcoming barriers to the uptake of cascade screening through a stakeholder-informed online intervention	$575,098
Recruitment	Roberts	Megan	Medical University of South Carolina	A25-0113-S001	7/1/24	4/4/25	Facilitating the implementation of population-wide genomic screening across diverse populations and settings (FOCUS)	$205,578
Recruitment	Rose	Tracy	Duke University	Pro00107408 ODYSSEY	4/16/24	3/28/34	Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma (ODYSSEY RCC)	$11,900
Recruitment	Rose	Tracy	Regeneron Pharmaceuticals Inc.	R10597-ONC-22114	2/20/25	2/20/30	A Phase 1/2A, Open Label, Dose Escalation and Dose Expansion First in Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) in Patients with Advanced Solid Organ Malignancies	$57,212
Recruitment	Rosenstein	Donald	Duke Endowment	7254-SP	7/1/24	6/30/27	Statewide Expansion and Spanish Cultural Adaptation of Get REAL and HEEL: A Tailored Exercise Program for People Affected By Cancer	$248,667
Recruitment	Rosenstein	Donald	American Cancer Society	107485	4/1/25	3/31/26	2025 Patient Lodging Grant	$50,000
Theme Investment	Rowe	Steven	Johns Hopkins University	2006424309	7/4/23	5/31/25	Clinical translation of a PD-L1 PET tracer to optimize immune checkpoint therapy in patients with non-small cell lung cancers	$89,659
Recruitment	Rubinstein	Samuel	Rhode Island Hospital	7137836	9/15/22	8/31/27	Enhancing the HemOnc Knowledgebase of Chemotherapy Drugs and Regimens	$18,411
Recruitment	Rubinstein	Samuel	American Society of Hematology	D0983564-2	7/1/22	6/30/26	ASH Research Collaborative Data Hub Protocol: A multicenter data hub of individuals living with hematologic disease	$105,000
Recruitment	Rubinstein	Samuel	Janssen Research Development, LLC	64407564MMY3002	2/17/23	2/28/29	A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy	$482,775
Recruitment	Rubinstein	Samuel	Regeneron Pharmaceuticals Inc.	R5458-ONC-2012	11/29/23	12/10/33	Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma	$688,581
Recruitment	Rubinstein	Samuel	Janssen Research Development, LLC	54767414NAP4001	6/13/24	12/31/25	A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)	$25,704
Recruitment	Rubinsteyn	Alexander	Rare Cancer Research Foundation	24-0888	11/5/23	11/4/25	Neoantigen identification from long-read sequencing	$420,672
Recruitment	Rubinsteyn	Alexander	Victor Family Foundation		4/1/24	4/1/26	Preclinical development of a shared antigen therapeutic vaccine for NUT carcinoma	$180,000
Recruitment	Rubinsteyn	Alexander	Natera, Inc	24-3809	6/25/24	9/1/25	Comparison of T-cell responses in mice from different vaccine formulations, adjuvants, and routes of administration	$134,012

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Rubinsteyn	Alexander	Jaime Leandro Foundation	25-2713	2/18/25	2/17/27	Optimization of personalized cancer immunotherapeutic approaches	$885,499
Investment (CC)	Samulski	Richard	AskBio, Inc	22-5401	8/2/22	8/1/27	AAV Gene Delivery in Collaborative Cross Mice	$400,000
Investment (HTSF)	Sancar	Aziz	NIH National Institute of General Medical Sciences	5-R35-GM118102-06-09	4/1/16	8/31/26	Molecular Mechanism of Mammalian DNA Excision Repair and the Circadian Clock	$1,002,711
Investment (HTSF)	Sancar	Aziz	NIH National Institute of Environmental Health Sciences	5-R01-ES033414-01-04	9/17/21	6/30/26	DNA Adduct Detection and Repair in Mammalian Cells	$556,623
Investment (Protocol)	Sanoff	Hanna	University of Iowa	S02645-01	7/1/21	6/30/25	Comparative Effectiveness Research for Neuroendocrine Tumors	$25,550
Investment (Protocol)	Sanoff	Hanna	Janssen Research Development, LLC	61186372COR3001	1/27/25	12/17/32	A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer	$69,550
Investment (Protocol)	Sanoff	Hanna	AbbVie, Inc.	M24-064	1/24/25	1/24/28	AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Expressed Refractory Metastatic Colorectal Cancer	$66,434
Recruitment	Savoldo	Barbara	Department of Defense	W81XWH2010890 0011479913	9/15/20	9/14/25	Phase I Study of Autologous Activated T-cells Transduced With a 3rd Generation GD2 Chimeric Antigen Receptor, Co-expression of IL-15 and iCaspase9 Safety Switch.	$161,852
Recruitment	Savoldo	Barbara	NIH National Cancer Institute	5-R01-CA247497-01-05	7/1/20	6/30/26	Tailoring CAR T cell therapy for Hodgkin Lymphoma	$599,281
Recruitment	Savoldo	Barbara	DOD DA Army Medical Research Acquisition Activity	W81XWH2211111 0011753836	9/30/22	9/29/26	GD2 CASRT for Lung Cancer	$316,459
Recruitment	Savoldo	Barbara	Arovella Therapeutics Limited		2/10/25	2/9/26	NKTs expressing anti Claudin 18.2 CAR and IL12	$280,836
Recruitment	Savoldo	Barbara	Department of Defense	HT9425-25-1-0301 0012277278	7/1/25	5/31/27	Revlutionizing Pediatric Brain Tumor Treatment with Off-the-Shelf CAR-NKT Cells	$310,960
Retention	Schoenfisch	Mark	NIH National Institute of Diabetes, Digestive, and Kidney Diseases	5-R01-DK132778-01-03	1/1/23	12/31/26	Nitric Oxide-Releasing Glycosaminoglycans for Treating Complex Wounds	$394,372
Retention	Schoenfisch	Mark	NIH National Institute of Dental and Craniofacial Research	5-R01-DE032060-01-03	5/1/23	4/30/28	Nitric oxide-releasing hyaluronic acid therapeutics for treating periodontal disease	$617,473
Recruitment	Schrank	Travis	NIH National Institute of Dental and Craniofacial Research	5-K08-DE029241-01-05	9/1/20	8/31/25	Mechanisms Determining Dysregulation of the NRF2 Oxidative Stress Response in Head and Neck Squamous Cell Carcinoma	$173,993
Recruitment	Schumacher	Jessica	University of Wisconsin at Madison	3615	4/5/24	3/31/25	Understanding patient-surgeon interactions to support deimplementation of preference-sensitive low value care	$46,823
Recruitment	Schumacher	Jessica	University of Wisconsin at Madison	3719	9/1/23	12/1/25	Modality-specific interval colorectal cancer rates	$45,263
Investment (Training)	Sekelsky	Jeff	NIH National Institute of General Medical Sciences	5-T32-GM135128-05	7/1/20	6/30/25	NRSA in Genetics	$769,103
Innovation Award	Sekelsky	Jeff	NIH National Institute of General Medical Sciences	5-R35-GM118127-06-10	6/1/16	3/31/26	Mechanisms of meiotic and mitotic recombination	$544,786
Innovation Award	Sekelsky	Jeff	NIH National Institute on Aging	5-F31-AG079626-03	9/1/22	8/31/25	Fellow: N Pazhayam Preventing Age-Associated Oocyte Aneuploidy: Mechanisms Behind the Drosophila melanogaster Centromere Effect	$40,721

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Investment (Training)	Sekelsky	Jeff	NIH National Institute of General Medical Sciences	2-T32-GM135128-06	7/1/20	6/30/30	NRSA in Genetics	$747,631
Recruitment	Sellers	Rani	North Carolina Biotechnology Center	2024-IIG-0015	4/15/24	4/14/25	Innovating Digital Pathology in North Carolina by Harnessing Technology: HALO Image Analysis Platform for High-impact Image Analysis.	$148,407
Recruitment	Sengupta	Soma	Shuttle Pharmaceuticals, Inc.	S22-11168	11/5/24	10/24/34	Phase 2 Study of Ropidoxuridine as a Radiation Sensitizing Agent During Radiotherapy in Patients with Newly Diagnosed IDH-Wildtype Glioblastoma with Unmethylated MGMT Promoter	$59,626
Recruitment	Sengupta	Soma	Ian's Friends Foundation		9/15/24	12/31/25	Feasibility of a Digital Art Therapy Application Designed to Improve Quality of Life in Young Cancer Survivors	$22,443
Retention	Serody	Jonathan	Merck Sharp and Dohme Corp.	54829	12/15/16	12/31/25	Correlative study of the activity of pembrolizumab in combination with gemcitabine and cisplatin as neoadjuvant therapy prior to radical cystectomy in patients with muscle-invasive urothelial carcinoma of the bladder	$99,132
Retention	Serody	Jonathan	Merck Sharp and Dohme Corp.	54823	12/15/16	12/31/25	Immune Biomarker Analysis of Pembrolizumab in AML	$105,491
Retention	Serody	Jonathan	NIH National Heart, Lung, and Blood Institute	5-R01-HL155098-01-04	9/1/21	6/30/25	Enhancing Innate Immune Reconstitution Post Allogeneic HSCT.	$679,845
Investment (Training)	Serody	Jonathan	NIH National Cancer Institute	5-T32-CA285257-02	9/15/23	8/31/28	UNC Immunotherapy Training Grant (IM-TAG)	$181,622
Retention	Serody	Jonathan	American Society of Hematology		7/1/24	6/30/26	Targeting a Novel Cyclic Dinucleotide Signaling Pathway in CAR T cells to Drive Antitumor Immunity	$100,000
Retention	Serody	Jonathan	NIH National Cancer Institute	1-F31-CA288161-01A1	7/10/24	7/9/27	Function of PD-1 Signaling on the Activity of B cells in the Tumor Microenvironment in Breast Cancer	$47,153
Recruitment	Serrano	Natalicio	Robert Wood Johnson Foundation	81521	2/15/24	2/14/26	A complex systems approach to understand the impacts of neighborhood development on physical activity in Latine and Black communities	$130,000
Retention	Shaheen	Nicholas	CDx Diagnostics		8/8/16	8/7/26	CDX 707 WATS Registry Services Agreement	$60,800
Retention	Shaheen	Nicholas	C2 Therapeutics		12/29/17	12/31/26	Safety and Efficacy of the CryoBalloon Ablation for Treatment of Patients with Resistant Barrett's Esophagus (BE) - The Resistant BE Trial (ReBET)	$192,114
Retention	Shaheen	Nicholas	University of Colorado Denver	FY22.1035.015	5/15/22	4/30/25	A Multicenter Randomized Controlled Trial of Surveillance vs. Endoscopic Therapy for Barrett's Esophagus with Low-grade Dysplasia: The SURVENT Trial	$151,409
Retention	Shaheen	Nicholas	GIE Medical, Inc.	PR2052	1/23/23	2/28/29	PATENT-E : Paclitaxel Coated balloon for the Treatment of chronic bEnigN sTricture- Esophagus	$145,567
Retention	Shaheen	Nicholas	Case Western Reserve University	RES603675	9/22/22	8/31/27	Validation of biomarkers for predicting Barrett's esophagus that will or will not: i) progress toward cancer, or ii) recur after ablation.	$108,283
Retention	Shaheen	Nicholas	NIH National Center for Advancing Translational Sciences	5-UM1-TR004406-02	4/28/23	3/31/30	1/3 North Carolina Translational and Clinical Sciences Institute (NC TraCS)	$989,710
Retention	Shaheen	Nicholas	Mayo Clinic in Rochester	THE-319907-02 P001764264	9/30/23	9/29/26	External Validation and Evaluation of a Novel Deep Learning Platform for the Diagnosis and Risk Stratification of Dysplasia in Barrett's Esophagus Histology	$57,226
Retention	Shaheen	Nicholas	Case Western Reserve University	RES604259	1/3/25	12/31/29	A Clinical Trial of Cancer Prevention by Biomarker Based Detections of Barrett's Esophagus and Its Progression	$45,127
Retention	Shaheen	Nicholas	Fred Hutchinson Cancer Center	1221020	1/1/25	12/31/26	Novel methylated HGD and early EAC early detection markers: discovery and validation studies	$34,210
Recruitment	Shea	Thomas	Alliance for Clinical Trials in Oncology		9/11/13	3/5/30	Alliance Prime eIPF	$59,105
Recruitment	Sheeran	Paschal	University of Colorado Boulder	1564540 1001918652	9/18/23	8/31/25	Exercise adherence and cognitive decline: Engaging with the Black community to develop and test a goal-setting and exercise intensity intervention	$17,209

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Sheeran	Paschal	North Carolina State University	PAM-P23-003103-SA01	9/1/23	8/31/26	IHBEM: Data-driven integration of behavior change interventions into epidemiological models using equation learning	$58,745
Recruitment	Shen	Colette	Nanobiotix S.A.		3/14/19	3/20/29	A Phase I/II Study Of NBTXR3 Activated By Radiation Therapy (SABR) For Patients With Advanced HNSCC or NSCLC Treated with an Anti-PD1 Antibody	$283,029
Recruitment	Shen	Colette	Hoosier Cancer Research Network	BRE18-360	4/1/21	4/11/31	BRE18-360: Phase I/II Study of Stereotactic Radiosurgery with Concurrent Administration of DNA Damage Response (DDR) Inhibitor (Olaparib) Followed by Adjuvant Combination of Durvalumab (MEDI4736) and Physician s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases	$19,343
Recruitment	Shen	Colette	University of Michigan	SUBK00014248	8/1/21	7/31/26	A clinical tool for automated detection and delineation of intracranial metastases from MRI	$47,550
Recruitment	Sheth	Sid	Merck Sharp Dohme LLC	60988	4/18/24	4/17/26	Tissue and plasma based changes of molecular response to pembrolizumab and olaparib in locally advanced HNSCC	$360,937
Recruitment	Sheth	Sid	Beigene, Ltd.	BGB-900-102	6/22/21	7/31/24	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 MonoclonalAntibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors	$24,221
Recruitment	Sheth	Sid	Merck Sharp and Dohme Corp.	LCCC 2047	8/10/21	4/12/32	A Phase II Trial of Induction and Maintenance Pembrolizumab and Olaparib in Locally-Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)	$150,000
Recruitment	Sheth	Sid	IconOVir Bio, Inc	1042-CLN01	1/26/24	2/1/34	Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors	$252,684
Recruitment	Sheth	Sid	VCU Medical College of Virginia		10/16/24	1/15/27	Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors	$80,000
Recruitment	Sheth	Sid	Janssen Research Development, LLC	61186372HNC2002	10/22/24	2/17/27	A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition toStandard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	$20,281
Recruitment	Sheth	Sid	Inhibrx	INBRX106-01-201	8/20/24	8/20/29	A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS greater than or equal to 20) (HexAgon-HN)	$65,349
Recruitment	Sheth	Sid	Replimune, Inc.	RPL-003-19	1/15/25	1/15/30	An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies [ARTACUS]	$56,660
Retention	Shih	Yen-Yu	NIH National Institute of Mental Health	5-R01-MH126518-01-05	4/1/21	3/31/26	Neural circuit mechanisms governing default mode network dynamics	$641,842
Retention	Shih	Yen-Yu	University of California at Santa Barbara	KK2357	3/15/23	2/29/28	Metal-free, genetically encoded reporters for calcium recording with MRI	$122,368
Retention	Shih	Yen-Yu	NIH National Institute of Biomedical Imaging and Bioengineering	5-R01-EB033790-01-02	8/1/23	7/31/27	SORDINO-fMRI for mouse brain applications	$609,429
Investment (Protocol)	Smith	Angie	University of Washington	PO#BPO38451	2/1/19	1/31/25	Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Recurrent Bladder Cancer	$74,759
Investment (Protocol)	Smith	Angie	University of Washington	UWSC16042 PO 0100155424	7/1/24	6/30/29	BEST CARE for Recurrent NMIBC: BladdEr-Sparing Therapy and Cystectomy As TREatments	$53,333

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Smith	Jennifer	DL Analytics, LLC	1	5/1/22	8/31/24	SBIR: Validation of a low-cost lab-free screening test for prevention of cervical cancer: automatic visual evaluation	$79,450
Recruitment	Smith	Jennifer	Cleveland Clinic Lerner College of Medicine	CCF23209065	9/1/22	3/31/27	SCALE: Single Visit Clinical Validation of Ampfire, a Low Cost HPV Test: Efficacy and Cost Effectiveness	$42,560
Recruitment	Smith	Jennifer	NIH National Cancer Institute	5-UG1-CA275403-03	9/2/22	5/31/27	UNC CASCADE Network Research Base	$615,041
Recruitment	Smitherman	Andrew	The Board of Trustees of the University of Alabama	000527577-SC008	3/24/21	2/28/26	Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescents and Young Adults with Acute Lymphoblastic Leukemia	$32,319
Recruitment	Smitherman	Andrew	Georgetown University	SUP-0002150 425038_GR424901-UNC	9/21/21	8/31/25	Randomized Trial of a Multilevel Intervention to Improve Adherence to Childhood Cancer Survivorship Guidelines	$88,437
Recruitment	Somasundaram	Ashwin	NIH National Cancer Institute	5-K08-CA259342-01-02	8/21/23	7/31/28	The role of IL6-induced LAG3 as a resistance mechanism to PD1 blockade in NSCLC patients	$275,561
Recruitment	Somasundaram	Ashwin	AbbVie, Inc.	M24-147	6/10/24	6/30/25	A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC-LIVIGNO-1	$60,602
Recruitment	Sondek	John	NIH National Institute of General Medical Sciences	5-R35-GM149299-01-03	5/1/23	3/31/28	Phospholipase C Isozymes	$384,915
Recruitment	Spanheimer	Philip	NIH National Cancer Institute	5-K08-CA280388-01-03	6/15/23	5/31/28	Repurposing RET Inhibitors for Endocrine Resistant Breast Cancer	$203,026
Recruitment	Spanheimer	Philip	University of Puerto Rico		11/6/23	12/31/25	Posttranslational Regulation of FOXA1 in Breast Cancer	$22,090
Recruitment	Spanheimer	Philip	Gilead Sciences, Inc.	24-2768	4/29/24	4/28/26	Targeting Reprogrammed Kinase Signaling Networks in Endocrine Therapy Resistant ER+ Breast Cancer	$90,000
Recruitment	Spanheimer	Philip	NIH National Cancer Institute	1-R37-CA292075-01	7/1/24	6/30/29	Predicting Endocrine Therapy Response in Male Breast Tumors	$604,746
Recruitment	Spees	Lisa	NIH National Institute on Minority Health and Health Disparities	5-K01-MD016989-01-03	9/25/22	12/31/26	Patient Navigation in Gynecologic Oncology: Improving Care among Rural Endometrial Cancer Patients	$134,829
Recruitment	Stanley	Natalie	NIH National Institute of Allergy and Infectious Diseases	5-R21-AI171745-01-02	8/3/23	7/31/26	Automating the Discovery of Clinically-Relevant Intracellular Signaling Responses in Immune Cell-Types	$219,336
Recruitment	Starbird	Chrystal	NIH National Institute of General Medical Sciences	5-R00-GM144683-02-04	2/24/23	1/31/26	The Structural Basis of TAM Receptor Oligomerization and Co-receptor Interactions	$224,085
Recruitment	Stover	Angela	UroGen Pharma Ltd.	22.2019	12/1/21	11/30/24	A mixed methods study of side effects and adverse events in a phase 3 trial of a medication gel for bladder cancer	$267,002
Recruitment	Stover	Angela	Pfizer Inc. (Connecticut)	73592487	12/12/22	2/28/26	Oncology pharmacist-facilitated PROM monitoring at UNC cancer clinics	$50,000
Innovation Award	Strahl	Brian	NIH National Institute of General Medical Sciences	5-R35-GM126900-06-08	5/1/18	4/30/28	Mechanisms of chromatin and transcriptional regulation	$586,513
Innovation Award	Strahl	Brian	American Cancer Society	DGB-24-1241663-01-DMC	1/1/25	12/31/26	Unlocking the function and histone-interaction landscapes of oncohistones	$300,000
Investment (Chair Package)	Stürmer	Til	NIH National Institute on Aging	5-R01-AG056479-05-07	9/15/17	5/31/27	Propensity scores and preventative drug use in the elderly	$614,717
Investment (Chair Package)	Stürmer	Til	Wake Forest University Health Sciences	1832-45828-11000002703	4/1/23	3/31/26	NCDRC Human Studies Consultation Core	$100,395
Investment (Chair Package)	Stürmer	Til	American Diabetes Association	1-25-PDF-96	1/1/25	12/31/27	Comparative safety of insulin glargine-yfgn (a biosimilar insulin) in a real-world population with novel pharmacoepidemiology methods: prevalent new-user study and clone-censored weight approach	$71,008

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Investment (HTSF)	Sullivan	Patrick	NIH National Institute of Mental Health	5-R01-MH123724-01-05	6/10/20	3/31/26	A Trans-Nordic Study of Extreme Major Depression	$79,519
Investment (HTSF)	Sullivan	Patrick	NIH National Institute of Mental Health	5-R01-MH124871-01-04	4/14/21	2/28/26	1/7 PGC: Advancing Discovery and Impact	$71,912
Investment (HTSF)	Sullivan	Patrick	Duke University	A034582	4/1/21	1/31/26	Beyond GWAS: High Throughput Functional Genomics & Epigenome Editing to Elucidate the Effects of Genetic Associations for Schizophrenia	$363,208
Investment (HTSF)	Sullivan	Patrick	NIH National Institute of Mental Health	5-R01-MH130671-01-02	9/1/22	6/30/28	1/3 Sequencing and Trans-Diagnostic Phenotyping of Severe Mental Illness in Diverse Populations	$760,305
Investment (HTSF)	Swanstrom	Ronald	NIH National Institute of Allergy and Infectious Diseases	3-P30-AI050410-27S1	8/20/01	5/31/26	The University of North Carolina Center for AIDS Research	$3,474,152
Investment (HTSF)	Swanstrom	Ronald	NIH National Institute of Mental Health	1-R01-MH138157-01A1	1/1/25	10/31/29	Evolution and Latency of T-Tropic and M-Tropic HIV in People Infected with Subtype C	$881,439
Recruitment	Tamir	Tigist	Burroughs Wellcome Fund	G-1021658-01	1/1/25	12/31/25	Postdoctoral Diversity Enrichment Program Transition to Faculty Award	$32,128
Recruitment	Tan	Ray	Department of Defense	W81XWH2110775 0011654672	9/1/21	8/31/25	Personalizing kidney cancer communication to support patient-centered decision-making	$232,405
Recruitment	Tan	Ray	Department of Defense	HT94252410386 0012085740	7/1/24	6/30/28	Virtual Testis Cancer Lay Support and Survivorship (VITALSS Study)	$377,884
Recruitment	Tan	Ray	American Urological Association Education and Research, Inc.		9/1/24	10/31/25	The Effect of Environmental Quality on Prostate Cancer-Specific and Overall Mortality	$40,000
Theme Investment	Tarantino	Lisa	Jackson Laboratory	210247-0625-07	9/1/22	6/30/27	Center for Systems Neurogenetics of Addiction	$236,653
Investment (CHAI Core)	Tate	Deborah	NIH National Institute of Diabetes, Digestive, and Kidney Diseases	5-R01-DK125779-01-05	7/10/20	6/30/26	Optimization of a mHealth Behavioral Weight Loss Intervention	$534,293
Investment (CHAI Core)	Tate	Deborah	NIH National Heart, Lung, and Blood Institute	5-R01-HL161836-03	6/10/22	5/31/27	Preventing weight gain in U.S. Air Force personnel using a novel mobile health intervention	$558,660
Investment (CHAI Core)	Tate	Deborah	University of Connecticut	160009447/KFS#5673160	5/15/22	4/30/27	Optimizing a couples-based behavioral intervention for weight management	$157,004
Investment (CHAI Core)	Tate	Deborah	George Washington University	23-M42	11/15/22	11/14/25	Effectiveness study of a lifestyle intervention versus metformin in mothers with recent gestational diabetes	$172,217
Recruitment	Thaxton	Jessica	Brigham and Womens Hospital	127349	7/1/22	6/30/27	Immunometabolic pathways enabled by PARP inhibition in breast cancer	$27,323
Recruitment	Thaxton	Jessica	NIH National Cancer Institute	3-R01-CA244361-06S1	7/1/20	6/30/25	Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy	$415,535
Recruitment	Thaxton	Jessica	NIH National Cancer Institute	1-R01-CA288976-01A1	12/3/24	11/30/29	Manipulating Lipid Metabolism to Reverse Immune Dysfunction in Solid Cancers	$496,391
Recruitment	Thom	Bridgette	Pfizer Inc. (Connecticut)	93233149	7/8/24	12/31/25	A patient-level intervention to reduce financial toxicity among young adult cervical patients and survivors	$150,000
Recruitment	Thompson	Caroline	NIH National Cancer Institute	5-R01-CA264176-02-05	7/1/21	6/30/26	Diagnosis of Cancer in the Emergency Room - Explaining Persistent Disparities (Grant Transfer)	$587,823
Recruitment	Thompson	Caroline	University of California at San Francisco	13498SC	8/1/21	7/31/25	Understanding the Multilevel Drivers of Liver Cancer Disparities	$19,993
Recruitment	Thompson	Caroline	Oregon Health and Science University	1022094_UNC	8/4/23	4/30/27	Health equity and the impacts of EHR data bias associated with social determinants	$33,075
Recruitment	Thompson	Caroline	Baylor College of Medicine	P700001073	7/1/24	6/30/25	Clinical Quality Measures to Improve the Diagnosis for GI Cancers	$60,000
Recruitment	Thompson	Caroline	Ovarian Cancer Research Fund Alliance	HEG-2025-2-1900	3/1/25	2/28/27	A Mixed Methods Study of Diagnostic Delay in Ovarian and Uterine Cancer	$50,000
Recruitment	Thompson	Tess	NIH National Cancer Institute	5-R37-CA277778-02-04	1/19/23	12/31/27	Dyadic Analysis of Unmet Social Needs Among Breast and Gynecologic Patients and Their Informal Caregivers	$136,605

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Thompson	Tess	American Cancer Society	MRSG-19-086-01	7/1/23	6/30/25	Mentored Research Scholar Grant (MRSG-19-086-01)	$96,359
Retention	Ting	Jenny	NIH National Cancer Institute	5-R35-CA232109-06	9/17/19	8/31/26	Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy	$879,456
Retention	Ting	Jenny	Duke University	303003694	8/1/20	7/31/25	Innate Immune Receptor Ligand and the Microbiota as Countermeasures for Radiation	$337,141
Retention	Ting	Jenny	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI158314-01-03	7/15/22	6/30/27	Role and Mitigation of Inflammasomes and Inflammation During COVID-19	$619,067
Retention	Ting	Jenny	NIH National Institute of Allergy and Infectious Diseases	5-K99-AI175479-01-02	5/23/24	4/30/26	Regulation of Pathologic Inflammasome Responses to SARS-CoV-2	$104,722
Retention	Ting	Jenny	National Multiple Sclerosis Society	FG-2307-41780	7/1/24	6/30/27	Investigating a Novel Beneficial Gut Microbe for Potential MS Therapy	$210,938
Retention	Ting	Jenny	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI029564-31-32	7/1/91	4/30/29	Molecular and Functional Analysis of Innate Immune Receptors	$571,581
Retention	Troester	Melissa	American Cancer Society	48195	8/23/17	12/31/27	Gene Expression Profiling of Breast Tumors from Cancer Prevention Study 3	$54,553
Retention	Troester	Melissa	ECOG-ACRIN Medical Research Foundation	UG1CA189828-06-UNC1	8/1/18	7/31/25	ECOG-ACRIN NCORP Research Base	$150,000
Retention	Troester	Melissa	NIH National Institute of Environmental Health Sciences	5-P30-ES-010126-24	4/1/21	2/28/26	UNC Center for Environmental Health and Susceptibility	$1,506,234
Retention	Troester	Melissa	NIH National Cancer Institute	5-R01-CA253450-01-05	4/6/21	3/31/26	P53, DNA Repair, and Immune Response in Breast Cancer Mortality Disparities	$581,738
Retention	Troester	Melissa	Susan G Komen for the Cure	TREND21686258	12/3/21	12/2/25	Breast Cancer Mortality Disparities: Integrating Biology and Access	$101,250
Retention	Troester	Melissa	Susan G Komen for the Cure	SAC210102	12/23/21	12/22/26	Impact of spatial heterogeneity in tumor and microenvironment on recurrence	$400,000
Retention	Troester	Melissa	North Carolina State University	PAM-P24-001939-SA02	9/21/21	8/31/27	Southern Liver Health Cohort	$564,999
Retention	Troester	Melissa	Susan G Komen for the Cure	OG22873776	5/18/22	5/17/25	Integrating Biology and Access to Understand Metastatic Breast Cancer Disparities	$166,667
Retention	Troester	Melissa	Susan G Komen for the Cure	OG230001	9/1/23	8/31/26	Carolina Breast Cancer Study, Phase 4	$351,667
Retention	Troester	Melissa	Department of Defense	HT94252310235 0011903639	9/15/23	9/14/27	Integrating Molecular Pathology, Radiology and Genetics to Improve Breast Cancer Risk Prediction	$965,973
Retention	Troester	Melissa	Breast Cancer Research Foundation	HEI-24-003	10/1/24	9/30/25	Breast Cancer Drivers in Black Women: Society to Cells	$974,720
Retention	Troester	Melissa	University of California at San Francisco	15801SC	9/11/24	8/31/29	WISDOM: A platform to optimize subtype-specific screening and prevention	$116,143
Recruitment	Trogdon	Justin	NIH National Cancer Institute	5-F30-CA254064-04	7/9/20	7/7/25	Fellow: Nul L Oh Cancer detection and care for dual-eligible beneficiaries in Medicare Shared Savings Program	$53,974
Recruitment	Tsagaratou	Ageliki	NIH National Institute of General Medical Sciences	5-R35-GM138289-01-05	7/1/20	6/30/25	Epigenetic Regulation of Lineage Specification	$378,288
Recruitment	Tuchman	Sascha	Karyopharm Therapeutics Inc		7/25/18	8/17/28	A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma	$13,268
Recruitment	Tuchman	Sascha	Alexion Pharmaceuticals, Inc.	CAEL 101-302	1/11/21	1/19/31	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis.	$202,839
Recruitment	Tuchman	Sascha	TeneoBio, Inc	TNB383B-0001	6/1/21	6/30/31	A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma	$19,418

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Turner	Kea	H Lee Moffitt Cancer and Research Institute	10-22879-99-01-G3	11/4/24	8/31/29	A Hybrid Effectiveness-implementation Trial to Integrate Precision Skin Cancer Risk Feedback in Federally Qualified Health Centers	$16,708
Recruitment	Turner	Kea	University of Florida	SUB00004772	11/4/24	8/31/25	De-Implementing Fall Prevention Alarms in Hospitals	$16,800
Recruitment	Turner	Kea	Department of Defense	HT94252410495	9/12/24	5/31/28	Support Through Remote Observation and Nutrition Guidance (STRONG) Program to Reduce Malnutrition Among Gastroesophageal Cancer Patients	$275,158
Recruitment	Turner	Kea	University of Oklahoma Health Sciences Center	RS20250060-02	11/4/24	7/31/29	Implementing Sustainable mobile health Technology to Optimize smoking cessation Program for Lao people with HIV (I-STOP)	$27,765
Investment (Training)	Valdar	William	NIH National Institute of General Medical Sciences	5-T32-GM135123-04	7/1/21	6/30/26	Predoctoral Training Program in Bioinformatics and Computational Biology	$274,680
Recruitment	Valdar	William	NIH National Institute of General Medical Sciences	5-R35-GM127000-06-07	4/1/18	8/31/28	Statistical Modeling of Multiparental and Genetic Reference Populations	$364,715
Investment (CC)	Valdar	William	NIH National Institute of Diabetes, Digestive, and Kidney	1R01DK130333-04	7/1/21	3/31/26	Foundational Studies for Precision Nutrition	$61,030
Recruitment	Valle	Carmina	NIH National Heart, Lung, and Blood Institute	5-R01-HL161373-01-04	1/15/22	12/31/25	A micro-randomized trial of JITAI messaging to improve adherence to multiple weight loss behaviors in young adults	$516,437
Recruitment	Valle	Carmina	NIH National Cancer Institute	5-R01-CA270111-01-03	4/1/23	3/31/28	Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors	$633,544
Recruitment	Van Duin	David	Duke University	303004308	12/1/20	11/30/25	Antibacterial Resistance Leadership Group COC	$114,921
Recruitment	Van Duin	David	Houston Methodist	AGMT00008232	6/1/22	5/31/25	VENOUS: A translational study of enterococcal bacteremia	$19,999
Recruitment	Van Duin	David	Houston Methodist Research Institute	AGMT00008429AM3	8/1/22	7/31/25	Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients	$14,993
Recruitment	Van Duin	David	Duke University	303004315	12/1/22	11/30/25	Antibacterial Resistance Leadership Group COC	$76,646
Recruitment	Van Duin	David	Merck Sharp Dohme LLC	MISP 102719	4/2/25	4/2/30	Antimicrobial Resistance in North Carolina: a One Health Approach	$74,845
Recruitment	Vincent	Benjamin	NIH National Cancer Institute	5-R37-CA247676-01-05	7/1/20	6/30/25	Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation.	$498,982
Recruitment	Vincent	Benjamin	Duke University	383000603	5/16/22	5/15/25	Personalized T-cell immunity against metastatic TNBC using MAVS immunostimulation.	$82,708
Recruitment	Vincent	Benjamin	NIH National Cancer Institute	5-F30-CA268748-03	8/1/22	7/31/26	Fellow: K Olsen Minor Histocompatibility Antigen T Cell Targeting in Acute Myeloid Leukemia	$53,974
Recruitment	Vincent	Benjamin	NIH National Cancer Institute	5-F30-CA278317-02	8/1/23	7/31/26	Effects of entinostat and neoantigen vaccination on bladder cancer	$53,974
Recruitment	Vincent	Benjamin	Conquer Cancer Foundation		7/1/24	6/30/25	Cancer-specific peptide vaccination to exploit the antigen unlocking, histone hyperacetylating activity of BRD4-NUTM1 in NUT carcinoma	$50,000
Recruitment	Vincent	Benjamin	Sage Bionetworks		7/1/24	9/30/25	CRI iAtlas Development	$195,038
Recruitment	Virkud	Yamini	NIH National Institute of Allergy and Infectious Diseases	5-R21-AI185550-01-02	6/3/24	4/30/26	Metabolomics of Food Allergen Immunotherapy	$147,725
Investment (HTSF)	Vogt	Matthew	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI169461-01-04	3/1/22	2/28/27	Human Antibody Cross-Reactivity in Non-Polio Enteroviruses	$611,746
Investment (HTSF)	Vora	Neeta	NIH National Institute of Child Health and Human Development	5-R01-HD105868-01-04	8/12/21	6/30/26	Genomics and functional dissection of fetal brain abnormalities using a prenatal cohort	$633,886
Recruitment	Wan	Yisong	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI160774-01-05	1/16/21	12/31/25	TGF-b superfamily signaling in controlling Th17 cell function in autoimmune neuroinflammation	$371,180

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Wan	Yisong	NIH National Institute of Allergy and Infectious Diseases	5-R01-AI123193-06-08	12/12/16	6/30/27	Functional protein networks underlying T cell growth, proliferation and differentiation	$385,283
Innovation Award	Waters	Marcey	National Science Foundation	CHE-2107685	7/1/21	6/30/25	Cooperativity Driven Communication through Noncovalent Networks in Biomimetic Systems	$120,000
Innovation Award	Waters	Marcey	NIH National Institute of General Medical Sciences	3-R35-GM145227-03S1	9/1/22	6/30/27	Mechanistic Investigation and Engineering of Histone Reader Proteins	$446,554
Innovation Award	Waters	Marcey	National Science Foundation	CHE-2404149	7/1/24	6/30/27	Cooperativity Driven Communication through Noncovalent Networks in Biomimetic Systems	$529,988
Investment (Protocol)	Weiner	Ashley	Lung Cancer Initiative of North Carolina		7/1/23	6/30/25	Predictive classifier for intensive treatment of locally-advanced non-small cell lung cancer using competing event regression	$25,000
Retention	Weiss	Jared	AstraZeneca Pharmaceuticals LP		4/28/17	11/28/25	Multimodality Therapy with Induction Carboplatin/nab-Paclitaxel/Durvalumab (MEDI4736) Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck	$55,868
Retention	Weiss	Jared	AstraZeneca Pharmaceuticals LP		2/8/18	4/30/28	A Phase I Study of Durvalumab with Radiotherapy and Durvalumab Plus Tremilumumab Together with Radiotherapy for the Adjuvant Treatment of High Risk Head and Neck Squamous Cell Carcinoma	$36,241
Retention	Weiss	Jared	Loxo Oncology, Inc.		5/29/18	6/14/28	A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer and Other Tumors with Increased RET Activity	$556,084
Retention	Weiss	Jared	Bluebird bio, Inc.	BBB47141US MAGE-A4-TCR	12/1/19	11/30/29	Phase 1 Study of the Administration of Autologous MAGE-A4 TCR T-cells for Relapsed/Refractory Solid Tumors	$123,813
Retention	Weiss	Jared	Mirati Therapeutics, Inc		7/12/19	8/31/29	A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation	$36,342
Retention	Weiss	Jared	MedImmune, Inc.		5/14/20	6/3/30	A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects with Advanced Solid Tumors	$60,286
Retention	Weiss	Jared	PDS Biotechnology Corporation	VERSATILE-002	1/19/21	1/19/31	Versatile-002: A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK - RDOTAP/HPV-16 E6 & E7 Peptides) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection (PDS0101-HNC-201)	$68,840
Retention	Weiss	Jared	Genmab	GCT1046-01	1/13/21	11/30/30	GCT1046-01: First-in-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects with Malignant Solid Tumors	$183,073
Retention	Weiss	Jared	Iovance Biotherapeutics, Inc.	IOV-LUN-202	9/1/21	8/29/31	A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer.	$28,555
Retention	Weiss	Jared	Department of Defense	W81XWH2211110 0011753834	9/30/22	9/29/26	GD2 CASRT for Lung Cancer	$145,913
Retention	Weiss	Jared	G1 Therapeutics	LCCC 2117	5/3/22	7/23/26	Phase II Study of Trilaciclib and Lurbinectedin in Small Cell Lung Cancer	$316,930
Retention	Weiss	Jared	Loxo Oncology, Inc.	LOXO-NGR-21001	11/4/22	10/11/32	A Phase 1 Study of Oral LOXO-260 in Patients with RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Refractory to Selective RET Inhibitors	$11,937
Retention	Weiss	Jared	Nurix Therapeutics, Inc.	NX-1607-101	4/26/23	5/4/34	A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types	$123,034

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Retention	Weiss	Jared	TScan Therapeutics	TSCAN-003	11/9/23	12/5/33	Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors	$310,117
Retention	Weiss	Jared	TScan Therapeutics	TSCAN-002	3/1/24	2/17/26	A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors	$115,633
Retention	Weiss	Jared	Phanes Therapeutics	PT 217 X1101	3/18/24	4/17/34	A Phase 1 Open-label, Multicenter, Dose Escalation and DoseExpansion Study of PT217 in Patients with Advanced RefractoryCancers Expressing DLL3	$63,729
Retention	Weiss	Jared	Janux Therapeutics	EGFR-008-001	6/6/24	6/5/34	Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies	$220,183
Retention	Weiss	Jared	Summit Therapeutics Sub, Inc	SMT112-3003	8/27/24	8/13/34	A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Nonsmall Cell Lung Cancer	$108,326
Retention	Weiss	Jared	NIH National Cancer Institute	1-R01-CA296807-01	12/1/24	11/30/29	iC9-CAR.CSPG4 CAR-T Cells for Head and Neck Squamous Cell Carcinoma	$627,456
Recruitment	Wheeler	Stephanie	Alliance for Clinical Trials in Oncology	202010116	9/1/20	7/31/25	Optimizing Endocrine Therapy Adherence - Pillsy Cap Shipping	$99,438
Recruitment	Wheeler	Stephanie	Alliance NCTN Foundation	ANF_A191901_01	8/1/23	7/31/24	Optimizing Endocrine Therapy Adherence - Pillsy Cap PURCHASE	$50,000
Recruitment	Wheeler	Stephanie	V Foundation for Cancer Research	GC2025-005	6/1/25	6/1/26	Understanding and Addressing Cancer Disparities Among American Indians in North Carolina: Youth and Young Adult Cancer Risk Factors	$100,000
Investment (HTSF)	Whitmire	Jason	Department of Defense	W81XWH2110919	9/30/21	9/29/25	Pathogenic T cells in Guillain Barre Syndrome	$300,118
Recruitment	Wilkerson	Greg	University of Colorado Boulder	1564563 1001916392	8/1/23	7/31/27	Characterizing Host-Virus Interactions in a New HIV Model Organism	$93,850
Recruitment	Williams	Scott	NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases	5-R01-AR077591-01-05	3/1/21	1/31/26	Intrinsic and extrinsic spindle orientation mechanisms in mammalian epidermis	$305,509
Recruitment	Williams	Scott	NIH National Institute of Dental and Craniofacial Research	1-F31-DE033915-01	12/1/24	11/30/26	Determining the role of cell-cell adhesions in palate closure	$41,218
Recruitment	Willson	Tim	Structural Genomics Consortium		9/30/18	9/30/27	Structural Genomics Consortium Grant Funding	$116,667
Recruitment	Willson	Tim	Seattle Children's Hospital Research Institute	12492SUB	9/22/20	8/31/25	Dual targeting of Mtb resistance mechanisms	$155,500
Recruitment	Willson	Tim	Structural Genomics Consortium		7/1/21	6/30/30	Structural Genomics Consortium	$133,333
Recruitment	Willson	Tim	University of Toronto	513954 SUBGRANT 1	3/22/22	2/28/27	Targeting the casein kinase 1 (CK1)-like kinase Yck2 in fungal pathogenesis	$310,704
Recruitment	Willson	Tim	Structural Genomics Consortium	2024-UNC-1-BMGF	9/1/24	8/31/26	Ligandability of Non-Hormonal Contraceptive Drug Targets	$287,289
Recruitment	Wood	William	Incyte Corporation	MA-GVHD-401	5/23/23	3/14/29	A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)	$60,592
Recruitment	Wood	William	National Marrow Donor Program	2207	11/20/24	11/18/34	A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia	$11,000
Recruitment	Yang	Y. Claire	The Trustees of Columbia University in the City of New York	G19728 1(GG019314-01)	9/23/24	8/31/27	Engaging aging minds: Labor force participation, stimulating activities, and cognitive aging across diverse international settings	$45,467

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Yarbrough	Wendell	Yale University	CON-80005428 (GR124735)	7/1/20	6/30/25	Yale SPORE in HN Cancer	$155,794
Recruitment	Yarbrough	Wendell	NIH National Institute of Dental and Craniofacial Research	5-U01-DE029754-05	7/1/20	4/30/26	Observational study to validate HPV DNA genotyping and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated HNSCC	$704,533
Recruitment	Yarbrough	Wendell	NIH National Institute of Dental and Craniofacial Research	5-R01-DE031297-01-03	3/1/23	12/31/27	Dissecting NF-kB pathway in HPV-associated head and neck cancer	$509,676
Recruitment	Yates	Melinda	University of Texas MD Anderson Cancer Center	3002380000	9/23/23	5/31/27	Overcoming the triple threat to diversity in the health science workforce: empowering the next gen.	$27,365
Retention	Yeh	Jen Jen	University of Rochester	GR533465 SUB000000558	2/1/23	8/1/25	A Phase 1b/2 Trial of Immunotherapy With Nivolumab and Pepinemab Combined With First Line Folfirinox For Treating Patients With Unresectable Pancreatic Adenocarcinoma	$197,942
Retention	Yeh	Jen Jen	Princeton University	SUB0000542	9/22/21	8/31/26	Pathway, Network and Spatiotemporal Integration of Cancer Genomics Data	$87,250
Retention	Yeh	Jen Jen	Lustgarten Foundation		1/2/23	1/1/26	PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study)	$150,000
Retention	Yeh	Jen Jen	University of North Carolina at Charlotte (UNCC)	20220451-01-UNC	8/1/22	7/31/27	Stimuli-responsive mucin1-specific nanoparticles for efficacious combinatorial chemotherapy of pancreatic ductal adenocarcinoma	$197,129
Retention	Yeh	Jen Jen	NIH National Cancer Institute	3-U01-CA274298-03S1	9/1/22	8/31/27	Integrating tumor and stroma to understand and predict treatment response	$869,831
Retention	Yeh	Jen Jen	NIH National Cancer Institute	3-P50-CA257911-03S1	9/16/22	8/31/27	Selective Targeting of Pancreatic Cancer SPORE	$2,165,780
Retention	Yeh	Jen Jen	NIH National Cancer Institute	5-R01-CA288145-01-02	2/1/24	1/31/29	Targeting EGFR for basal subtype cancer	$639,879
Investment (Training)	Yeh	Jen Jen	NIH National Cancer Institute	2-T32-CA244125-06	9/20/19	6/30/29	UNC Integrated Translational Oncology Program (UNC-iTOP)	$567,329
Retention	Yeh	Jen Jen	Conquer Cancer Foundation	24-0994	7/1/25	6/30/26	Liquid biopsy-based molecular subtyping of pancreatic cancers	$50,000
Retention	Yeh	Jen Jen	American College of Surgeons	25-1121	7/1/25	6/30/27	The role of TNIK (Traf2 and Nck interacting kinase) in pancreatic adenocarcinoma	$60,000
Recruitment	Zaharoff	David	North Carolina State University	501388	9/1/24	8/31/25	Intravesical Immunotherapy of Spontaneous Canine Invasive Urothelial Carcinoma	$43,708
Recruitment	Zamboni	William	NIH National Cancer Institute	5-R01-CA247652-01-05	4/1/21	3/31/26	Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors	$500,267
Recruitment	Zamboni	William	Wake Forest University Health Sciences	1930-45107-11000001894	7/1/23	6/30/28	Nanodelivery of FP polymers to improve treatment of metastatic colorectal cancer	$108,013
Recruitment	Zamboni	William	DHHS FDA National Center for Toxicological Research (NCTR)	75F40124P00492	9/30/24	9/29/25	Evaluating the Effect of Obesity on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies in Pediatric Patients	$86,019
Recruitment	Zeidner	Joshua	Beat AML, LLC		2/25/19	7/21/25	BAML16-001 (BEAT)_Phase 1/2 Umbrella Study-A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)	$400,255
Recruitment	Zeidner	Joshua	Takeda Development Center Americas, Inc.	Pevonedistat-2002	1/26/21	11/30/24	A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy.	$47,383
Recruitment	Zeidner	Joshua	Gilead Sciences, Inc.	GS-US-546-5857	11/2/21	11/30/24	A Phase 3, Randomized, -Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine versus Physician s Choice of Venetoclax plus Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 MutantAcute Myeloid Leukemia.	$30,747
Recruitment	Zeidner	Joshua	Newave Pharmaceutical, Inc.	LP-118-US-101	5/22/23	8/29/31	A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects with Relapsed or Refractory Hematological Malignancies	$38,732

Category	Last Name	First name	Sponsor	Sponsor Award No	Begin	End	Title	Total Award
Recruitment	Zeidner	Joshua	Sumitomo Pharma Oncology, Inc.	DSP-5336-101	10/31/22	11/6/32	DSP-5336-101: A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation	$115,370
Recruitment	Zeidner	Joshua	Shattuck Labs, Inc.	SL03-OHD-104	12/24/22	1/15/33	An Open-Label Phase 1a/1b Dose Escalation and ExpansionCohort Study of SL-172154 (SIRP?-Fc-CD40L) in Combination With Azacitidineor With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)	$330,818
Recruitment	Zeidner	Joshua	Gilead Sciences, Inc.	GS-US-590-6154	6/28/23	2/28/26	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy	$53,218
Recruitment	Zeidner	Joshua	Beat AML, LLC	BAML-16-001-S12	5/2/23	6/22/33	A Randomized Phase 2 Trial of 28 Day (Arm A) versus 14 Day(Arm B) Schedule of Venetoclax (Ven) + Azacitidine (Aza) innewly diagnosed acute myeloid leukemia (AML) patients ? 60years.	$82,307
Recruitment	Zeidner	Joshua	SELLAS Life Sciences Group	GFH009X2101	9/14/23	7/2/33	A Phase I, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent in Patients with Relapsed/Refractory Hematologic Malignancies	$1,210,039
Recruitment	Zeidner	Joshua	Novartis Pharmaceuticals Corporation	CABL001AUS08	10/23/23	12/31/28	A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)	$173,946
Recruitment	Zeidner	Joshua	K-Group Alpha, Inc	ZN-d5-004C	1/3/24	1/10/34	A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia	$35,464
Recruitment	Zeidner	Joshua	Faron Pharmaceuticals	FP2CLI004	2/6/24	2/23/34	Phase I/II Open-Label Study to Assess Safety, Tolerability and Preliminary Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination with Standard of Care Therapy in Patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia	$60,489
Recruitment	Zeidner	Joshua	Hoosier Cancer Research Network	HCRN-AML20-472	3/27/24	4/7/34	HCRN AML20-472: Phase II Study of Tagraxofusp in Newly Diagnosed Secondary AML after Previous Exposure to Hypomethylating Agents (TAGALONG Study)	$45,043
Recruitment	Zeidner	Joshua	Beat AML, LLC	T23-03	3/7/24	4/3/34	A comparator study of a Tasso device to traditional venous blood sampling methods for complete blood count (CBC) with 5-part differential in patients with leukemia, lymphoma, and/or other blood cell disorders	$101,403
Theme Investment (Biostatistics	Zou	Fei	Vanderbilt University Medical Center	VUMC102856 25-0837	12/10/21	5/31/25	Vanderbilt University: Biostatistics Fellowship	$10,513
Investment (HTSF)	Zylka	Mark	University of California at San Diego	706661	9/1/23	8/31/26	Testing Optimal Gene Editor for an Alzheimer's CRISPR therapeutic	$201,303

UNC | LINEBERGER COMPREHENSIVE CANCER CENTER

The UNIVERSITY *of* NORTH CAROLINA *at* CHAPEL HILL